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Abstract
Normal human keratinocytes possess a finite replicative lifespan
whereas most advanced squamous cells carcinomas are immortal. The
mechanisms, whose abrogation's can be considered necessary to achieve
immortality, include those involving the negative cell cycle regulators p53,
p161NK4A,and the telomere repair reverse-transcriptase enzyme, telomerase.
Other specific chromosomes have also been demonstrated to carry functions
whose loss is necessary for the development of immortality, through immortal
phenotype reversion upon reintroduction into an immortal cell line.
We demonstrate here the phenotypic reversion of immortal HNSCC-
derived keratinocyte cell lines to a mortal growth-arrest upon reintroduction of
a resistance marker tagged wild-type human chromosome 4. We further
demonstrate that this phenotypic reversion occurs only in cell lines, which
display LOH on 4q (BICR6 and BICR31), and not in those with intact
endogenous chromosome 4 copies (BICR3 and BICR19), and that it is
chromosome 4-specific, chromosomes 6, 11, and 15 having no effect on
proliferative lifespan following introduction into BICR6 by MMCT. Through
XMMCT-based truncated chromosomal fragment generation the functional
complementation was localised to 4cen-q23, whilst fine mapping in
segregants arising from the MMCT experiments identified an approximate
1.5Mb locus containing a minimal number of candidate genes.
Through biological assay we have further determined the growth-arrest
to have characteristics of crisis. This was determined through low BrdU
incorporation balanced with high levels of apoptosis to statistically significance
levels «0.05). We found no evidence for involvement of telomeric attrition in
the observed phenotype, through insufficient phenotypic lag (3-10 MPD) and
growth-arrest in the presence of ectopic hTERT expression, suggesting the
operation of an alternative mechanism. This suggests the presence of
gene(s) at 4cen-q23 whose loss is advantageous to the development of
immortality in advanced tumours including HNSCC.
xvi
Chapter 1: Introduction
1
1) Cancer as a Multistage Process
1.1) Theories of Tumourigenesis
The initiation and progression of a normal cell to the molecular
dysfunctionality of a malignant cell is brought about through the accumulation
of genetic alterations that deregulate controlling pathways. Tumour
progression and its development in a qualitative manner was first proposed by
Foulds (1957) such that multiple rather than single specific changes were
required for malignancy to develop. This multistep deregulation brings about
the activation of oncogenes accompanied by, although not in every instance,
the inactivation of tsg's (Bishop, 1987). The malignant threshold however is
defined by the accumulation of genetic aberrations rather than the sequence
of events. The paradigm that genes were implicated in malignant progression
was first provided by the isolation of dominantly acting transforming genes,
oncogenes, from both avian and mammalian retroviruses followed by the
identification of cellular homologs, proto-oncogenes. The observation that
these oncogenes could induce the neoplastic transformation of rodent cells in
culture demonstrated the dominance over their cellular counterparts and
provided molecular evidence for the involvement of genes in neoplastic
progression.
The concept that biological events in tumour progression represented
the effects of genetic instability and the resultant sequential selection of
variant subpopulations based on that instability was proposed by Nowell
(1976). However, intrinsic to this theory was the idea that the genetic
instability was due to the activation of specific gene loci rather than the loss of
regulatory loci whereas it is now recognised to be due to both effects. The
idea that two copies of a 'recessive' gene must be lost or inactivated to allow
neoplastic development was first postulated in the Knudsons 'two hit'
hypothesis' (1971) developed in reference to childhood retinoblastoma. This
is reinforced now by observations that the loss of one copy of a 'recessive'
gene can increase the potential for the second copies inactivation. A unifying
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somatic mutation theory of cancer was also proposed by Comings where loss
of regulatory genes and activation of proto-oncogenes had a role in
tumourigenesis drawing on both Nowells earlier proposition and Knudsons
hypothesis. This developed a unifying thread common to both earlier theories
where tumour progression through loss of function mutations characterised by
point mutations, frameshift mutations and deletion of chromosomal regions
was accompanied by amplification of chromosomal regions encoding
oncogenes. Therefore mutational events in the development of a tumour can
be largely characterised as either a gain of function (oncogenes) or a loss of
function (tsg's).
1.2) Functional Demonstrations
Early studies into tumourigenicity suggested that it was a dominant trait
in murine fusion experiments (Barski et al., 1962), although this interpretation
did not incorporate the initial suppression of tumourigenicity, which had
occurred in hybrids. This initial observation was refuted in studies, which
showed that in fusions between non-malignant and malignant cells the
malignancy was recessive to the normal phenotype (Harris et al., 1969;
Stanbridge, 1976) illustrating a non-malignant dominance. This was followed
by the suggestion that specific chromosomes were involved in the
suppression of malignancy whose loss was required for malignancy to
develop (Harris et al., 1971). The observed early dominance feature (Barski
et al., 1962) was most likely therefore to be due to the in situ loss of
chromosomes from the hybrid populations allowing the outgrowth of revertant
segregants through positive selection pressures (Peehl and Stanbridge,
1981). The genesis of the idea that specific chromosomes could in some
form regulate a cells predisposition to form a tumour was found some 60-80
years earlier. The pair of Von Hansemann (1890) and Boveri (1914) were
perhaps the first to propose the idea of chromosomal imbalance leading to
malignant progression. Both their earlier theories were reinforced by the
postulation that the balance between specific chromosomes would determine
controlling factors, which would either potentiate or suppress malignant
3
development (Hitotsumachi et al., 1972). Further reinforcement was provided
by the demonstration that an excess of 57 over 73 (hamster chromosome
nomenclature; Yamamoto et ai, 1973) led to an expression of malignancy in
tumour clones (Benedict et al., 1975). In a refinement of the earlier works and
theories the first tentative evidence that specific chromosomal loss could lead
to a re-emergence of tumourigenicity was shown in fusions between normal
diploid fibroblasts and HeLa cells where the loss of an unassigned copy of
chromosome 11 or 14 led to the re-expression of the tumourigenic phenotype
(Stanbridge et al., 1981). This work was reinforced with the further
observation that a single chromosome loss could be responsible for the re-
emergence of tumourigenic variants (Stoler and Bouck, 1985; Saxon et al.,
1986). Therefore over an approximate 1eo-year period the idea of
chromosomal change being key to progressive tumour development
proceeded from hypothesis to an evidenced fact.
Although loss of function mutations and oncogene amplifications are
perhaps the best characterised mechanisms of gene expression deregulation
a further non-mutagenic form of gene silencing is demonstrated by DNA
methylation. This process involves the covalent modification at the fifth
carbon position of cytosine residues within CpG dinucleotides that cluster in
CpG islands at the 5' ends of many genes. Methylation can affect gene
expression by preventing the binding of transcription factors to promoter
sequences, through preferential binding of repression factors to the
methylated sites, and through methylation perhaps changing chromatin
structure to an inactive form. The cell cycle factors; PCNA, p161NK4A,and
p21WAF1,have been linked to methylation regulation suggesting possible
regulation of the cell cycle in this manner. Transcriptional silencing has been
shown to occur by hypermethylation of promoter regions in pRB and the von
Hippel-Lindau tsg in retinoblastoma and renal cancer respectively (Ohtani-
Fujita et al., 1993; Herman et al., 1994).
The progression of tumourigenesis is due to perhaps three key
mechanisms of genetic dysfunction, which exert their functions largely on
deregulation of the cell cycle. These can be characterised as discussed
4
above as loss of function through LOH or mutation removing an intrinsic
highly regulated tsg and therefore in effect losing important cell cycle
regulatory blocks, as gain of function amplifications inappropriately leading to
a constitutive activation of otherwise induction-controlled oncogenes driving
cell cycle machinery in an uncontrolled manner, and undergoing inactivation
through promoter silencing by methylation or conversely activation by
silencing of a repressor.
1.3) Colorectal Carcinoma Model
An early demonstration of tumourigenic development occurring in a
multistep process was provided by studies into colon cancer. The rare
dominantly inherited susceptibility to colon cancer, familial adenomatous
polyposis (FAP) gene, adenomatous polyposis (Ape), was identified initially
through microdeletion of the 5q21 locus in a patient with developmental
disorders and APe (Herrera et al., 1986). The analysis of rare cancer
predisposition syndromes like FAP «1% of colorectal carcinomas) can lead to
the discovery of genes involved in sporadic cancers through abrogation of
mutual pathways. Linkage analysis suggested that the 5q21 locus was tightly
linked to the disorder (Bodmer et al., 1987; Leppert et al., 1987) whilst LOH
evidence suggested that 5q21 allelic loss occurred in up to 40% of all cases of
colorectal carcinoma (Bodmer et al., 1989). Further analysis demonstrated
the APe gene had not only undergone somatic alteration in tumours of
sporadic colorectal cancer patients but also showed germline mutations in
FAP patients (Groden et al., 1991; Nishisho et al., 1991). Germ-line
mutations and LOH or somatic mutation of the remaining allelic copy meets
the minimal requirements of a tsg as outlined by Knudson (1971). However,
germline mutations of APe were not sufficient for tumour formation, as
evidenced by FAP patients (Kinzler and Vogelstein, 1996), although mutation
of the parental wild-type allele is the rate-limiting step in colorectal carcinoma
development (Ichii et al., 1992; Levy et aI, 1994; Luongo et al., 1994). Studies
into FAP led to the identification of the gene APe which itself is the rate-
limiting factor in colorectal carcinoma development. APe inactivation has
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been shown in dysplastic aberrant crypt foci (ACF), which are the earliest
examinable form of neoplastic lesion believed to be adenoma precursors (Jen
et al., 1994). This led to the suggestion that APC was a 'gatekeeper' of
colonic epithelial proliferation whose mutation led to an imbalance of cell
division over cell death (Kinzler and Vogelstein, 1996), this suggestion came
in some part from the observation where introducing wild-type expression in
APC mutant epithelial cells resulted in apoptotic cell death (Morin et al., 1996)
and an evidenced involvement in the WNT signalling pathway (Erdmann et
al., 2000). Further evidence suggested that in the development of colorectal
carcinoma recessive alterations occurred on chromosome 17 and 18; the
chromosome 17 alteration site, p53, was altered in >80% of tumours analysed
(Baker et al., 1990). However, p53 cannot induce colorectal carcinoma in an
APC-independent manner (Garber et al., 1991). The chromosome 18 gene
has several candidates although Deleted in Colorectal Cancer (DCC) and
SMAD may be good candidates for this abrogation site (Hahn et al., 1996;
Cho and Vogelstein, 1992). Changes that were implicated in the further
development of colorectal carcinoma included dominant mutations of the ras
oncogene and expression alterations of human leukocyte antigen (HLA)-A, B,
and C determinates (Bodmer et et., 1989). A similar situation to that seen
with p53 is observed with ras such that although mutations occur frequently in
colonic tumour progression, APC mutation is still required for colorectal
neoplastic development (Jen et al., 1994). Through further analysis a pattern
of progression in a multistep fashion had began to emerge, this showed a
sequential pattern of LOH which correlated well with tumour stage (Boland et
al., 1995) which ultimately is thought to require a minimum of four changes.
The transition from normal colonic epithelium to benign adenoma is
characterised by the inactivation of APC, and the loss of proliferation control;
this is followed by the dominant activation of ras, and inappropriate mitogenic
stimuli; the accumulation of LOH on 18q, presumably inactivating DCC;
followed by LOH on 17p, p53, at the transition from adenoma to carcinoma
undoubtedly accompanied by further genetic changes. Therefore the analysis
of the rare FAP disorder led to the unravelling of a multistep neoplastic
developmental pathway with a rate-limiting step (APC) requirement for
6
colorectal carcinoma development. A representation of events in colorectal
cancer development is shown in Figure 1.1.
1.4) Multistage Progression in Other Cancers
The proposition that progressive tumourigenesis was the result of the
accumulation of genetic changes proposed by theories such as those
described above has been suggested for a number of further tumour types.
Although chromosomal amplifications occur frequently in tumourigenesis,
demonstrated in regions containing oncogenes, in this instance we are
concerned with the loss of chromosomal sequences and their accumulation in
the advanced stages of tumourigenesis. Studies into the genetics of bladder
cancer development have shown LOH in a number of common sites many of
which are necessary for tumourigenic progression at 3p, 4p, 4q, Bp, 9p21,
9q22, 9q32-q33, 9q34, 10q23, 11p, 11q, 13q14, 14q, and 17p13 although not
necessarily thought to occur in that order (Knowles, 1999). Cervical
carcinoma has been shown to demonstrate losses repeatedly on a number of
different chromosomes on 3p14-p22, 4p16, 5p15, 6p21-p22, 11q23, and
17p13.3 again indicative of a multiple step requirement for tumourigenesis
(Lazo, 1999). Malignant mesothelioma accumulates losses on chromosomes
1p, 3p, 6q, 9p, 13q, 15q and 22q although in the development of this
aggressive tumour the order of losses does not seem to be as critical as their
occurrence (Murthy and Testa, 1999). Poor prognosis in prostate cancer has
been shown to be accompanied by LOH at 5q, 6q, 7q, Bp, Bq, 10q, 13q, 16q,
17p, 17q, and 1Bq although the order of these accumulative losses occur has
not been determined (Verma et al., 1999). Fundamentally, these
observations serve to highlight that not only do similar chromosomal regions
undergo LOH in the development of a wide range of tumour types but that
they may also occur in an undetermined order where tumour advancement is
reliant on a minimal change. This suggests that loss of the same genetic loci
at similar
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Figure 1.1. Colorectal carcinoma model of
tumour progression through multiple
changes
Schematic demonstrating the sequential genetic changes, that occur in the
progression from normal epithelium to metastatic colorectal carcinoma.
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stages are required in a number of diverse tumours indicative of common
pathways undergoing abrogation. This is therefore in agreement with the idea
of accumulative changes adding to the tumourigenic potential of neoplastic
development.
1.5) HNSCC as an Example of Multistage Cancer.
The development of HNSCC is associated with overexposure to the
common carcinogenic factors tobacco and alcohol as well as other
environmental and occupational factors (Landrigan and Baker, 1991. The
standard treatment regime as described by Zatterstrom et al. (1991) was in
brief; patients with T1 tumours underwent primary surgery, patients with T2
and resectable T3 and T4 tumours received preoperative radiotherapy (50Gy)
followed by surgery, laryngeal T1-3 carcinomas and non-resectable T3 and
T4 underwent radiotherapy (64-70Gy) and followed by selective salvage
surgery, patients with regional metastasis at diagnosis were treated with
radiotherapy followed by neck dissection. The 'T' system of tumour
classification represents the stage of the growth, Le. T1 is the smallest tumour
size with no local invasion whereas T4 is the largest classification with
invasion of local tissues. Generally there is an increasing tendency to follow
organ preservation protocols where chemotherapy is combined with
radiotherapy for advanced lesions in place of that described above with a
reversion to surgery where treatment fails (Collins, 1998).
Several candidate genes have been proposed whose loss or
amplification is essential for SCC development including carcinoembryonic
antigen (CEA) (Kimura et al., 2000); p16'NK4A (Lydiatt et al., 1998), p21 (Erber
et al., 1997), and cyclin 01 (Kyomoto et al., 1997; Capaccio et al., 2000), p53
(Cabelguenne et al., 2000) and pRB; ras and c-myc (Field et al., 1989); EGFR
and HER-2/neu; collagenase and matrix metalloproteinase; and SCC antigen
(SCCA) 1 and 2 (Kimura et al., 2000). None of these have been conclusively
demonstrated as successful prognostic indicators of HNSCC (Villaret et al.,
2000), indeed some have been demonstrated not to be e.g. ras (yarbrough et
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al., 1994), and CEA (Kimura et al., 2000). As the number of genes whose
deregulation is linked to tumourigenesis increases the idea of a single gene
whose loss is predictive of therapeutic response and patient mortality is
perhaps slightly optimistic although the development of microarrays may
provide patterns of alterations in HNSCC providing a global expression
change pattern.
In keeping with the nature of multistep development LOH is seen
frequently on a number of chromosomes in HNSCC although these events do
not occur simultaneously but rather are ordered in an approximate sequential
series of events as expected in the progression of tumourigenesis. Allelic
losses were demonstrated in HNSCC on chromosome 3p14 (Mao et al.,
1996), 3p13-cen, 3p21, and 3p25-pter (Maestro et al., 1993; Gotte et al.,
2000; Schantz et al., 2000), 6p21.3 (Feenstra et al., 1999,2000), 7 (Berker-
karauzum et al., 1999), 8p (Li et al., 1994), 9p21 (Mao et al., 1996; Reed et
al., 1996; Waber et al., 1997; Lydiatt et al., 1998), and 9q22.3 (Loughran et
al., 1994; Van der Riet et al., 1994; Ah-See et al., 1994), 10q (Ah-See et al.,
1994), 10q22-q26 (Gasparotto et al., 1999), 11P (Ah-See et al., 1994), 13q14
(Van der Riet et al., 1994), and 13q34 (Maestro et al., 1996; Gunduz et al.,
2000; Sanchez-Cespedes et al., 2000), 14q (Lee et al., 1997), 15q (Feenstra
et al., 1999), 16q24 (Wang et al., 1999), 17p (Li et al., 1994), 18q (Pearlstein
et al., 1998), 18q21.1-q23 (Takebayashi et al., 2000) and 22q (Poli-Frederico
et al., 2000). In the published data outlined above and elsewhere there are
over 19 separately identified loci of which 4 may represent known tsg's, this
would imply there are at least a further 14 genes whose deregulation can
proffer a growth advantage onto the developing HNSCC tumour. It is not
clear however which loss events are critical and which are consequential and
therefore which losses represent the true rate-limiting steps in the
development of HNSCC. An approximate ordering is thought to occur from
normal mucosa with an early 9p loss followed by 3p and 17p loss in precursor
lesions, dysplasia loss of p16, 11q, 13q and 14q accompanied by p53
mutation leading to carcinoma in situ followed by loss of 6p, 4q and 8p leading
to invasive carcinoma (Califano et al., 1996) (Figure 1.2). A number of case
studies (discussed in more detail below and in Chapter 3) have described
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Figure 1.2. HNSCC model of tumour progression
through multiple changes
Schematic demonstrating an approximation of the sequential genetic
changes. that are thought to occur in the progression from normal mucosa to
invasive carcinoma.
12
gp, 3p and 17p LOH
Normal Mucosa
Precursor Lesion
Dysplasia
p16 and p53 LOSS, I
11q, 13q and 14q LOH.~-~
Carcinoma in situ
4q, 6p, and Bp LOH
Invasive Carcinoma
•
13
LOH on chromosome 4 (Nawroz et al., 1994; Loughran et al., 1994, 1997;
Pershouse et al., 1997) and have contributed to the observation that these
allelic losses are a late event in HNSCC tumourigenesis (Califano et al., 1996,
Lee et al., 1997, Rosin et al., 2000). These observed losses implicate a
region on the long arm of chromosome 4 but provide no evidence for a locus
on 4p in HNSCC (Loughran et al., 1994).
The loss of p53 may represent a relatively early event in HNSCC
neoplastic development. The overexpression of p53 in dysplastic lesions and
CIS was shown to occur before the development of invasive carcinoma
(Pavelic et al., 1994), which may suggest a response to tumour progression
and accumulating DNA damage by the gene. The implication here is that p53
loss correlates with a more advanced, aggressive, and less amenable to
treatment tumour phenotype. Mutation of a p53 homologue, p63, was found
in a HNSCC line of epidermal origin although p53 was also mutated in the line
preventing determination of whether the mutation was relevant to the
development of the tumour (Osada et al., 1998). Conversely, the p63 locus,
3q28, was shown to be over-represented in HNSCC tumours, which itself is
generally indicative of gene amplification, although both p53 status and stage
were unknown (Yamaguchi et al., 2000). Clearly the role of p63 in HNSCC
requires further demonstration to determine what role, if any; it plays in this
cancer progression (see Section 3.2). The putative tsg p33'NG1 which has
been functionally linked into the p53 pathway did not demonstrate any
somatic mutations in a HNSCC study suggesting it may not have a role in
these tumours (Sanchez-Cespedes et al., 2000) although a further study
found 8% (3/34) of HNSCC analysed possessed missense mutations of the
gene (Gunduz et al., 2000). The low number of mutations demonstrated
would suggest that the position of p33'NGl in HNSCC development is far from
clear although does not seem to be a critical factor. Furthermore in studies of
HNSCC lines normal pRS activity was present (Loughran et al., 1996)
although LOH was shown frequently at 9p21 suggesting inactivation of the
G1/S phase transition checkpoint mechanisms through abrogation of p161NK4A
(Loughran et al., 1994; Reed et al., 1996). The p16'NK4A gene has been
shown to be deficient in a number of HNSCC lines through mutation (Yeudall
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et al., 1994; Zhang et al., 1994; Reed et al., 1996) and homozygous deletion
(Loughran et al., 1994; Cairns et al., 1995; Munro et al., 1999). The
oncogene c-myc was shown to be frequently amplified in HNSCC however
this is at odds with later studies and therefore should be interpreted with
caution (yokota et al., 1986). The overexpression of EGFR has been
associated with SCC tumourigenicity (Santon et al., 1986) and suggested to
be necessary for SCC derived cell lines (Modjtahedi et al., 1993) however a
study using 10 HNSCC lines found no obvious correlation between elevated
levels of EGFR and tumour progression (Stanton et al., 1994) and no link with
EGFR expression. Analysis of oncogenes in the same HNSCC lines found no
ras mutations (Clark et al., 1993) and no c-myc amplifications (Agochiya et al.,
1999) although a consistent increase in cyclin D1 was observed (Nikolic,
1993) which had no obvious relationship with EGFR expression. From these
observations it is clear that the same critical pathways are subject to
abrogation in HNSCC tumour lines as would be expected in any advanced
tumour, that is a deregulation of the cell cycle through mutation and silencing
of the prominent tsg's that control the key regulatory pathways.
2) Role of Cellular Immortality in Human Cancer
2.1) Biological Examples
The phenomenon of cellular immortality has been described for a
number of advanced tumours, although not in every instance. Tumour
immortality has obvious clinical implications, as a consequence of the
accumulated genetic changes, which lead to greater likelihood of recurrence
following therapy and a general decrease in responsiveness to treatment.
The genetic changes, which occur in association with the development of
immortality, vary from cell type to cell type, although there are similarities,
which in some instances reflect the same critical genetic events.
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2.1.1) Melanoma
Normal melanocyte proliferation and differentiation disruption is thought
to arise and progress through the accumulation of genetic defects that lead
ultimately to the development of melanoma (Albino, 1995). The development
of malignant and immortal melanoma has been characterised through
accompaniment by key genetic changes, where although the exact order of
changes have not been characterised, which can be categorised into
approximate groupings; those necessary for neoplastic development, and
those necessary for immortal development. Immortal melanomas themselves
characteristically arise from the dermal infiltrating 'vertical growth phase'
rather than the 'radial growth phase' lesion. The reasons for this are not
completely clear although may be due to forced clonal selection through
immune response leading to increasing rates of mutation (Prehn, 1996).
Initial analysis suggested LOH at 9p and 10q were losses associated with
early stage melanoma lesion development whereas 6q, 18q, 1p, 11q, and 17q
were associated with melanoma progression (Walker et al., 1995). Paired
sample analysis went on to show that whereas LOH on 9p, 6q, 8p, and 18q
was found on both primary tumours and their respective metastasis in a
number of cases LOH of 6q, 11q and 7q was detected in the metastasis and
not in the primary tumours (Morita et al., 1998). Further evidence from
primary tumours and their metastases showed LOH at 9p21 was a common
event in neoplastic development and found additional allelic losses on 14q
and Xq which also reflected an early change (Rubben et al., 2000). Loss of
either p161NK4A or less frequently pRB accompanies sporadic melanomas
and cell lines derived thereof indicating the importance of this pathway loss for
the development of deregulated proliferation (Bartkova et al., 1996). The
association of the p 16NK4A gene with poor proqnosis in 'vertical growth phase'
melanoma and the early-stage losses of 9p21 suggest that in melanoma this
gene acts as a 'gatekeeper' (see Section 3.1) (Straume et al., 2000). This is
further reinforced by the frequent inactivation of p161NK4Ain familial melanoma
kindreds (Hussussian et al., 1994). Interestingly, virtually all immortal
melanoma lines have defects in the p16/pRB pathway (Walker et al., 1998).
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Conversely, 'vertical growth phase' tumours lacking p53 expression delivered
better patient prognosis indicating that mutation of this gene is likely to be a
later event in advanced tumourigenic development (Straume et al., 2000).
This evidence of accumulative LOH is indicative of a positive selection within
the tumour biased towards a propensity for accumulation of genetic
alterations. In immortal tumours this clearly may be a reflection of immune
response exposure along with p161NK4Aloss allowing advanced neoplastic
progression to occur. Although not all metastases are immortal these
changes must reflect the minimal possible changes accompanied by the
reactivation of telomerase (see Section 4.2.2) to achieve immortality.
2.1.2) Colorectal Carcinoma
The model of sequential alterations checked by the existence of
biological rate-limiting steps is illustrated in Section 1.2 by the well-understood
mechanisms behind the development of colorectal carcinoma. However,
further genetic events underpin the progression to immortality by the
carcinoma once developed. Through the development of an immortalised
non-tumourigenic epithelial cell line from a large pre-malignant colorectal
adenoma and subsequent observations the loss of chromosome 1 was
implicated in immortal development suggesting it may have been a rate-
limiting event in the development of this phenotype (Paraskeva et al., 1988).
A further implication from this study was that the acquirement of immortality
was a late event as the cell line was derived from a large adenoma and no
immortal cell line generation was seen from smaller adenomas. Further
karyotypic analysis detected abnormalities of chromosomes 1, 7, 14, 17, 18,
and 22, which had occurred in premalignant adenoma cell lines. The
observation that colon adenomas of <1crrr' are rarely capable of infinite
growth in vitro whereas adenomas of >1ern" are often immortal (Paraskeva et
aI, 1988; 1989) confirms the idea that the accumulation of changes through
lifespan can be sufficient to achieve immortality.
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2.1.3) Bladder
The process to immortalisation is well characterised as resulting from
recessive changes, through loss of gene function, leading to deregulation of
proliferation and DNA-repair control. However, dominant alterations can also
contribute to immortalisation as evidenced in bladder cells where amplification
of 20q in SV40 E7-infected cells resulted in a mortality bypass and the
development of the immortal phenotype (Savelieva et al., 1997; Cuthill et al.,
1999). Therefore in this instance a dominantly acting oncogene has enabled
a bypass of mortality into immortality. Further analysis of bladder cell lines
showed that certain losses; 3p14, 8p21, 11p15, 13q14, and 17p13 (Presti et
al., 1991; Hubuchi et al., 1993; Knowles et al., 1994), correlated with late-
stage disease whereas others were grade and stage independent; 9q (Ross
et al., 1996). Inactivation of tsg's in TCC pathogenesis is best characterised
for pRB (13q14), p16 (9p21) and p53 (17p13) (Presti et al., 1991; Xu et al.,
1993; Esrig et al., 1994; Spruck et al., 1994; Cairns et al., 1995).
Interestingly, where immortal TUC lines do not contain a p16'NK4A alteration,
they show a pRB alteration (Yeager et al., 1995), which demonstrates that
abrogation of the same pathway results from these separate alterations. The
critical alteration in TCC immortalisation can be either pRB or p16 loss
accompanied by one additional alteration, such as amplification of 20q11-q12,
or loss of either 3p13-p14 or 8p21-pter (Yeager et al., 1998). Recent data
also suggests most immortal TCCs also carry defects in the p53/ARF pathway
(Sarkar et al., 2000).
2.1.4) HNSCC
In line with the studies described earlier it was shown that immortality
of HNSCC is recessive to a mortal phenotype (Berry et al., 1994) suggesting
the inactivation of tsg's in the immortal lines. Mutation of p53 has been shown
to be a common (45-90%) feature of immortal HNSCC lines (Hollstein et al.,
1991; Sakai and Tsuchida, 1992; Boyle et a/., 1993; Burns et al., 1993)
although non-immortal neoplastic cultures usually possess an unaltered copy
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of the gene (Burns et al., 1994). Immortalisation is usually accompanied by
loss of p53 activity therefore, perhaps unsurprising was the demonstration
that p53 mutation, but not overexpression, correlated with decreased median
patient survival (Mineta et al., 1998), as this is indicative of a replicative
senescence bypass. The p16'NK4A gene was shown to be expressed normally
in senescent neoplastic cultures (Loughran et al., 1996) demonstrating the
necessity of its inactivation for cellular immortality of these cells. The
generation of an immortal phenotype is considered to be a late event in the
progression of HNSCC that may be indicative of a late, rather than an early,
acquirement of a genetiC change in malignant progression. LOH was not seen
at 3p13-cen, 3p21, 3p25-ptel, 9p21, 9q22.3 and 13q14 in senescent cultures
demonstrating these losses as being a later event in tumourigenesis
(Edington et al., 1995). The implication in the development of immortality in
HNSCC is the necessary abrogation of the 'gatekeepers', p161NK4Aand p53,
along with deregulation of the enzyme telomerase (see Section 4.2.2)
accompanied by accumulative changes through advanced progression.
Mutation of pRB is an infrequent event in HNSCC development with G1/S
phase dysregulation tending to occur through p161NK4A(Lang et al., 1998). In
the presence of constitutive p53, E2F-1, and p21CIP1 expression telomerase
was not sufficient to rescue HNSCC lines from apoptosis further
demonstrating the necessity of these pathways abrogation's (see Section 3) in
HNSCC immortality (Henderson et al., 2000). However, unlike melanoma,
bladders, and colon cancer where immortality is a late event, some HNSCC
that pass through a pre-malignant dysplastic stage, show immortality (Dr. F.
McGregor, BICR, unpublished data). This may suggest two distinct forms of
HNSCC where the timing of immortality is different (Edington et al., 1995)
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3) Tumour Suppressor Genes
Immortalisation
Inactivated in
3.1) Gatekeepers and Caretakers
The observations that similar genes were undergoing
inactivation in neoplastic development led to the development of the
theoretical grouping proposed by Kinzler and Vogelstein (1997). The main
proposition of this theory was that genes which were involved in proliferation
control would operate as 'gatekeepers' whereas those concerned with
maintaining genetic integrity could be classified as 'caretakers'. The
inactivation of a 'gatekeeper' would result in inappropriate proliferation and
tumourigenic development whereas caretaker inactivation would lead to an
increasing propensity to acquire new mutation and hence the potential for
increasing neoplastic potential. The idea of 'gatekeepers' providing a rate-
limiting step to tumourigenesis is illustrated in colon cancer and
retinoblastoma by APe (see Section 1.2) and pRB (see Section 3.3)
respectively. Through tumourigenic development other mutations are clearly
accumulated although they are not sufficient to initiate the process (Garber et
al., 1991; Jen et al., 1994). Loss of caretaker gene function on the other hand
is not sufficient for tumourigenesis although it can increase the likelihood of
this occurring through acquirement of further changes. Examples of
'caretaker' genes include the nucleotide-excision repair genes responsible for
xeroderma pigmentosum (XP), ATM which is responsible for ataxia
telangiectasia, and BReA 1 and -2 (Breast cancer) which are responsible for
familial breast cancer susceptibility (Sharan et al., 1997).
Regulatory genes whose functions are commonly lost through LOH,
mutation, and promoter silencing have frequently gone on to be characterised
as tsg's whose loss has deregulated cell cycle control and hence allowed
uncontrolled proliferation of a cancer cell. These genes therefore fit the
designated assignment of 'gatekeepers'. The best-characterised tsg's are
perhaps p53, pRB and p16'NK4A, although, due to the increasing complexity of
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cross talk, in many senses they can be described as being on the same
pathway although functioning in distinctly different manners. p53 itself acts as
a transcription factor in response to DNA damage, induced by a number of
different agents leading to a block in the cell cycle until the damage is
repaired, or alternatively, driving an unrepairable cell into apoptosis (Lane,
1992). pRS acts as both a transcriptional activator and repressor dependant
on its phosphorylation state and through this function exerts control on G1/S
phase progression. p161NK4Aacts as an inhibitor of the cyclin/cdk complexes
that phosphorylate pRS turning it into a transcriptional activator and primarily
functioning as a negative regulator of the cell cycle. Therefore all three
proteins exert a control on the G1/S phase of the cell cycle and are sufficient
to induce a growth arrest at this stage. That abrogation of some or all of
these three genes is important in tumourigenesis is evidenced by the
observation that where DNA tumour virus infection has taken place no
abnormalities are found in these genes although in all other cell lines a degree
of inactivation has occurred (Whitaker et al., 1995).
3.2) p53; 'Guardian of the Genome'
3.2.1) p53 as a Gatekeeper
One of the first two tsg's cloned p53 reinforces many of the ideas
concerning the classical tsg. The evidence that a p53-germline mutation
resulted in Li-Fraumeni syndrome (LFS), an autosomal-dominant inherited
predisposition to multiple cancer types, suggested that p53 fitted the definition
of the 'gatekeeper' gene (Li and Fraumeni, 1969; Lustbader et al., 1992).
Before cancer progression in kindreds the second p53 allele must be lost in
an approximation of Knudsons model (see Section 1.1) Le. through LOH or
somatic mutation. Situated on 17p13 the p53 gene encodes a nuclear
phosphoprotein transcription factor with a plethora of target sites and
interacting molecules. However, the two major functions of p53 are the
negative regulation of the cell cycle and the induction of apoptosis. The p53
negative regulation response is seen due to DNA-damage caused by y-
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irradiation, u.v-irradiation, hypoxia, or carcinogens. The molecule itself can
detect and bind to damaged DNA through its C-terminal domain resulting in
further p53 activation, increase in p53 protein levels and activation of
downstream target genes by the transcription factor activity of the protein.
The C-terminal domain itself can also interact with a number of DNA repair
proteins including the XP-B and XP-D components of TFIIH (Wang and
Prives, 1995) and the Rad51 protein (Buchhop et al., 1997) demonstrating a
great utility of domain function. Many of the target genes are components of
cell cycle arrest machinery at both the G1IS and G2/S checkpoints further
evidenced by p53-dependant arrests at both of these phase transitions. This
suggests that loss of p53 function would lead to compromised cell cycle
checkpoints allowing survival of DNA-damaged cells and leading to
accumulation of sufficient genetic 'hits' to potentially initiate tumourigenesis.
Cells lacking a functional p53 fail to arrest in G1 following induced DNA
damage (Kastan et al., 1991; Kuerbitz et al., 1992; Bond et al., 1994) although
re-introduction of wild-type p53 leads to G1 arrest in such cells (Baker et al.,
1990) clearly demonstrating p53-dependance. The role of p53 is less clear in
G2 arrest as cells lacking a functional copy can still undergo this form of
growth arrest (Passalaris et al., 1999) although the various isoforms of p53
may have some role in this ability (see below) and therefore redundancy
cannot be ruled out. It is perhaps unsurprising then that cells from individuals
suffering from the rare inherited heterozygous p53+/· Li-Fraumeni syndrome
(Li and Fraumeni, 1969) which carries a predisposition to several cancer
types occasionally undergo spontaneous immortalisation with loss of the wild-
type p53 allele (see Knudson's model) (Rogan et al., 1995; Shay et al., 1995)
having lost both regulatory control of the cell cycle and the key mechanism to
initiate repair genetiC damage or remove critically damaged cells.
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3.2.2) p53; Structure and Effector Molecules
A feature of p53 is its multiple, unique, functional domains including the
NH2-terminal transactivation domain (TD), the sequence-specific DNA-
binding domain (DBD) necessary for transcription transactivation, and the
COOH-terminal domain containing the oligomerisation domain (OD) and the
apoptotic domain (Wang et al., 1996); or DNA-damage domain (Reed et al.,
1995). Covalent regulation of p53 occurs by phosphorylation, 0-
glycosylation, and acetylation at multiple sites throughout the gene in all
domain structures (Prives and Hall, 1999). Stimuli for covalent regulation are
shown in Figure 1.3. Transcriptional activation targets of p53 include those
associated with growth control and cell cycle checkpoints; p21wAF1/CIP1/SDI1(EI-
Deiry et al., 1993), WIP1, MDM2, GADD45, EGFR, PCNA, cyclin 01, cyclin
G, TGF-f3, and 14-3-30; DNA repair; GADD45, PCNA, and p21wAF1/CIP1/SDll;
and apoptosis; BAX (Miyashita and Reed, 1995), BCl-Xl, FAS, IGF-BP3
(Rajah et al., 1997), PAG608, XPB, XPD and DR5 (Nagane et al., 1997;
Admundson et al., 1998; levrero et al., 2000). Although these transcriptional
targets have been targeted into appropriate functional groupings it should be
noted that redundancy of molecules exists and in inappropriate situations will
perform atypical roles. Further mutual control exists with the tsg p331NG1
where the presence of both tsg's is required for either to function properly
(Garkavtsev et al., 1998). Clearly p331NG1cannot be said to be under p53
transcriptional control but more accurately transcriptional targets of both are
under a form of unspecified mutual control. DNA binding by p53 is optimal
when the protein is in a tetrameric state where binding occurs via the OD of
four p53 molecules (Jeffrey et al., 1995). Although the tetrameric state is the
optimal configuration wild type protein complexed with mutant protein can be
sufficient for inactivation. The binding of p53 to p300/CBP regulates its ability
to bind cognate sequences and activate transcription and also provides a
platform for the MDM2 degradation complex to form and is therefore
necessary for normal function. The ubiquitin-like protein, SUMO, has also
been shown recently to have p53 binding and activation properties (lohrum
and Vousden, 2000), which suggests that it may form part of the p300/CBP
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Figure 1.3. Signals leading to the modification
and activation of p53
Schematic of p53 activation signals, accessory proteins and molecular
endpoints.
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platform. Transcriptional repression targets of p53 feature both cellular and
viral promoters, which do not necessarily contain p53-binding sites, include
bcl-2 (Miyashita et al., 1994), c-fos and SV40 large T antigen. Conversely
p53 is a target for inactivation itself by a number of virally encoded proteins
including SV40 large T antigen, HPV E6, HBV X antigen, and adenovirus E1a.
Clearly there are a number of further cascades of activation in response to
p53 activation although viral removal of p53 negative regulation of the cell
cycle allows unchecked cell proliferation and virus particle production
demonstrating the importance of its functional removal. Therefore in
response to DNA damage recognition p53 regulates expression of a number
of genes that can either arrest a cell until the damage is repaired or prompt
the cell to apoptose. The p53-responsive gene p21c1P1 is an inhibitor of
cyclin/cdk complex formation at the G1 phase and therefore also exerts
control over pAB phosphorylation (Dimri et al., 1994). This is evidenced by
the observation that deletion of p21c1P1 in human fibroblasts prevents
senescence although is not sufficient to bypass crisis (Brown et al., 1997).
However, in p21c1P1_nullmice development is normal with no evidence of
malignancy which itself suggests no prevention of senescence (Deng et al.,
1995). This was further evidenced by the demonstration of p21c1P1-nullmice
derived fibroblasts, which underwent senescence (Pantoja and Serrano,
1999). These observations indicate mechanistic differences between murine
and human systems such that p21c1P1is an effector of senescence in the
human model, although in the murine model it may be redundant through
distinct molecules carrying out similar processes. This model was greatly
enhanced recently with the observations that G1-arrest in senescence was
p21c1P1-dependentand that in p21c1P1-nullMEFs (Mouse embryo fibroblasts)
the cells had lost the ability to instigate a G1-arrest senescence and instead
underwent a crisis-like death instigated through continued divisions whilst
assuming the appearance of a senescent culture (Dulic et al., 2000).
Therefore, both in the murine and human system p21c1P1is required for
appropriate senescence although in humans the p53-induced response is
stronger than that seen in the murine model. The oncoprotein MDM2 can
inhibit both p53 and pAB although under p53 transcriptional control it operates
in an autoregulatory feedback loop (Ko and Prives, 1996). Once transcribed
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MDM2 binds to the transcriptional activation domain of p53 and blocks the
regulatory function whilst also promoting the rapid reduction of protein levels
through promotion of degradation by ubiquitin complexes (Prives, 1998). In
fact MDM2 acts to transport p53 from the nucleus to the cytoplasm (Honda et
al., 1997) where MDM2 functions as an E3 ubiquitin ligase catalysing p53
degradation (Roth et al., 1998). Discussed in more detail below is the further
example of cross talk provided by the observation that p14ARFregulates p53
and is encoded by a sequence overlapping with p161NK4Awhich negatively
regulates pRS. Over 5000 published p53 mutations in both tumours and cell
lines have been identified indicating the importance of the gene to cellular
integrity (Souza et al., 1997; Hainaut et al., 1998; Lu, 2000).
3.2.3) p53 Homologues
For a number of years p53 was thought, perhaps surprisingly given the
important role it performs, not to belong to a gene family unlike the situation
seen with both p161NK4Aand pRB. However that situation is now clearer with
the identification of a number of homologues with some conservation of
function between members. Evolutionarily the identification of an invertebrate
p53 homologue was indicative of an adaptive history even though there is
very little functional data to accompany the much longer mollusc version
(Soussi and May, 1996). The remaining family members, p73 (Kaghad et al.,
1997) and p63 (Schmale and Bamberger, 1997), both encode multiple
polypeptides (p73 has 6 variants, p63 has 14 variants) all of which share
functional domains with p53 although not every domain in every instance
(Lohrum and Vousden, 2000) (Figure 1.4). All members of the p53 family do
contain the TO, a DSD, and OD. The highest levels of homology are found in
the DBD suggestive of common targets although demonstrating homology in
the OD only homo-oligomers have been shown to form with no hetero-
oligomers observed (Levrero et al., 2000). An observation from SAGE
analysis suggests that 6/36 p53-induced transcripts are induced by a p73
isoform (yu et al., 1999), which is suggestive of homologue-specific targeting
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Figure 1.4. Structural isoforms of p53 share
similar domain structures and possess
distinct motifs
Cartoon illustrating similar domain structures of p53 and isoforms p63 and
p73.
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although it is not clear what the activated transcripts function as. Additionally
these homologues have considerably longer C-terminal domains that contain
a protein-protein interaction domain called a sterile alpha motif (SAM) (Chi et
al., 1999) this domain is also found in mollusc p53. The SAM domain is found
in proteins that regulate development although those found in p63 and p73 do
not mediate homo- or hetero-dimerisation. Although these homologues share
a number of features of the perhaps evolutionarily refined p53 no convincing
mutations of either homologue has been identified and therefore they are not
likely to be bone fide tsg's as first postulated (Prives and Hall, 1999). The role
of p63 in fact may be more concerned with correct development, whilst p73
may also be concerned with this function and with a slight tumour suppressive
capability. Furthermore, viral oncoproteins known to inhibit p53; SV40 Large
T, HPV-16 E6, and E1B 55kDa; do not inhibit p73 although adenovirus
E40RF6 does though through a conserved domain and therefore not
specifically targeting it, this would suggest that p53 is the primary cellular
target (Levrero et al., 2000). Of great interest is the observation that a
particular p53 sequence polymorphism which seems to play a role in the
ability of p53 to inactivate p73 is more frequently altered in some cancers (Di
Coma et al., 1999) which is suggestive of a preferential inactivation although
the specifics behind this are not clear. Further functions of p73 were
highlighted recently with the demonstrations that where p53 was abrogated
E2F-1 could still induce apoptosis although through activation of p73, whereas
in T-cells E2F-1 could induce apoptosis in a p53-independent manner which
operated through the activation of p73 (Lissy et al., 2000; Irwin et al., 2000).
This is perhaps unsurprising as both molecules share a great deal of
structural homology and familial conservation, clearly a great deal is still to be
learnt about this family structure. There are two human homologues which
were identified simultaneously; p40, was identified which shared strong
conservation with the DBD although functionally its role remains unclear
(Trink et al., 1998) and p63 (p51), which shares greater homology with a p73
homologue in the key functional domains (Osada et al., 1998). Although p63
shares greater homology with p73 it shares to a lesser degree characteristics
of p53 such as suppression of colony formation, apoptotic death, and p21
promoter transcriptional activation. There is now no doubt that p53 belongs to
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a family of similar molecules of which examples are found further down the
'evolutionary tree'. However these identified homologues do not fulfil the
majority of the p53 functions and may therefore be earlier models of the
protein, which through progressive 'gain of function' mutation and
recombination have given rise to the current version of the negative regulator
of the cell cycle. Clearly work remains to be done in this area that should
provide a great deal of further information on the degrees of redundancy that
exist between family members.
3.3) p16 and pRB; G1/S Checkpoint Control
Although p53 exerts control over both G1/S and G2/S, although not
absolutely in the case of the latter, a further control exists at the G1/S
checkpoint prior to the initiation of DNA synthesis. The pathway central to the
regulation of the G1/S phase transition of the cell cycle is characterised by
four genes, at least one of which is mutated in many forms of cancer, p16-
eyelin D1-CDK4-pRB. In some tumour forms, p161NK4 dysfunction is the
common mechanism leading to inactivation of the pathway, Le. NSCLC,
although pRS inactivation is preferred in others, Le. SCLC, but generally both
are not inactivated in immortal cell lines (Whitaker et al., 1995). It is also clear
that other members of this pathway can contribute to or provide the
dysfunctional step in the pathway.
3.3.1) Cloning of pRB
The path to the identification and cloning of the proto-tsq, pRB,
provides an interesting insight into the scientific process. Retinoblastoma is
an autosomal dominant hereditary ocular tumour that occurs in childhood.
The postulate made by Knudson (1971) was to suggest that this heritable
cancer was due to recessive, loss of function mutations occurring in a putative
tsg. This theory proposed that the familial transition of a germ line mutation
complemented by a further somatic mutation would be sufficient to initiate
tumourigenesis. Knudson hypothesised that in instances were no familial
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precedence existed two separate somatic mutations would be necessary to
initiate tumourigenesis. This formulated the basis behind the now famous
Knudson 'two hit' hypothesis, which is now accepted as the paradigmatic
model behind tsg silencing. The discovery of individuals with inheritable
retinoblastoma and deletions at 13q14 provided the evidence required to
demonstrate the first 'hit' (Yunis and Ramsay, 1978), this was followed by the
demonstration of LOH at 13q14 arising through chromosome loss, deletion,
mitotic recombination or gene conversion in both familial and sporadic cases
which provided the necessary evidence for the second 'hit' (Cavenee et al.,
1983; Knudson, 1978). The isolation of pRS was undertaken after the
discovery of a homozygous deletion on 13q14 enabled the identification of
sequences expressed in normal retinoblasts but missing from retinoblastomas
(Friend et al., 1986). Through this identification, and demonstration of
reversion of tumourigenic properties in cell culture by the normal cDNA, pRB
was identified as a bone fide tsg (Friend et al., 1986). Aside from
retinoblastoma tumours mutations of pRB have now been found in a number
of different tumours including EC, sarcomas, SCLC, bladder carcinomas and
breast carcinomas (Horowitz et al., 1993; Lee et al., 1999; Lu, 2000).
3.3.2) pRB Function and Effectors
The pRS protein is a ubiquitously expressed, 105 kDa nuclear
phosphoprotein which when hypophosphorylated binds to and controls a
number of cellular proteins and transcription factors (E2F family) which are
essential for G1/S phase transition, pRS also antagonises transcription factor
complexes essential for S phase entry (see Figure 1.5). The phosphorylation
of pRS results in an inactivation of its binding ability to transcription factors
allowing release and appropriate transcription to occur prior to entry into S
phase. The phosphorylation of pAS is due to cyclin D1/cdk4 and other
cyclin/cdk complexes (Sherr, 1994; Lundberg & Weinberg, 1998) that lift the
inhibition of G1/S transition progression. Therefore a failure to phosphorylate
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Figure 1.5. Regulation of pRB during the mitotic
cell cycle through phosphorylation (P) by
cyclin/cdk complexes releasing transcription
factors (E2F)
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pRB would result in a G1 block, a block on de novo DNA replication, and the
potential to enter senescence (Stein et aI, 1990). Dephosphorylation of pRB
occurs through protein phosphatases (type 1) (PP1) (Berndt et al., 1997)
allowing repression of target transcription factors, PP1 activity is regulated by
cdk phosphorylation (Ludlow and Nelson, 1995), which inactivates the
enzyme. This is indicative of a level of feedback control in pRB
phosphorylation where the same molecule operates in a regulatory loop
controlling both inactivation and activation of the protein, which is evidenced
throughout these cell cycle regulatory proteins. A further transcriptional
repression exerted by pRB is weighed on all three classes of nuclear RNA
polymerases (Pol I, Pol II, and Pol III) demonstrating obvious relevance to its
G1/S phase transition blocking role. A number of DNA tumour viruses
inactivate pRB as an early consequence of infection to deregulate the cell
cycle such as SV40 (T antigen), adenovirus (E1A), and high risk HPV (E7) all
of which are capable of inducing tumourigenesis. As seen with p53 this
demonstrates the importance involved in removal of the pRB protein to
deregulate the cell cycle allowing unchecked production of viral particle. Two
structurally and functionally related members of the pRB gene family have
also been identified; p107 and pRB2Ip130, and implicated to have an role,
albeit unclear in tumourigenesis (Mulligan & Jacks, 1998) although all three
proteins can induce a G1-arrest when over expressed (Zhu et al., 1993; Lukas
et al., 1995; Qin et al., 1992) and have been observed to display
combinatorial effects on G1 progression block effects (Classon et al., 2000).
The proto-oncogene CCND1/PRAD1/BCL 1 located on chromosome 11q13
encodes cyclin D1 and its amplification is seen in a number of types of
tumours. Therefore as cyclin D1 associates with cdk4 to phosphorylate pRB
this amplification could be an alternative mechanism to pRB growth control
disruption.
3.3.3) INK4A Locus
Situated in chromosome 9p21 is the negative cell cycle regulator
p 16'NK4A/CDKN2IMTS1, not only is 9p21 allele loss frequently observed but
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mutations in the gene and transcriptional silencing through promoter
methylation are common in a wide range of cancers (Okamoto et al., 1994;
Loughran et al., 1994; Cairns et al., 1995; Loughran et al., 1996; Reed et al.,
1996; MacGrogan and Bookstein, 1997; Wong et al., 1997; Sharpless and
DePinho, 1999; Lu, 2000). The p 16NK4A gene is encoded by three exons (1a,
2, and 3) however at the same locus a second gene p14ARF, murine pUfRF,
(Quelle et al., 1995) is transcribed using an alternative first exon which lies 5'
to exon 1a and then spliced onto exon 2. A second reading frame is used on
exon 2 so that p14ARFshares no sequence homology with p161NK4Aand does
not share any cdk-inhibitory activities; the locus structure is shown in Figure
1.6. The protein itself is a cell cycle modulator that regulates pRB function by
inhibiting cyclin D1/cdk4 activity; through inhibition of cdk4 kinase activity
(Serrano et al., 1993; Koh et al., 1995), and thereby preventing the alleviation
of the hypophosphorylated pRB block on G1/S phase transition.
Transcriptional repression of p161NK4Ahas been shown to occur through pRS
suggesting a regulatory feedback loop also involving the cyclin-dependant
kinases (Li et al., 1994), which operates in the normal cellular environment.
Where LOH of 9p21 occurs methylation of the 5' CpG island on a remaining
allele is sufficient to down regulate the gene thereby preventing activity
providing an alternative mechanism to Knudsons 'two-hit' paradigm.
Mutations have been demonstrated in several tumour types, which specifically
affect p161NK4Aand not p14ARF(Munro et al., 1999; Sharpless and DePinho,
1999) in fact no reported point mutations of p14ARF have occurred which are
predicted to affect its functional domains. A solitary silent mutation in
p16NK4A, which alters p14ARF, has been reported, although this does not occur
in a conserved region and as such is probably a polymorphism. Further
observations suggest that exon 1~ contributes most if not all of the domain
functions of p14ARF.A keratinocyte study found no detectable p14ARFprotein
in senescent cells suggesting that its involvement in this process may be
minimal (Munro et al., 1999). However p14ARF does possess tumour
suppressor characteristics in murine models and therefore may reveal
relevance to the human system although perhaps will not have such
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Figure 1.6. Structure of the INK4 locus
Cartoon illustrating the structure of the INK4A locus at 9p21, the
organisational relationship of p14ARF, p15'NK4B, and p161NK4A, and the
functions of their gene products.
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significance as p53, pRB, and p161NK4A.p14ARFitself undergoes upregulation
in response to mitogenic stimuli response genes such as E1A, myc, ras, V-
abl, and E2F-1, which leads to p53 stabilisation and therefore permits
appropriate G1/S arrest or apoptosis to occur in the instance of mitogenic-
induced inappropriate proliferation (Palmero et al., 1998). Mitogenic stimuli
such as ras and raf when constitutively activated have been demonstrated to
induce senescence in human fibroblasts with a correlatory production of
p161NK4Aand p53. This is perhaps an unsurprising result given that
constitutive activation could cause a deregulation of the cell cycle and a
resultant drive into senescence caused by p161NK4Ainhibition of pRB
phosphorylation and p53 upregulation in response to increased sequestration
of MDM2 by the hypophosphorylated pRB (see below) rather than a direct
p14ARF-mediatedgrowth arrest.
3.3.4) Cdk-inhibitory Genes
There are other cdk inhibitory genes, which share some degree of
functional similarity with p161NK4Aalthough most work has focused on that
family member. One of these is p1SlNKB that lies centromeric to p16'NK4A and
shares about 70% amino acid similarity and although co-deletion of these
genes frequently occurs events specifically targeting p 1SlNK4B were shown to
occur rarely (Izumoto et al., 1995; Kamb et al., 1994; Flares et al., 1996),
although methylation silencing of p151NK4B has been recorded in HCC (Wong
et al., 2000). A role for p151NK4Bwas demonstrated in G1-arrest in response
to TGF-j3, which itself is indicative of a response through an alternative
pathway to p161NK4A(Hannon and Beach, 1994). Two other family members,
p1SNK4C and p19'NK4D, have not been shown to be mutated and therefore are
not likely to be important for tumourigenesis (Batova et al., 1997). All of this
family specifically inhibit cyclin D-associated kinases (Parry et al., 1995).
Similarly, only rare mutations of the p21cIP1IWaf1/sdi1 family members, p2rlP1 or
psrlP2, have been demonstrated although the former may be downregulated
in some cancers (breast, prostate, colon, gastric, lung, and esophageal
(Tsihlias et al., 1999) and the latter, situated at 11p15, was found to be
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maternally imprinted and downregulated through LOH of one allele copy in
cancer predisposition cases studied (Nijjar et al., 1999; Lee et al., 1999). This
kinase inhibitory protein family bind and inhibit cyclin E/cdk2 and cyclin Ncdk2
complexes (Sherr and Roberts, 1995) suggesting an active role in late G1 and
S-phase regulation.
3.4) Cross talk
As alluded to above pRS can form a trimeric complex in vivo and in
vitro with p53 and MDM2 (Hsieh et al., 1999), which is a clear example of the
cross-talk complexity that exists at the molecular level. The antiapoptotic
function of MDM2 on p53-induced apoptosis is overcome by pRS in this
instance. This occurs through pRS binding to MDM2 through its conserved C
pocket domain (Xiao et al., 1995), the same domain which interacts with E2F1
(Weinberg, 1995) and c-abl (Welch and Wang, 1993) which in turn prevents
MDM2-mediated p53 degradation although it does not de-repress p53-
mediated transactivation or alleviate p53-mediated transrepression
suggesting important differences to these two mechanisms. Interestingly
MDM2 can stimulate the transactivation function of E2F1 , which could in turn
be due to the MDM2-pRS interaction (Xiao et al., 1995). E2F1 itself has been
shown to be an upstream mediator of p53-mediated apoptosis (Pan et al.,
1998) and a transcriptional activator of p14ARF suggesting the transcription
factor has a wide range of activities, which may be under dual control of both
pRB and p53-mediated MDM2 transcription. MDM2 itself binds to the
hypophosphorylated form of pRS (Xiao et aI., 1995) suggesting binding
occurs in early G1 sequestering MDM2 and allowing p53-mediated apoptosis
to progress. MDM2 amplification has been shown in primary tumours (Oliner
et al., 1992), which could be beneficial to tumourigenesis through preventing
the p53 apoptotic response by elevating the p53-degradation. MDM2 and the
alternative transcript from INK4A gene provide a further example of cross talk
again. p14ARF itself can bind to MDM2 through its exon 1(3-encoded domain
and thereby prevent the cytoplasmic degradation of p53 (Pomerantz et aI.,
1998) through promoting the degradation of MDM2 (Zhang et al., 1998). This
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action permits stabilisation and p53-mediated apoptosis or growth arrest to
occur depending on the cellular situation. Therefore, two genes encoded from
the same locus can separately effect the regulation of two important tsg's
(Figure 1.7). The p21c1P1cdk inhibitor can also provide some interaction
between the pRS and p53 regulatory pathways due to its inhibitory effects on
pRS phosphorylation and its status as a transcriptional target of p53
(Weinberg, 1995). The underlying basis of regulatory cell cycle progression
control could therefore be described as being dependant on two key tsg's,
pRS and p53, and the molecular cross-talk which exists between them and its
mediation by a number of key molecules.
4) Biological Mechanisms of Replicative Senescence
Replicative senescence and crisis (alternatively known as M1 and M2)
are both examples of potential intrinsic tumour suppressor mechanisms as
both provide blocks to the proliferative lifespan of divisive cells. Replicative
senescence differs from crisis in that it is an obligatory default end-point of
replicative lifespan in response to progressively shortening telomere ends and
perhaps other undefined signals. Replicative senescence therefore acts to
prevent the cell accumulating sufficient genetic damage through unrestrained
proliferation coupled with genetic instability to instigate tumourigenesis. Crisis
is characterised as an apoptotic response to appropriate signals, such as
critically short telomeres. Crisis is perhaps not a tumour suppressor
mechanism as such in that unless the cell has bypassed replicative
senescence and carried on dividing its telomeres can't shorten sufficiently to
induce apoptosis. The proposition that the end-point replication problem of
telomeres and hence their progressive shortening could be linked to the
behaviour of cells in replicative senescence and crisis was first postulated by
Cooke and Smith (1986). Although crisis is a response to a senescence
bypass it occurs as a by-product of the uncontrolled proliferation, rather than
as a controlled response to the prolonged lifespan. However replicative
senescence and crisis, although referred to as unassociated processes, in
physiological terms, overlap significantly as evidenced by the appearance of
41
Figure 1.7. Figurative description of cross-talk
described in section 3.4
Flow diagram describing molecular cross-talk between p53 and pRS mediated
by effector molecules. Lines ending in horizontal bars indicate a repression
by the molecule from which the line originates.
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dicentric chromosomes, chromosomal fragments and endoreduplication in the
later stages of senescence (Saksela and Moorehead, 1963; Yanishevsky and
Carrano, 1975; Benn, 1976; Bayreuther et al., 1992). This is perhaps
unsurprising, given the asynchronous nature of cell populations leading to
different growth potentials in different sub-populations. There are other
mechanisms, which are proposed to induce replicative senescence in
mammalian organisms such as calorific restriction and 'culture shock'
although neither has been demonstratively proven and accordingly may not
be immediately relevant to the human system. Models of senescence and
abrogation points are shown in Figure 1.8.
4.1) Replicative Senescence
The phenomenon of replicative senescence can be characterised
succinctly as a non-replicating, viable state where a block is present in the cell
cycle preventing progression from G1 to S phase therefore preventing de
novo DNA synthesis. Whilst held in the GO/G1 phase cells assume an
enlarged, flattened morphology with an altered gene expression and a general
increase in protein, RNA, glycogen, lipid, and Iysozymes with no increase in
DNA content (Harley et al., 1980). Senescent cells are therefore distinct from
terminally differentiated cells in that they undergo further differentiation
without division. The metabolic activity retained by senescent cells is such
that they can remain in culture for up 2 years in their non-divisive state
(Matsumura et al., 1979) and are therefore resistant to apoptosis. One of the
triggers for entry into senescence is probably due to the shortening of a
subset of telomeres such that they are no longer indistinguishable from DNA
damage prompting upregulation of cell cycle inhibitors p53 and p161NK4A
(Harley, 1991; Shay et al., 1991; Robles and Adami, 1998; Shapiro et al.,
1998) leading to a block prior to S phase entry. It is precisely this block in the
replicative lifespan that has led to the development of the hypothesis that
senescence may be a cellular tumour suppressor mechanism controlled by a
number of dominantly acting genes (Sager, 1989).
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Figure 1.8. Models of senescence and
immortalisation
Diagram illustrating the growth-arrest checkpoints, M1 (replicative
senescence) and M2 (crisis), in relation to cell population doublings and time.
Molecular events allowing escape from replicative blocks are indicated.
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Senescence of normal human fibroblasts was described initially as a
recessive trait overcome by fusion with the dominant immortal HeLa cell line
(Gey et al., 1952) although malignancy was recessive to the normal
phenotype in the same study (Stanbridge, 1976). However later studies
showed that senescence was the dominant phenotype and that recessive
changes in the abnormal cell resulted in cellular immortality (Pereira-Smith
and Smith, 1983). Senescence was also shown to be due to active
mechanisms rather than random 'weathering' effects in these studies,
perhaps most clearly where in cell-cell fusions between senescent cells with a
protein synthesis block and young cells the dominance of senescence was
alleviated indicating a probable mediation of senescence by proteins
(Norwood et al., 1974). Replicative senescence of cells in culture was first
documented in the studies of Hayflick and Moorehead (1961) where cells
were shown to enter a viable non-replicative state after approximately 60
population doublings in an asynchronous population. Furthermore, the
number of cell doublings remaining in a population was shown to be linked to
the sample donor age (Schneider and Mitsui, 1976), indicating some form of
replicative potential which was fundamentally intrinsic to the culture and not to
the culture system. Senescence itself was shown to be an intrinsic
mechanism of tumour suppression in normal cells (O'Brien et al., 1986)
although a mechanism which itself seems fairly open to abrogation. Sasaki et
al (1994) discuss the propriety of senescence as a tumour suppressive
mechanism by drawing parallels to the situation as it would occur in vivo.
They postulate that all of the changes necessary to accumulate for neoplastic
development, without loss or gain of lifespan potential, would turn an
individual cell into an approximate maximum of 5.4 X 108 (229 cells or 29
doublings). Devita et al (1975) suggest that a tumour comprising 230 cells
would be approximately 1ern" in size which itself would not exert an
immediate impact on lifestyle in a large organism.
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4.1.1) Replicative Senescence: Effector Molecules
An important mechanistic approach to study alterations in senescent
cultures was to examine them alongside serum-starved quiescent cultures.
Quiescent cultures will reinitiate DNA synthesis and re-enter the cell cycle
when serum stimulated whereas senescent cultures will not. From studies
such as these it became clear that senescent cultures had impaired c-fos
expression and therefore lacked full the S-phase requirement transcription
factor AP-1 expression (Seshadri and Campisi, 1990; Riabowol et al., 1992a).
Senescent cultures are also deficient in PKC and phospholipase 0 activation
that is likely to be due to elevated levels of ceramide (Riabowol et al., 1992b;
Venable et al., 1994). Senescent cells demonstrate repression of cell cycle
regulators cyclin A and cdc2 (Stein et al., 1991), DNA synthesising enzymes
such as PCNA, dihydrofolate reductase and histones (Pang and Chen, 1994)
E2F-1 (Oimri et al., 1994, E2F-5 (Good et al., 1996), and pRB remains
constitutively underphosphorylated (Stein et al., 1990). The bHLH (basis
helix-loop-helix) transcription factors Id1 and Id2 are also repressed in
senescent cells which combined with the observed immortalisation of
keratinocytes with a crisis bypass through telomerase reactivation stimulated
by Id family members (Alani et al., 1999) suggests a critical role in
proliferation control by this family (Hara et al., 1994). Functionally senescent
human fibroblasts and endothelial cells have both been shown to overexpress
interleukin-1 a whilst levels of TIMP-1 and TIMP-3 (Tissue inhibitors of
metalloproteinases) have been shown to rise in the former (West et al., 1989;
Millis et al., 1992; Wick et al., 1994) and ICAM (intercellular adhesion
molecule) overexpression has been shown in the latter (Maier et al., 1990;
1993), additionally, senescent mammary epithelial cells, normal fibroblasts,
and keratinocytes overexpress RAR~ (Retinoic acid receptor ~) (Swisshelm et
al., 1994; Si et al., 1995; Or F. McGregor, BICR, personal communication).
Further changes in senescent cultures are demonstrated by the presence of
large amounts of the G1 and G1/S phase cyclins complexed with the
respective cdk's, Cyclin D1/Cdk4 and Cyclin E/Cdk2, although lacking
catalytic activity (Dulic et al., 1993) probably due to elevated expression of the
48
ubiquitous cyclin/Cdk inhibitors p161NK4Aand p21CIP1(Noda et al., 1994;
Alcorta et al., 1996) although p161NK4Aaccumulates gradually whereas p21CIP1
undergoes rapid accumulation followed by a decline. This could be indicative
of p21CIP1initiating and p161NK4Amaintaining a senescent growth arrest state
(Stein, 1999). The candidate tsg p331NG1has also been shown to be
upregulated in senescent cells and to be an inducer of senescence
(Garkavtsev et al., 1998). The p53 growth inhibition induction cannot function
without the presence of p331NG1and vice versa demonstrating a critical
pathway to senescent arrest. The repression of p331NG1expression has been
observed in a number of metastatic breast cancers although it is very rarely
mutated in this and other tumour types (Toyama et al., 1999; Gunduz et al.,
2000; Sanchez-Cespedes et al., 2000), which would not rule out
transcriptional silencing in advanced tumours. The changes which occur in
senescent cells v's normal cells encompass a number of different pathways
and functional roles including the previously characterised negative regulators
of the cell cycle, mitogenic response elements, and structural elements
demonstrating a global cellular response once committed to the senescent
growth-arrest.
4.1.2) Replicative Senescence: Viral Abrogation
One clear mechanism to overcome senescence was demonstrated in
senescent HDF (Human diploid fibroblasts) where after infection with the
SV40 virus DNA synthesis was reinitiated (Gorman and Cristafolo, 1985).
The real observation behind this demonstration was that the cellular
machinery required for DNA synthesis was still intact although not functioning
during senescence. When the SV40 T antigen was placed under a steroid-
inducible promoter and infected cells nurtured carefully through crisis to
immortality upon removal of the steroid the immortal cells arrested in G1
(Wright et al., 1989). This demonstrated that although the T antigen could
sequester the proteins required for senescence growth arrest once released
p53 and pRS were still sufficient to block unrestrained proliferation. This
would suggest that other mechanisms aside the key genes for the senescent
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arrest to occur are p53 and pRB (and genes contained in the same pathway)
as both are functionally abrogated in tumours and targeted by specific
proteins from DNA tumour viruses.
4.1.3) Telomeric Basis of Replicative Senescence
Telomeres are composed of guanine-rich nucleotides that serve to cap
the ends of eukaryotic chromosomes when bound by a complex of proteins
and are maintained by the enzyme telomerase, itself a specialised reverse
transcriptase. The hexanucleotide repeat nAGGG represents the telomeric
sequence in humans and constitutes approximately 10 Kb at the end of each
telomere. The genome contains a number of intrachromosomal repeats
which are frequently associated with chromosomal fragile sites, these are
almost certainly evolutionary remnants of chromosomal fusions, but have also
been proposed as hotspots for recombination (Azzalin et al., 1997; Hastie and
Allshire, 1989). The telomere end replication problem is such that the
unidirectional DNA polymerases are not able to replicate the 3'-end of the
telomere leading to their progressive shortening through divisive lifespan
(Levy et al., 1992). Telomere end 3' overhangs generally consist of a variable
stretch of approximately 50-100 nucleotides (Greider, 1999). Early
observations suggested that the progressive shortening of telomere ends
might have a role in senescence (Olovnikov, 1973; Harley et al., 1990;
Allsopp et al., 1992) with the demonstrations that telomeres shortened by 50-
60bp per population (Harley et al., 1990; Counter et al., 1992) and that they
therefore over the course of a 60 population doubling lifespan they would
shorten by 3.6Kb. Senescent cell telomere has been reported to decline to
approximately 6Kb before precipitating growth arrest although this may not be
a ubiquitous cellular property (Allsopp et al., 1992), as this would assume a
common starting telomere length of approximately 10Kb, which may not be a
common feature of all telomeres. The demonstration that ectopic expression
of hTERT led to a halt and stabilisation of telomere degradation and length
and an immortalisation of primary human fibroblasts was perhaps the first
direct proof that replicative senescence was due, at least in part, to telomere
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shortening (Bodnar et al., 1998; Vaziri and Benchimol, 1998). The short
telomere recognition mechanism remains to be unravelled although
decreasing telomere length may not be sufficient to prevent chromosome
ends resembling a double-strand DNA break through failure in forming a 't-
loop' structure. Intriguingly, where the transient expression of hTERT
prolonged normal human fibroblast lifespan by 50% the telomeres at
senescence were shorter than those found in matched untreated senescent
cells (Steinert et al., 2000). This is indicative of either an elongation of the
shortest telomere to a matched average, or alternatively, of hTERT assisting
in the assembly of a stabilising telomeric 'scaffold'. The telomere end is
buried in a 't-Ioop' structure (Griffith et al., 1999) bound by a complex of
proteins, including TRF1 (TERF1 locus) (Chong et al., 1995), PIN2 (Protein
interacting with NIMA) (alternative splice product from TERF1) (Shen et al.,
1997), TRF2 (Chong et al., 1995; Broccoli et al., 1997), Tankyrase (Smith et
al., 1998) and TIN2 (TRF1-interacting nuclear protein 2) (Kim et al., 1999)
(Figure 1.9). Tankyrase and TIN2 both bind to TRF1 at the telomere end and
acts to regulate its activity in distinct manners, which serve to regulate
telomere length (van Steensel and de Lange, 1997) whilst TRF2 protects the
3' chromosome end which is buried in the 't-Ioop' structure (van Steensel et
al., 1998) and also plays a role in regulating telomere length (Smogorzewska
et al., 2000). TRF1 homodimerises prior to telomere binding where it induces
a shallow bend in the telomeric sequence, which could define the degree of
curve at the telomere end (Bianchi et al., 1999). The demonstration that cells
deficient in TRF2 underwent apoptosis in an experimental manner reminiscent
of a DNA-damage response reinforces the critical role of telomere end
protection within the cell (Karlseder et al., 1999). Shortened telomere ends
may not be able to successfully invade the loop, although may still be
protected by TRF2 preventing DNA-damage recognition, which could in itself
provide a senescence signal through inappropriate structure allowing
chromatin-condensation dependant transcription to occur. PIN2 is virtually
identical to TRF1 and forms both homo- and hetero-dimers with it and
demonstrates an upregulation in G2/M and a decrease in G1 (Shen et al.,
1997) suggesting it is linked into the mitotic phase of the cycle perhaps
assisting in telomere stabilisation and 't-Ioop' formation prior to this point.
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Figure 1.9. Telomeric 't-Ioop' and binding
proteins
Model of hypothesised structure of the protective chromosomal end structure,
the telomere. Telomere structure is stabilsed by binding proteins TRF1,
TRF2, Tankyrase , and TIN2. PIN2 is not included in this diagram although
can be presumed to belong to the complex formed by TRF1, Tankyrase, and
TIN2.
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4.1.4) Oncogene-induction of Replicative Senescence (Culture Shock)
There is evidence to suggest that the senescence programme can be
activated in response to certain oncogenes. The demonstration that the H-
RAS-V12 could activate the senescence program in primary mouse and
human cells and that this response was associated with accumulation of p53
and p1SlNK4Ais perhaps mechanistically unsurprising (Serrano et al., 1997). A
further demonstration showed that H-RAS-V12 activated p1gARFblocking p53
degradation, presumably through MDM2 degradation and allowing the p53
senescence response to occur. However, as p14ARF specific targeting has not
been shown in human cancers it may be that this observation has more
relevance to the murine system where the senescence response may be
more dependent on the mitogen response system. Indeed there is evidence
to suggest that mouse and human senescence are both mechanistically
different. Murine telomeres are approximately five times longer than human
(40-S0Kb v's 10Kb) and murine telomerase is expressed in far more tissues
than its human counterpart (Greenberg et al., 1998; Martin-Rivera et al.,
1998). After 20 population doublings in culture MEFs enter a state likened to
senescence with appropriate gene expression such as p53, p161NK4A,p1gARF,
and p21CIP1 • However given the extremely long telomeres, the constitutive
MEF telomerase expression, and the insufficient divisions for telomeric
attrition to occur it seems very unlikely that telomere length is the basis for
MEF senescence. As the emergence of any telomere-based senescence
would likely not arise until a large number of divisions had passed a tumour
cell could have formed a life threatening mass in a smaller mammal by that
point which is indicative of a necessity for distinct cellular failsafe mechanisms
between organisms. The senescence induced by H-RAS-V12 in MEFs
(Pantoja and Serrano, 1999) greatly resembles that which occurs normally
suggesting that MEF senescence may be oncogene induced, or perhaps
linked into the RAS/MAP kinase signalling pathway, and that p19ARF,not
p161NK4A,may be pivotal in the murine system. This was further underlined by
the earlier demonstration that mouse cultured growth arrest was not
dependant on the pRS pathway (Zalvide and DeCaprio, 1995) and that
p161NK4Awas not therefore critical to the mouse senescent arrest.
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4.2) Crisis and Immortality
Crisis is the final checkpoint preventing the progression of the errant
cell within the population from accumulating sufficient genetic changes to
achieve cellular immortality. Escape from the M1 checkpoint, achieved most
commonly through abrogation by loss of function mutations, promoter
silencing, or viral sequestration of p53, pAB and other cell cycle inhibitors
results in progressive telomere shortening and resultant chromosomal
instability. The observed chromosomal instability is due to end-to-end
(Robertson ian) chromosomal fusions and non-disjunctions during mitosis that
ultimately lead to cell death induced by massive genetic catastrophe. Escape
from crisis requires that the errant cell reactivate the mechanisms designed to
protect telomere ends and chromosomal integrity in subpopulations of cells.
Escape from senescence itself is not sufficient to immortalise a tumour
although it may predispose to this phenotype, however not all tumours are
immortal demonstrating that the required genetiC events have not yet
occurred (Barrett and Wiseman, 1987). Therefore to escape from the
massive genetic damage incurred in crisis and achieve cellular
immortalisation the re-establishment of chromosomal end integrity may be the
minimal positive selection requirement. The potential targets of inactivation,
even given the accumulation of genetic instability, which can provide an
escape from crisis however may not be that great on a genome scale given
that this escape is based on telomeric stabilisation. This would suggest that
as a tumour suppressor mechanism crisis might provide an important role in
the telomere-biased human system although conventionally would not be
expected to fill the same role in the murine system.
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4.2.1) Telomeric Basis of Crisis
The first demonstration that broken chromosomes without telomere
ends led to aberrant recombination's, end-to-end fusions, and 'breakage-
fusion-bridge' cycles were undertaken in Zea mays (McClintock, 1941)
although broken chromosomes do not strictly resemble critically short
telomere ends both instigate a DNA-damage response and therefore can be
considered sufficiently similar. With the observation that the mean telomere
length in fibroblasts passaged in vitro decreased by approximately 2kb before
the cultures ceased division, a mean 40 population doublings (Harley et aI,
1990) and the previous observations of limited replicative lifespan in normal
diploid fibroblasts (Hayflick, 1961) this led to the hypothesis that telomere
length was intrinsic to the replicative capacity of ordinary cells. Indeed
chromosomal instability and telomere end-to-end fusions are seen in the last
few doublings of senescent fibroblast cultures (Sherwood et al., 1988; Benn,
1976) providing evidence that telomeres may act as 'mitotic clocks' capable of
defining an endpoint to replicative lifespan. The last few divisions prior to
senescence could therefore be the point where sufficient genetic instability
occurs to inactivate tsg's allowing further divisions and the development of
further accumulatory genetic damage prior to crisis. Genetic instability itself
has therefore been defined as a hallmark of crisis highlighted by chromosomal
fusions and aneuploidy (Counter et al., 1992) where the mean telomere length
was 1.5Kb in a crisis population suggestive of approximately 70 populations
beyond senescence arrest, this assumes no increase in telomere degradation
beyond senescence. The emergence of immortalised clones from a culture in
crisis is a very rare event that is invariably accompanied by re-established
telomere maintenance that can be due to either telomerase (Counter et al.,
1992, 1998) or the ALT (Alternative lengthening of telomeres) mechanism
(Lundblad and Blackburn, 1993; Bryan et al., 1995; 1997) (see Section 4.2.4)
as evidenced by the re-expression of telomerase in post-crisis immortal cells
and by the fact that the ectopic expression of hTEAT enables cells to bypass
crisis (Counter et al., 1998; Zhu et al., 1999). More rarely human cancer cells
use the ALT mechanism, discussed in Section 4.2.4.
56
Although capable of driving cells beyond the M1 checkpoint and
extending life span by 20-30 population doublings through sequestration of
the checkpoint genes pRB and p53, infection with SV40 is not generally
sufficient to drive cells beyond crisis and therefore not solely sufficient for
immortalisation (Stein, 1985; Wright and Shay, 1992). Post-infection with
DNA viruses such as SV40, adenovirus, and human papillomaviruses (HPV)
the extended lifespan prior to crisis would provide the opportunity for further
genetic events to occur. The observation that immortalised cells emerge
post-infection with DNA viruses is therefore in keeping with theories of genetic
event accumulation being a prerequisite for immortalisation of neoplastic
tumours (Chang, 1986). Human cells expressing SV40 Large T antigen which
have bypassed senescence immortalise upon transfection with hTERT
indicating the inability of T antigen to rescue telomere ends alone and again
providing further evidence for a telomere-directed crisis (Counter et al., 1998;
Zhu et al., 1999). In a similar manner hTERT can complement HPV E7 to
drive cells beyond crisis, which in part could be a response to deregulated cell
cycle mechanics (Kiyono et al., 1998) as E7 constitutively activates pRB
alleviating its block on G1/S progression. HPV E6 expression in pre-crisis
human keratinocytes was itself sufficient to activate telomerase (Klingelhutz et
al., 1996) through a mechanism where c-myc deregulation occurs prompting
upregulation of hTERT mRNA (Wang et al., 1998) although this result shows
some variance across cell types as seen with hTERT -induced immortalisation.
4.2.2) Telomerase
The enzyme telomerase has been described previously to be sufficient
to rescue cells from replicative senescence and furthermore as sufficient for
immortalisation through crisis escape (Montalto et al., 1999). The
holoenzyme consists primarily of the hTERT catalytic subunit (Kilian et al.,
1997; Meyerson et al., 1997; Nakamura et al., 1997) and the hTR RNA
subunit (Feng et al., 1995). A number of other proteins are bound to
components of the holoenzyme such as TEP1 (Telomerase protein
component 1) (Harrington et al., 1997), molecular chaperone proteins p23 and
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Hsp90 (Holt et al., 1999), and to hTR such as hStau (double-stranded RNA-
binding protein) and L22 (nucleolus-localised RNA-binding protein) (Le et al.,
2000). TEP1 has also been shown to be a component of the large
cytoplasmic ribonucleoprotein complexes termed 'vaults' which are suggested
to associate with nuclear pore complexes, although this may reflect a utility of
function for this RNA-binding protein (Kickhoefer et al., 1999). Telomerase
has been demonstrated to be inappropriately active at high levels in >80% of
human cancers (Shay and Sacchetti, 1997). This activity allows the tumour to
escape the crisis stage through stabilisation of telomere ends and the cancer
cells to continue dividing indefinitely and essentially achieve cellular
immortality. Regulation of telomerase at the transcriptional level is exercised
through the gene encoding the catalytic subunit hTERT (Meyerson et al.,
1997) such that most normal human somatic cells lack hTERT mRNA and
undergo telomere shortening as a function of cell division (Harley et al., 1990;
Allsopp et al., 1992). The RNA template component of telomerase, hTR, is
ubiquitously expressed although where endogenous hTERT is expressed the
hTR mRNA levels and half-life rise considerably (Vi et al., 1999) further
demonstrating the importance of hTERT regulation. Telomerase activity has
been reported in normal keratinocytes although this is postulated to arise from
a subpopulation of basal stem cells, which are thought to display base activity
levels not sufficient to prevent telomeric shortening and senescence
(Vasumoto et al., 1996; Harle-Bacher and Boukamp, 1996). This is
suggestive of a minimal threshold telomerase level for effective telomere
stability below which insufficient telomeric reconstruction occurs. Using a
catalytically active C-term hemagluttinin-tagged hTERT it was demonstrated
that this was not sufficient to avert crisis (Feng et al., 1995) suggesting the
possibility of a stabilising role (not simply an elongatory role) performed by the
telomerase enzyme although the C-term hemagluttinin-tag has been reported
to interfere with the catalytic activity of hTERT on its substrate (Ouellette et
al., 1999) perhaps intimating an existence of an experimental artefact. The
observation that the restoration of telomerase activity and stabilisation of
telomere ends led to immortalisation of human fibroblasts (Bodnar et al.,
1998; Counter et al., 1998; Vaziri and Benchimol, 1998; Halvorsen et al.,
1999; Zhu et al., 1999) provided proof that immortalisation provided an
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escape from crisis and therefore crisis was due to critically shortened
telomeres. Conversely when telomerase activity was disrupted in human
cancer cells the telomeres underwent drastic shortening with continuing
division and entered crisis (Hahn et al., 1999; Zhang et al., 1999).
Conflictingly a study showed that the telomeres were elongated and
maintained well above crisis lengths whereas a similar study found the
telomeres were stabilised and maintained well below the crisis threshold
(Counter et al., 1998; Zhu et al., 1999). Although this seems at odds the
critical message is the stabilisation of the telomere ends is required for crisis
escape and therefore the minimal requirement is hTERT deregulation.
Although the ectopic expression of hTERT was sufficient for immortalisation of
presenescent fibroblasts and retinal pigment epithelial cells (Bodnar et al.,
1998) and normal mesothelial cells (Dickson et al., 2000) this is not the case
for every cell type analysed.
The catalytic subunit of telomerase hTERT has been characterised as
the site of enzyme repression in normal cells. In telomerase-expressing
tumours the deregulation of expression control is likely to occur as a
consequence of repression control rather than 'gain of function' mutation. A
number of candidate transcriptional repressors have come to the fore in
recent times, which act, directly on the hTERT promoter sequences. The
myeloid-specific zinc finger protein 2 (MZF-2) has been shown to interact
directly with a sequence 400 bp silencer sequence upstream of the hTERT
proximal core promoter (Fujimoto et al., 2000) whilst the Mad transcription
factor was also shown to repress the hTERT promoter although this
repression was removed by ectopic c-myc expression (Oh et al., 2000) which
is in agreement with other findings where the transcription factors Sp1 and c-
myc cooperate to activate hTERT transcription (Kyo et al., 2000). The Wilms'
tsg (WT1) has also been shown to repress hTERT transcription although it
has been described as interacting with the promoter sequences immediately
upstream from the MZF-2 interaction sites (Oh et al., 1999). Further evidence
for a repressor of hTERT comes from functional studies where introduction of
chromosome 3 into cell lines with functional telomerase and LOH on 3p
resulted in telomerase repression and growth-arrest entry (Ohmura et al.,
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1995; Cuthbert et al., 1999), deletion analysis in this study identified 3p21.3-
p22 and 3p12-21.1 as potential chromosomal locations of this gene, the latter
region was also identified as a putative telomerase repressor gene location in
an earlier study (Tanaka et al., 1998; Cuthbert et al., 1999). The catalytic
subunit of telomerase may be under the repressional control of a number of
transcription factors although some of these exert an inappropriate positive
control on the promoter sequences and there would seem to be further
repressors still to be cloned.
4.2.3) Keratinocyte Immortalisation
Normal human keratinocytes and mammary epithelial cells have been
reported to require inactivation of the pRS/p1SINK4Apathway alongside ectopic
hTERT expression to achieve immortalisation in culture (Kiyono et al., 1998;
Dickson et al., 2000). These findings suggest furthermore that keratinocyte
senescence is reliant on p1SINK4Abut can operate independently of telomere
length. Although differences clearly exist between different cell types this
stochastic mechanism of senescence, which is independent of telomere
length, clearly requires more in depth research. The bHLH protein Id-1 which
functions as a negative regulator of basic HLH transcription factors was found
to be sufficient for immortalisation of primary human keratinocytes (Alani et
al., 1999) with no crisis stage observed. Ectopic expression of Id-1 led to the
activation of telomerase, phosphorylation of pRB and a decrease in the p53-
mediated DNA-damage response through repression of cell cycle regulatory
transcription factors enabling bypass of both M1 and M2. Immortal human
cervical carcinoma cell lines which were p53 and pRS wild-type through
HPV18 ES and E7 presence underwent rapid senescence following
abrogation of the viral proteins demonstrating the need for further genetic
changes beside telomerase deregulation in this instance for keratinocyte
immortalisation (Goodwin et al., 2000). From these lines of evidence it is
clear that the minimal requirements for immortality in keratinocytes may differ
from other cell types although clearly the same basic mechanisms are utilised
in each instance demonstrating their importance to normal cell regulation.
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4.2.4) Alternative Lengthening of Telomeres (ALT)
An alternative pathway to telomerase-based telomere maintenance
was proposed following the identification of telomerase-negative human cell
lines which exhibited telomere maintenance at lengths greatly exceeding
those expected from the observed replicative lifespans (Bryan et al., 1995;
Bryan and Reddel, 1997). This mechanism was termed ALT and was
postulated to function via a recombination basis, based on observations in
yeast (Lundblad and Blackburn, 1993; Lundblad, 1997). Interestingly,
immortal cell lines, which maintain their telomeres by the ALT mechanism,
have been shown to contain a novel form of PML body that colocalises to the
telomeric ends in a subset of cell populations (Yeager et al., 1999). The novel
PML bodies contain promyelocytic leukaemia protein (PML), telomeric DNA,
TRF1, TRF2 and additionally replication factor A, RAD51 and RAD52 which
are involved in recombination and DNA metabolism (New et al., 1998). The
presence of these proteins at the telomere ends in the novel PML bodies led
the authors to suggest that they could either be sites of telomeric
maintenance or staging platforms for said process (Yeager et al., 1999). Of
further interest was the observation that Ras-induced premature senescence
in human fibroblasts involved an upregulation of PML protein (Ferbeyre et al.,
2000) which may be evidence of a 'culture shock' pathway occurring through
telomere ends in certain cell lines. However in cell-cell fusions between ALT
immortal cells and normal fibroblasts the hybrids quickly senesced, whereas
cell-cell fusions between ALT immortal and telomerase-positive immortal cells
resulted in a repression of the ALT pathway (Perrem et al., 1999). This is
suggestive of ALT repression pathways existing in both normal fibroblasts and
telomerase-positive cells. The ALT mechanism is still relatively poorly
understood although it does not appear to be the dominant pathway in cellular
immortalisation especially in immortal cells from naturally-occurring human
tumours (Kim etal., 1994; Bryan etal., 1997).
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4.2.5) Telomeric-dependence?
As discussed above there are differences between human and murine
senescence programmes insofar as they are not both dependent on telomere
signals. The demonstration that after 5 generations telomerase-deficient
mice started to exhibit growth and proliferative organ defects (Lee et al., 1998)
and late generation spontaneous tumour formations which harboured end-to-
end chromosome fusions (Rudolph et al., 1999) showed that although much
longer than their human counterparts if shortened significantly murine
chromosomes would behave in the same manner after a significant latency.
Further experimentation with mTR/- p53+1- mice showed after 5-7 generations
the development of epithelial carcinomas and lesions of the large intestine
(Artandi et al., 2000) rather than the characteristic murine soft tissue
sarcomas and lymphomas. This may be due to the shortening of the
telomeres to the point where they resemble the situation as seen in human
tumours allowing the development of these characteristic tumours. This
would seem to indicate that out with the laboratory situation there are key and
intrinsic differences to the murine and human forms of growth arrest and as
such this might reflect different evolutionary priorities in each respective
system. Importantly the frequency of escape from crisis in murine cells (mTR
1- p53-1-) approaches 100% compared to 10-7 in SV40 infected telomerase
negative human cells (Shay et al., 1993; Wright and Shay; 2000).
Fundamentally crisis may not have a role in the murine system although its
role as an inhibitor of further tumour progression in the human system should
not be presumptively underestimated.
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4.3) Calorific Dependency
The demonstration that calorific restriction can lead to an extension of
lifespan was provided in a number of model organisms. Observations in
S.cerevisiae showed that a family of proteins, the SIR (silent information
regulator) genes were determinants of lifespan. The family is composed of
SIR1, SIR2, SIR3, and SIR4, which were all identified initially through
silencing of mating type loci (Ivy et al., 1986; Rine and Herskowitz; 1987),
which in itself provided a good clue as to their function. Further lines of
evidence suggested involvement in nonhomologous end joining (NHEJ),
which is a mechanism utilised to repair breaks in DNA (Critchlow and
Jackson, 1998). Mammalian homologues of yeast proteins involved in this
process also carry out NHEJ although in yeast efficient functioning requires
SIR2, SIR3, and SIR4 (Tsukamoto et al., 1997; Boulton and Jackson; 1998)
this process has implications when considered along with potential telomere
recognition as double-strand breaks in aging mammalian cells. The aging
process in yeast has been demonstrably shown to be due to the accumulation
of extrachromosomal rONA circles (ERCs), which arise through inappropriate
expression, replication block and DNA-double strand repair, by homologous
recombination (Sinclair and Guarente; 1997). However, the demonstration
that NHEJ did not affect aging and that sir2, sir3, or sir4 haploids had
shortened lifespans through increase in ERC formation suggested a
mechanism with very little in common with a mammalian system (Kaeberlein
et al., 1999). The increase in ERC formation was shown to be due to sir2
mutation whilst deletion of FOB1 (gene required for ERC formation
(Kobayashi and Horiuchi; 1996)) alleviated the observed lifespan shortening.
This demonstrated that not only was ERC formation responsible for lifespan
shortening but also that SIR2 acted to repress ERC formation. SIR2 is the
only member of the SIR gene family conserved in higher eukaryotes. SIR2
and the mouse homologue were both then shown to be nicotinamide adenine
dinucleotide (NAD)-dependent histone deacetylases, the enzymatic
processes were driven by NAD which itself suggests that the protein could
respond to the cellular levels of NAD, and where high exert a deacetylation
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silencing control over chromatin, repressing transcription and thereby
controlling the divisive potential (Imai et al., 2000). The demonstration of
SIR2 lifespan extension in an NAD-dependent manner showed that calorie
restriction, at least in yeast, extends lifespan and thereby postpones
senescence in a seemingly telomere-independent pathway based on the
inhibition of toxic free radical formation (Lin et al., 2000). Calorific restriction
in mouse models has led to an extension of lifespan, although obvious
difficulties lie in extrapolating this data to the human system. The presence of
SIR2 homologues may imply that these pathways still exist to some degree in
higher eukaryotes, although under the control of a much larger set of
molecules than evidenced in S.cerevisiae.
4.4) Culture Shock
The actions of carcinogens have been shown to be sufficient for the
immortalisation of normal cells in culture (Newbold et al., 1982) where Syrian
hamster cultures became immortal at a frequency of 0.9-7 X 10-5 and 1.6-6 X
10-7 for embryo and dermal cells respectively. It was proposed that this effect
was an early event that enhanced the cells for further malignant
transformation by oncogenes (Newbold and Overall, 1983). This carcinogen-
induced immortalisation demonstrates features of a multistep pathway
(Thomassen et al., 1985; Barrett and Fletcher, 1987; Bois et al., 1991), which
although greatly accelerated clearly has similarities with the neoplastic
development in vivo. That repeated treatments with 4-Nitroquinoline 1-oxide
were required before immortalisation of normal human fibroblasts further
evidenced the necessity for multiple mutational events for this phenotype to
develop (Bai et al., 1993). However, later studies showed that the
immortalisation of Syrian hamster fibroblasts was not telomere-based, as they
were telomerase-positive throughout culture lifespan and senescence, but
rather SV40-T-antigen was sufficient to bypass senescence and crisis in a
single-step immortalisation (Russo et al., 1998). This was furthered by the
demonstration of Syrian hamster embryo cells which underwent senescence
after approximately 30 population doublings with no telomeric shortening and
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high telomerase expression (Carman et al., 1998). This has characteristics of
the 'culture shock', described in Section 4.5, where inappropriate mitogenic
signalling overrides the cellular transcription machinery driving a premature
senescence. Therefore, the repetitive carcinogen exposure, which
immortalises rodent cultures, is likely to occur through eventual abrogation of
the p53 and p16lNK4A-signallingpathways although not through a telomeric
maintenance process. The MMCT of chromosome 9 into rodent cells to some
extent supports this idea as this led to the deletion of the INK4A locus
whereas the p161NK4AcDNA led to growth-arrest of hybrids (England et al.,
1996).
The observed differences in senescence induction pathways has led to
the proposition that murine cells a undergo growth-arrest based on the
acquirement of damage through tissue culture conditions (Sherr and DePinho,
2000) leading to 'culture shock'. Murine cells paced in culture proliferate
beyond in vivo levels (Toldaro and Green, 1963) but eventually undergo a
cessation of division accompanied by upregulation of p161NK4A,p21CIP1 ,
p1gARF, and p53. MEFs undergo growth arrest after approximately 30
doublings although immortal variants do frequently emerge that possess
mutant p53 alleles and loss of the INK4 locus. However MEFs derived from
p53-null or ARF-null mice can be propagated indefinitely whereas those
lacking pRB or p21CIP1 undergo growth-arrest (Kamijo et al., 1997; Zindy et
al., 1998). Therefore, the disruption of p53 regulation is the critical
mechanism in the mouse for senescence. However, overexpression of ras in
MEFs led to a premature senescence accompanied by accumulation of
p161NK4A,p151NK4Band p53 (Malumbres et al., 2000). Indeed, in the absence
of p161NK4Aand p53 the ras-induced premature senescence pathway does not
function in rodent cells (Serrano et al., 1997). The ras induction of p161NK4A
and P151NK4Bwas shown to operate through the Raf-Mek-Erk pathway
suggesting inappropriate mitogenic pathway signalling, whilst constitutive
MEK mitogen signalling reinforces this idea by inducing premature
senescence in a p53- and p16lNK4A-dependentmanner (Lin et al., 1998). The
oncogenic Ras stimulated accumulation of p53 was shown to occur through
an activation of p1gARF (Palmero et al., 1998), which suggests that at least in
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the murine system Ras can activate both the p53 and pRS systems of growth-
arrest. Explant of MEFs into culture is associated with the accumulation of
p1gARF, and hence stabilisation of p53, which could explain the shorter, than
expected, lifespan of these cells in culture (Zindy et al., 1998). The
observation that the p53-induced late G1/S phase, kinase inhibitory, p21CIP1
is not an effector of ras-based premature senescence in MEFs and that
p21CIP1-null cells could still undergo proliferative arrest (Pantoja et al., 1999)
is suggestive of an elevated mitogenic signalling pathway in these cells
driving a senescent response in reply to a recognition of dysfunction. Similar
ras-induced premature-senescence phenotypes have been observed in
human models operating through the same molecules. In human non-
immortal fibroblasts activation of Raf-1 also led to premature onset of
senescence in a p16-dependent manner (Zhu et al., 1998), whilst Ras also
induced promyelocytic leukaemia (PML) protein (see Section 4.2.5) which
itself promoted premature senescence (Ferbeyre et al., 2000) (see Section
4.2.5). Overexpression of E2F-1 and p14ARF also led to a premature growth-
arrest in human fibroblasts (Oimri et al., 2000). These observations that in
response to the overexpression of components of the MEK pathway a cell can
be driven into premature senescence through regular proliferative-arrest
components could be due to a number of factors. An earlier report suggested
that MEFs could be maintained in culture for over 200 population doublings
(Loo et al., 1987), this is at variance with other reports where 30 doublings are
more commonly observed (Toldaro and Green, 1963). A key difference
between these figures is that the longer lifespans were achieved in serum-free
situations as compared to the shorter lifespans observed with serum. If
indeed the presence of serum is responsible for the drastic shortening of
lifespan it is conceivable that in a similar fashion to those situations described
above, the mitogenic signalling pathways are forcing the cells into the
premature senescence. Forced expression of mitogen signalling pathways
could in effect shorten lifespan through a overloading of transcription
machinery, forcing errors, leading to activation of negative cell cycle
regulators. However, human cells grow for longer in culture, which suggests
that mitogen pathways may be under greater regulation in these cells
66
whereas mouse cells are more susceptible to the deregulation of these
pathways resulting in the premature senescence of 'culture shock'.
5) Methods of Tumour Suppressor Gene Detection
A number of powerful techniques are used to clone novel tsg's. These
techniques are used in combination rather than reliance on a sole mechanism
thereby aligning complementary data sets to provide clarity in a frequently
confusing situation. Additionally due to the development of new technologies
methods can change and acquire new characteristics at a rapid rate.
5.1) Comparative Genome Hybridisation
The fundamental basis behind CGH is that in tumour progression
chromosomal regions, which contain oncogenes, are likely to be over-
represented and therefore the oncogenes amplified. Conversely,
chromosomal regions in which tsg's are located are likely to show a
decreased copy number through deletion of one allele and mutation of the
other leading to deregulation of growth control. The basis of the technique is
the simultaneous hybridisation of immunohistochemically-labelled normal
(driver) and tumour (tester) DNA is hybridised to normal human metaphase
chromosomes. Conventionally the driver and tester DNAs are labelled with
green and red flourochromes respectively. The resultant ratio of green to red
fluorescence specifically decreases and increases, provides an indication of
relative copy number in the tumour line (Kallioniemi et al., 1992). Although a
powerful technique CGH has its limitations it cannot be used to detect point
mutations, small deletions or amplifications, or translocations. Realistically it
can be used to detect 10 megabase copy number increases or decreases or
smaller high-level DNA copy number increases.
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5.2) Expression Microarrays
The technology behind expression microarrays has come as a direct
result of the vast increase in public domain data available of cDNA clones and
their sequences (reviewed in 'The Chipping Forecast', Nature Supplement,
1998. The fundamental approach to microarrays is the hybridisation of mRNA
samples to arrays of cDNA (or oligonucleotide sequence derivatives) clones.
The cDNA samples are chemically attached to slides or chips upon which the
hybridisations take place. Both species are labelled with different coloured
flourochromes (red (tumour) or green (normal)) and following the hybridisation
the slide (or chip) is analysed using appropriate software to develop an
expression pattern, for instance where a sample chamber is red then this
would indicate an overexpression in the tumour, green would suggest an
expression reduction in the tumour, and yellow would suggest no change in
expression from tumour to normal mRNA. This technique is particularly well
suited to large-scale analysis containing up to 40,000 different clones and
would be expected to provide some exciting results in the future.
5.3) Linkage Analysis
The principle behind genetic mapping is to discover how often two loci
are separated by meiotic recombination. Familial linkage analysis has led to
the identification of a number of tsg's whose mutation creates a predisposition
to cancer susceptibility and therefore is thought of by many as the 'gold
standard' of cancer gene identification. In the first instance families are
sought who demonstrate disease susceptibility and are then subject to whole
chromosome screens using a variety of restriction fragment length
polymorph isms (RFLPs), minisatellites, microsatellites, and single nucleotide
polymorph isms (SNPs). This screen would be performed at a density of
approximately one marker per 10cM. Following typing by polymorphic
markers the likelihood that the markers are linked (or not) is calculated
through the lod (logarithm of odds) score, where +3 and -2 define linkage and
exclusion respectively. The lod score is defined as the logarithm of the
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likelihood ratio. Scores, which are greater than 3 are then refined through
finer mapping of, identified locus and candidate genes identified. Linkage
analysis has lead to the identification of the genes responsible for Li-Fraumeni
syndrome (P53), retinoblastoma (PRB), FAP (Ape), familial breast and
ovarian cancer (BRCA 1 and 2), and familial melanoma (p16'NK4A) (Malkin et
al., 1990; Srivastava et al., 1990; Yunis and Ramsay, 1978; Bodmer et al.,
1987; Leppert et al., 1987; Easton et al., 1993; Hussussian et al., 1994)
5.4) Loss of Heterozygosity
The ability to inactivate tumour suppressor genes through loss of a
copy of an endogenous chromosome accompanied by mutation on the
remaining gene copy has been proposed as an important mechanism in the
development of carcinogenesis (Knudson, 1971). This manifestation of allelic
loss has been termed LOH and has been implicated in a variety of tumour
types and has been instrumental in the positioning of a number of loci
implicated in tumourigenesis. Defects in components of the mitotic machinery
have been implicated in the development of this chromosomal instability
allowing aneuploidy to develop (Pihan et al., 1999). The study of LOH is
based on the peR amplification of highly polymorphic endogenous
microsatellite repeats (Weber and May, 1989; Loius et al., 1992;
Weissenbach et al., 1992; Gyapay et al., 1994) and resolving the two alleles
using gel electrophoresis. In this manner it can be clear if the tumour has lost
an allele copy as compared to the matched normal tissue. LOH results from
approximately 50% of second events that lead to inactivation of a tsg. Large
deletions of chromosomal arms, whole chromosome loss, and mitotic
recombination result in LOH whereas point mutations do not. The LOH
technique has provided the major pathway to the finding of a number of new
tsg's. Amongst these are Smad4/DPC4 (Hahn et al., 1996), PTEN/MMAC1
(Steck et al., 1997), and PPP2R1 B (Wang et al., 1999).
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5.5) Representational Difference Analysis
This technique and CGH operate on intrinsically the same principles
although representational difference analysis (RDA) operates at the nucleic
acid level rather than chromosomal (Lisitsyn and Wigler, 1993; Diatchenko et
al., 1996, 1999). Technically the two genomes to be analysed undergo
restriction enzyme digestion and are ligated to genome specific adaptor/linker
oligonucleotides. This generates the representations of both genomes to be
analysed, which can then be PCR amplified using specific adaptor/linker
oligonucleotide primers. These representations are then denatured and
hybridised to each other, i.e. one representation forms the 'tester'
(conventionally tumour DNA) and the other the 'driver' (conventionally normal
DNA). DNA sequences that are common to both genomes form
heteroduplexes whilst unique tester sequences form homoduplexes, which
can then be enriched through PGR amplification using the specific
adaptor/linker oligonucleotide primers. In this manner changes in the DNA
representation changes resulting from deletion, amplification or mutation can
be identified and sequenced in an attempt to identify novel genes important to
the tumourigenic phenotype. A further variation on this technique exists which
operates on the same principles although mRNA is extracted, reverse-
transcribed and the cDNA amplified and hybridised in the same manner from
both 'tester' and 'driver' populations although affinity separation is used to
remove driver-driver and tester-driver sequences (Lopez-Fernandez and del
Mazo, 1993). This enables differences in expression to be analysed and
novel or missing mRNA's to be identified.
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6) Evidence for a Tumour Suppressor Gene and
Mortality Gene on Chromosome 4
6.1) Functional Evidence
The first evidence of a link between chromosome 4 and tumourigenicity
was provided by cell-cell fusions between a fibrosarcoma cell line and normal
fibroblasts (Benedict et al., 1984) followed by injection into athymic mice. The
reappearance of tumourigenicity in the mice correlated with the loss of
chromosome 4. This was suggestive of chromosome 4 carrying a gene
whose loss was beneficial to the progression of tumourigenesis. A variety of
cell-cell fusions between normal and immortal cell lines where senescence
was the dominant phenotype (Pereira-Smith and Smith, 1988) led to the
suggestion that similar pathways may be inactivated in tumourigenesis in
differing cell types. This study led to the assignment of a group of cells to the
same phenotypic grouping; GM2096SV9 (Origin-defective SV40-transformed
XP skin fibroblasts), T98G (Glioblastoma). HeLa (Cervical carcinoma), and
J82 (Bladder carcinoma). Further evidence of this grouping was provided by
the MMCT of chromosome 4 into the same subset of cells, with the exception
of GM2096SV9, causing the reversion of the immortal phenotype to a
phenotype characteristic of replicative senescence (Ning et al., 1991).
Therefore the observed senescent phenotype was due to the introduced
chromosome 4 and the phenotype was characterised by a flattening cellular
morphology and a resemblance to typical senescent cells. Clearly this is an
ambiguous definition that could be due to effects other than senescence.
However in all of the flattened colonies retention of the exogenous
chromosome 4 copy was demonstrated showing that the phenotype was due
to the introduced chromosome. This demonstrated that the functional
complementation that was occurring was likely replacing a component in a
commonly lost pathway, which enhanced the tumourigenic potential in the
target cell lines.
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6.2) Locus Identification
Losses on chromosome 4 are seen in a wide variety of tumour types
using powerful techniques such as CGH, LOH, and RDA (as described
above). The identified loci on both 4p and 4q are discussed at length in
Chapter 3 therefore we will provide a defined overview of those findings in this
section.
6.2.1) Comparative Genome Hybridisation
CGH studies in breast cancer demonstrated frequent losses on 4q
(Schwendel et al., 1998). Further CGH studies on colorectal carcinogenesis
found chromosome 4 copy number reduction to be a frequent event in
advanced tumours (Ried et al., 1996) and losses of a locus on 4p16 were
implicated to be beneficial to malignant development (Paredes-Zaglul et al.,
1998). SCLC has shown common losses using CGH on 4p15-p16, 4q11-q23,
4q24-q26, and 4q32 (Levin et al., 1994; Petersen et al., 1997; Schwendel et
al., 1997; Petersen et al., 2000). One locus was suggested through CGH
analysis at 4q28 in RCC (Renal cell carcinoma) although no further definition
was provided (Jiang et al., 1998). Although a powerful technique CGH does
not allow definition between allelic copies and instead simply provides an
overall amplification or reduction of generalised chromosomal areas. From all
the available CGH data however, chromosomal regions 4p15-p16, 4q11-q23,
4q24-q26, 4q28, and 4q32 have shown copy number reductions, which are
suggestive of allelic loss.
6.2.2) Loss of Heterozygosity
LOH studies in bladder cancer revealed two areas of common deletion
at 4p15 and 4q34, which correlated with an advanced tumour stage (Knowles
et al., 1994; Polascik et al., 1995). Further LOH studies in breast cancer
revealed losses at the same loci identified in bladder and two additional loci at
4p16.3 and 4q25-q26 (Shivapurkar et al., 1999). CC (Cervical carcinoma)
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LOH studies showed losses at 4q21-q23 (Mitra et al., 1994) whilst CIN
(Cervical intraepithelial neoplasia) LOH studies demonstrated losses at 4ptel
and 4qtel (Larson et al., 1997. In HNSCC four loci have been identified using
LOH including one at 4p11-p12, 4q21, 4q25, and 4q32-q34 (Loughran et al.,
1997; Pershouse et al., 1997). A number of LOH studies in HCC have shown
losses at 4q21-q22, 4q25, 4q26-q27, 4q31, 4q32, 4q33, and 4q34 (Chou et
al., 1998; Piao et al., 1998; Rashid et al., 1999; Bando et al., 1999). OSCC
(Oral squamous cell carcinoma) LOH studies showed a locus at 4q25 was
frequently lost (Wang et al., 1999) whilst EA (Esophageal adenocarcinoma)
LOH studies revealed three regions of common LOH at 4q21 .1-q22, 4q32-
q33, and 4q35 (Rumpel et al., 1999) and ESCC (Esophageal squamous cell
carcinoma) LOH studies revealed three regions of LOH at 4p16, 4p12-p14,
and 4q21.3-q22 (Hu et al., 2000). LOH analysis based on linkage studies in
two syndromes, which predispose to neoplastic development revealed two
loci at 4q23 (Irritable Bowel Disease (IBD); Cho et al., 1998) and 4q21
(Scleroatrophic Syndrome; Lee et al., 2000). Fundamentally therefore
although a number of different loci are identified through these described LOH
studies these define regions of common loss at 4p16, 4p15, 4p12-p14, 4p11-
p12, 4q21-q22, 4q23, 4q25, 4q26-q27, 4q31, 4q32, 4q33, and 4q34. It is
extremely unlikely however that chromosome 4 harbours 12 separate tsg
although it is likely to harbour a tsg on both of its chromosomal arms.
Additionally a number of intrachromosomal telomere-like repeats have been
identified on chromosomes 4, which are proposed to be fragile sites, at 4cen,
4q13, 4q25, and 4q28 (Azzalin et al., 1997). These do not account for all the
LOH observed on chromosome 4 however a number of regions could be
interpreted as resulting from fragile site breakpoints. Precedence for multiple
targets of tumour suppression on a single chromosome arm has been
documented on 18q where the tsg Smad4/DPC4 is inactivated by deletions in
colorectal carcinoma (Hahn et al., 1996) although some of these deletions
also involve the putative tsg, DCC (Hahn et al., 1996) indicating that there
may be other targets.
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6.2.3) Representational Difference Analysis
RDA analysis in osteosarcomas identified a region from 4q32-qtel
although no suitable candidate genes were found (Simons et al., 1999).
There have been no further published RDA studies concerning chromosome 4
although this technique does rely on changes in expression and as such
would perhaps not detect mutations with any effect on expression but solely
on function.
6.4) Chromosome 4 Losses May Represent a Late Stage Event
A significant number of lines of evidence have suggested that LOH on
chromosome 4 occurs as a late event in tumourigenesis perhaps as a key
event for neoplastic immortality. Indeed gynaecological carcinoma showed 4q
LOH was the fourth most frequent site of loss after 17p (P53), 9p (p16NK4A),
and 13q (PRB) indicating its advantage as a late event loss (Fujii et al., 2000)
coming after deregulation of the three classical tsg described above. A
correlation with LOH on chromosome 4 and advanced tumour stage was
shown in bladder cancer (Polascik et al., 1995) and again where eGH losses
were shown in muscle invasive Tee (transitional cell carcinomas) with no
corresponding losses in superficial Tees (Yeager et al., 199B). A eGH study
in colorectal carcinomas found no chromosome 4 copy number reduction in
less advanced samples (Ried et al., 1996) and that in colon cancer
metastases there was an increasing frequency of losses (Paredes-Zaglul et
al., 199B). Epithelial hyperplasia and low-grade dysplasia have also shown
an associated loss of chromosome 4 to cases that have shown progression
(Rosin et al., 2000). Therefore the loss of chromosome 4 may occur at a later
stage of tumour proqression, perhaps beyond the replicative senescence
checkpoint as p53 and p 16NK4A, mutations have been cited to occur prior in
tumourigenesis (Loughran et al., 1997).
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7)Aims
The fundamental aim of this project was to test for the existence of a
HNSCC mortality gene on chromosome 4. Further aims were to map
chromosomal losses in an attempt to define the mortality gene locus on
chromosome 4. Previous work had demonstrated LOH of chromosome 4 in
immortal HNSCC lines and tumours. Functional evidence however, was
limited to earlier by studies by Benedict et al., (1984) which suggested the
presence of a tsg, and Ning et al., (1991) which suggested the presence of a
mortality-associated gene. However, no functional studies had been
undertaken in immortal HNSCC to demonstrate immortal reversion.
Therefore, in the course of this project we aimed to test for a mortality function
associated with chromosome 4 through utilisation of MMCT, to undertake to
determine the nature of this mortality effect through biological assay, and to
map the position of the gene(s) responsible for this phenotype.
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Chapter 2
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1) Materials
1.1) Cell lines
Source Cell line
ATCC,
12301 Parklawn Drive,
Rockville,
Maryland,20852.
USA
3T3 Swiss Mouse Embryos
Cat. No. CCl92.
HT1080 Fibrosarcoma,
Cat. No. CCl121.
Mycoplasma Indicator,
Cat. No. CRl 6509
A92 Mouse Fibrosarcoma.
NRK
Dr R F Newbold
Brunei University,
Middlesex,
UK
A9HYTK4
A9HYTK6
A9HYTK11
A9HYTK15
Mouse A92 cells containing a single resistance marker tagged human
chromosome (Cuthbert et al., 1995).
Dr Olivia Periera-Smith,
Baylor College of Medicine,
Houston, Texas,
USA
Mouse A92 cell containing a fragment of Neomycin resistance tagged
Hela
A9F4
Cervical Carcinoma
chromosome 4. The fragment was generated from an intact chromosome 4
introduced into HT1080 and then transferred back into A9 cells.
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Dr G. P. Nolan,
Stanford University Medical Centre,
San Francisco, California,
USA
Pheonix A Retroviral Packaging
Cell Line
Cell Lines obtained from Dr. E. K. Parkinson are listed in Table 2.1.
1.2) General cell culture media and supplies
Supplier Material
NS Nunc
Botolph Claydon,
UK
1ml Cryotubes
Autogen Bioclear
Holly Ditch Farm,
Mile Elm, Caine,
Wiltshire,
UK
Fetal Bovine Serum
Cat. No. S011S
Becton Dickinson Labware
Plymouth,
UK
Falcon tissue culture dishes,
full range
Calbiochem-Novabiochem UK Ltd
Boulevard Industrial Park,
Padge Road,
Beeston,
Nottingham, NG9 2JR,
UK
Hygromycin B,
Cat. No. 400051.
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Table 2.1. Cell lines obtained from Dr. E. K.
Parkinson.
Description of immortal keratinocyte cell lines used in experimental
processes. The table indicates the site of each tumour along with TNM
staging and proliferative fate. Table adapted from Edington et al., 1995.
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Keratinocyte Site Tumour Stage Proliferative Fate
(TNM)
BICR3 Alveolus T2NoMo Immortal
BICR6 Hypopharynx T4N1Mo Immortal
BICR 18 Larynx Metastasis Immortal
BICR 19 Epidermis Not Applicable Immortal
BICR 22 Tongue Metastasis Immortal
BICR 31 Tongue T4N2BMo Immortal
BICR 56 Tongue T4N1Mo Immortal
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Fisher Scientific UK
Bishop Meadow Road,
Leicestershire, LE11 5RG,
Loughborough,
UK
Gibco BRL life Technologies
Paisley,
UK
Sigma Chemical Company
Fancy Road
Poole, Dorset,
UK
Worthington Biochemical Corporation
Reading,
UK
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Dimethylsulfoxide
(CH3·S0.CH3)
Cat. No. BPE231-1.
DMEM, Cat No. 21969-035
HEPES Buffer,
Cat No. 15630-056
L-Glutamine,
Cat. No. 25030-032.
Geneticin (G418 Sulphate),
Cat. No. 11811-098.
Penicillin G (benzylpenicillin)
sodium salt, Cat No. P3032
Streptomycin Sulphate BP,
Cat. No. S9137.
Hydrocortisone
21Hemisuccinate,
Cat No. H2270.
Bovine Donor Calf Serum,
Cat No. C-9676
Trypsin, Cat. No. 39J3128.
1.3) Specialized Cell Culture Techniques
Supplier Material
Costar
Bucks,
UK
5 mm filter membranes
Gibco 8RL Life Technologies,
Paisley,
UK
Nalge Nunc International Corp.,
2000 North Aurora Road,
Naperville, IL. 60563-1796,
USA
25cm2 (40ml) Straight Sided
Flasks, Cat. No. 52094A.
8 Well Permanox® Slide,
Cat. No. 177445.
Sigma Chemical Company
Poole,
UK
Chloroquinine, Cat. No.
C6628.
Cytochalasin B,
Cat. No. C6762.
Demecolcine, Cat. No. D6165.
Phytohemaglutinin,
Cat. No. C9017.
Polybrene (Hexadimethrine),
Cat. No. H9268
Polyethylene Glycol-1 000,
Cat. No. P3515.
Hoeschst 33258,
Cat. No. 81155.
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1.4) Immunocytochemistry antibodies and materials
Supplier
Autogen Bioclear UK
Caine,
UK
Boehringer Mannhiem UK (Diagnostics &
Biochemicals) Ltd
Bell Lane,
Lewes,
East Sussex, BN7 1LG,
UK
Calbiochem-Novabiochem (U.K.) Ltd
Boulevard Industrial Park,
Padge Road,
Beeston,
Nottingham, NG9 2JR,
UK
Intergen Company
The Magdalene Centre,
The Oxford Science Park,
Oxford, OX4 4GA,
UK
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Material
Mortalin C-19 [GRP 75] Goat
Polyclonal Antibody,
Cat. No. sc-1058
5-Bromo-2' -deoxy-uridine
Labelling and Detection Kit 1,
Cat. No. 1296 736.
Normal Goat Serum,
Cat. No. 566380.
Apoptag® Fluorescein Direct
In Situ Apoptosis Detection
Kit. Cat. No. S7160
Lab Vision (UK) Ltd
The Pines,
Fordham Road,
Newmarket,
Suffolk, CB8 7LG
UK
Sigma Chemical Company
Poole,
UK
Vector Laboratories Inc.
16 Wulfric Square,
Bretton,
Peterborough, PE3 8RF,
UK
1.5) Molecular Biology Kits
Supplier
QIAGEN Ltd
Boundary Court, Gatwick Rd,
Crawley, West Sussex, RH10 2AX,
UK
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Tubulin Ab-4 (Clone DM1-A +
OM1-B) Mouse Monoclonal
Antibody,
Cat. No. #MS-719-P1
Nonidet P-40 (NP-40),
Cat. No. N-3516.
Bovine Serum Albumin (BSA),
Cat. No. A9647.
Donkey Anti-goat IgG-FITC
Cat. No. sc-2024.
Vectashield With OAPI,
Cat. No. H-1200.
Texas Red Anti-Mouse IgG,
Cat. No. TI-2000.
Material
Rneasy® Mini Kit,
Cat No. 74104
QIAamp® DNA Mini Kit,
Cat No. 51304
QIAshredder,
Cat No. 79654
Plasmid Midi Kit,
Cat No. 12143
1.6) Chemicals
Solutions and buffers were prepared using dH20 from a Millipore MilliRO 15
System.
Supplier Chemical
Agar Scientific Ltd
66a Cambridge Road,
Stanstead,
Essex, CM24 BDA,
UK
Paraformaldehyde
«CH20)nH·OH»,
Cat. No. R1018.
Amersham International
Little Chalfont,
UK
Redivue [a32P]dCTP-
3000Ci/mmol.
Cat No. AA0005.
BioFine Ltd
London,
UK
X-Gal
James Burrough (F.A.D) Ltd
70 Eastways Industrial Park,
Witham,
Essex, CM8 3YE,
UK
Ethanol (C2H50H)
Cat. No. SIN 1170.
Fisher Scientific UK
Bishop Meadow Road,
Loughborough,
Leicestershire, LE11 5RG,
UK
o (+) Glucose (C6H1206),
Cat. No. G/0500/53
Glycine (NH2CH2·COOH),
Cat. No. BPE381-1.
Magnesium Chloride
(MgCI2·6H20) ,
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Sigma Chemical Company
Poole,
UK
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Cat. No. M/0600/53.
Methanol (CH30H),
Cat. No. SPE1105-1.
Sodium Chloride (NaCI),
Cat. No. SPE358-1.
Ethidium bromide,
Cat. No. E1510,
Giemsa's Stain,
Cat. No. GS500
Glacial Acetic Acid (C2H402),
Cat. No. A6283;
MES (2- [N-Morpholino]
ethanesulfonic acid),
Cat No. M8250,
TEMED
(N,N,N',N'-Tetramethyl-
ethylenediamine), Cat. No.
T8133;
EDTA (Ethylenediaminetetra -
acetic acid,
C1QH14N20sNa2·2H20), Cat.
No. ED2SS;
Potassium ferricyanide
(~Fe(CN6», Cat No. P3667;
Potassium ferrocyanide
(~Fe(CN)s-H20),
Cat No. P9387;
Rhodamine S, Cat No. R6626.
1.7) peR Reagents
Supplier
PE Applied Biosystems
Warrington, Cheshire,
UK
1.8) Laboratory plasticware
Supplier
Becton Dickinson Labware
Plymouth,
UK
Bibby-Sterilin
Stone,
UK
Elkay
Galway,
Eire
Greiner Labortechnik
Stonehouse,
UK
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Enzyme
Taqman Gold RT-PCR Kit,
Cat No. NBOB-0232;
AmpliTaq® DNA Polymerase,
Cat. No. NB01-0060;
10X PCR Buffer & MgCI2
Solution, Cat. No N808-0010.
Material
Falcon tubes
5 ml Bijous; 20ml Universals
Microcentrifuge tubes; Pipette
tips.
Filter pipette tips
PE Applied Biosystems
Warrington, Cheshire,
UK
1.9) Electrophoresis gels
Supplier
Gibco BAL life Technologies
Paisley,
UK
National Diagnostics
Hull,
UK
1.10) Paper and X-ray film
Supplier
Sigma Chemical Company
Poole,
UK
Whatman International
Maidstone,
UK
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MicroAmp® Optical 96-well
Reaction Plate and Optical
Caps. Cat No. PIN 403012
Material
Agarose, electrophoresis
grade;
SequaGel Buffer,
Cat No. EC-835
Sequagel Concentrate,
Cat No. EC-830
Sequagel Diluent,
Cat No. EC-840
Material
Kodak X-OMAT Film,
Cat. No. F5263.
3mm Chromatography paper,
Cat. No. 3030917.
1.11) Microbial host, media and supplies
Supplier Material
Difco,
Central Avenue,
West Molesey,
Surrey, KT8 2SE,
UK
Tryptone, Bacto
Cat. No. 0123-15
Yeast extract, Bacto
Cat. No. 0127-15
Bibby-Steril in
Stone,
UK
Petri dishes
Gibco BRL Life Technologies
Paisley, UK
Library Efficiency DH5a™
Competent Cells
Cat. No. 18263-012
S.O.C. Medium
Cat. No. 15544-018
Sigma Chemical Company
Poole,
UK
Ampicillin, Cat. No. A9393.
1.12) Plasm ids
See Figure 2.1 for schematics of. plasmids
pBabe Hygro obtained from Dr S. Barnett, Department of Neurology.
University of Glasgow. U.K.
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Figure 2.1. Plasmids used in transfections
Cartoon representing the structures of pexSVneo, plasmid used as a vector in
MORF4 transfections (see Chapter 6, Section 6.2), pBabeHygro, plasmid
used to generate Hygromycin resistant 3T3 feeder cells, and pBabest2,
retroviral cassette used in keratinocyte infections.
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91
p8abe Hygro
IMultiple Cloning Site
palbe Hy TO iiii!;
"~.I'.i,...."".,.~-------:
......,
-----
Expansion of Multiple Cloning Site.
BamHI BstXI SnaBI EcoRI BstXI Sail.
p8abest2
I B a
~
hTERT
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pexSVneo, pexSVneoMORF4FS, pexSVneoMORF4 plasmids were obtained
from Dr Olivia Periera-Smith, Baylor College of Medicine, Houston, Texas,
USA.
pBabest2, and pBabe Neo retroviral plasm ids obtained from H. Vaziri and S.
Benchimol. Stanford University School of Medicine, Department of Molecular
Pharmacology, Edward's Building, 300 Pasteur Drive Stanford, California, CA
94305-5332, USA.
1.13) Internet Links
Centre d'Etude du Polymorphisme Humain (CEPH)
http://www.cephb.fr/
Cooperative Human Linkage Centre (CHLC)
http://lpg.nci.nih.gov/CHLC
National Centre for Biotechnology Information (NCBI)
http://www.ncbi.nlm.nih.gov/
UK Human Genome Mapping Project Resource Centre
http://www.hgmp.mrc.ac.uk
Whitehead Institute/MIT Center for Genome Research
http://www.genome.wi.mit.edu/
Golden Path
http://www.genome.cse.ucsc.edu
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2) Methods
2.1) Cell culture techniques
2.1.1) Culture of cell lines
All keratinocyte cell lines except when stated otherwise were cultured in
DMEM supplemented with 10% FBS (see Table 2.2), 20mM HEPES Buffer, 2
mM L-glutamine, SOU/ml Penicillin, 20ng/ml Streptomycin, and 0.4ng/f.t1
Hydrocortisone. All other tumour-derived lines were cultured as above
excepting the Hydrocortisone supplement. The Swiss 3T3 fibroblasts were
cultured in DMEM supplemented with 10% DCS, 40mM HEPES Buffer, 2 mM
L-glutamine, SOU/ml Penicillin, 20ng/ml Streptomycin, All chromosome donor
cell lines were cultured in DMEM supplemented with 10% FBS, 40mM
HEPES Buffer, 2 mM L-glutamine, SOU/ml Penicillin, 20ng/ml Streptomycin,
containing 800 U/ml Hygromycin B. The donor line A9F4 was cultured as for
those previously stated with a 1mg/ml G418 supplement replacing the
Hygromycin B. All cell lines were maintained in a humid 37°C/S% CO2
incubator.
Cryopreserved cell stocks were prepared from early-passage cell lines
and hybrids as follows. Cells were maintained in culture until they reached
approximately 7S% confluence. They were then trypsinised, neutralized with
normal growth medium and pelleted. The cell pellet was resuspended in
freezing medium (10% DMSO in normal growth medium) to an appropriate
density and the suspension transferred into cryotubes (1 ml per vial). The
cryotubes were wrapped in cotton wool and placed into a -70°C freezer
overnight to slow freeze, and the following day were immersed in liquid
nitrogen for long-term storage. Cryotubes were recovered from liquid nitrogen
by immediate immersion in a large volume of water at 37°C. The cell
suspension was then made up to a volume of 10 ml with normal growth
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Table 2.2. Optimal culture conditions for all
keratinocyte lines
Supplemented FBS concentrations at which immortal keratinocytes were
judged to grow optimally. Derived from Edington et et., 1995.
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Keratinocyte Line Optimal Serum
BICR3 10%
BICR6 10%
BICR 18 2%
BICR 19 10%
BICR 22 2%
BICR 31 10%
BICR 56 10%
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medium and the cells pelleted by gentle centrifugation, 1000rpm for 5min.
Cells were resuspended and plated at an appropriate density.
2.1.2) Mycoplasma Testing
Media of at least 48hrs contact with cells to be tested was added to 104 NRK
cells and incubated for 96hrs. Media was then removed and cells were
washed twice with PBS followed by fixing in Methanol/Acetic Acid (3:1) twice
consecutively and finally for 10min. After fixative removal O.05~g/ml Hoechst
33258 (Chen, 1977; fluorescent DNA stain) was added and left for 10min
followed by two consecutive washes in distilled water. Cells were mounted in
Mcllvaines's Buffer (0.2M Na2HP04, 0.1M Citric Acid) and examined using
fluorescence microscopy.
2.1.3) Selection Determination
Kill curves were used to determine the appropriate level of antibiotic selection
to use in MMCT and Transfections. Cells were plated at 105 per 60mm dish
and placed under selection media after 48hr. Thereafter selection media was
changed twice weekly. Complete cell death after 2 weeks was taken to be the
appropriate antibiotic selection. Appropriate cell line selection determination
values are listed in Table 2.3.
2.1.4) Transfection
Cells to be stably transfected were seeded 24hr previously in 60mm dishes at
an appropriate density to reach approximately 60% confluence. 5~g plasmid
DNA dissolved in TE, pH7.4 was diluted with DMEM containing no serum or
antibiotics to a total volume of 150~1. The solution was then mixed, spun
down briefly, 20~1of Superfect Transfection Reagent added and vortexed for
10sec prior to incubation for 10min at room temperature to allow complex
formation. Whilst complex formation was taking place the recipient plates
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Table 2.3. Selection determination for cell lines
Selection agent (Hygromycin and Neomycin) sensitivity for immortal cell lines
determined through kill curve construction (see Section 2.1.3).
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Cell Line Hygromycin B Neomycin concentration
concentration (U/ml) (G418 Sulphate)
(mg/ml)
HeLa 300 1.2
HT1080 200 N.d
BICR3 SO O.S
BICRS 125 O.S
BICR 18 SO N.d
BICR 19 80 N.d
BICR 22 25 N.d
BICR 31 SO N.d
3T3 150 1.0
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were washed once with PBS. After complex formation 1ml normal growth
medium was added to the reaction tube, mixed, and transferred to the
recipient plate and incubated for 2-3hrs. Following incubation cells were
washed 4 times with PBS, fresh growth medium added and incubated for
48hrs. Finally cells were passaged 1:8 into appropriate selection media and
selected until the appearance of clones. Table 2.4 outlines the plasmids used
for transfections.
2.1.5) Mlcrocell-mediated monochromosome transfer
Donor cells (murine A92 cells containing an individual Hytk-tagged human
chromosome) were plated into six straight-edged 25 cm2 flasks at a donor
specific density in the range of 1.3 x 106 to 1.45 x 106 cells per flask. After 24
hr Demecolcine was added to a final concentration of 75 ng/ml, and the flasks
were incubated at 37°C for a further 48 hr. Following this incubation the
medium was then replaced with 30 ml of 10 mg/ml Cytochalasin B in serum-
free medium supplemented with 40mM HEPES Buffer and 2 mM L-glutamine
and incubated for 30 minutes. The flasks were then placed in a GSA rotor
(cushioned with 75gm mQH20) and spun in a pre-heated Sorvall RC 28S
centrifuge, programmed with the following parameters: slow start, 15 min;
7600 rpm/9500g; 75 min; slow stop 10 min; 37°C; brake off. Following the
run the pellets (consisting of micro cells and cell debris) were resuspended in
a small amount of supernatant and transferred into a single 15 ml sterile
Falcon tube. The suspension was centrifuged (3470 rpm, RT, 5 min), and the
pellet resuspended in 10 ml of serum-free medium. The microcell suspension
was then passed through three sterile 5 mm filters, and the final suspension
centrifuged as before. Meanwhile the recipient cells, approximately 80%
confluent on 10 cm plates (seeded 48hrs previously), were rinsed twice with
serum-free medium. The microcell pellet was resuspended in 3 ml of 20
mg/ml PHA-P in serum-free medium, and the whole suspension added to a
plate of recipient cells, the control plate was treated with PHA-P/serum-free
medium only. The cells were then incubated at 37°C for approximately 2
hours. Following this incubation 3 ml of 45% PEG-1000 in serum-free
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Table 2.4. Plasmids used in transfections
Table listing plasmid names and their sources. See Figure 2.1 for schematic
of plasmids
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Plasmid Source
pbabeHygro Dr. Sue Barnett
pexSVneo Dr.Olivia Periera-Smith
pexSVneoMORF4FS Dr.Olivia Periera-Smith
pexSVneoMORF4 Dr.Olivia Periera-Smith
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medium with 17% DMSO was added gently to the cells, to give a final
concentration of 22.5% PEG and 8.5% DMSO, and moved continuously for
45s at RT. After this incubation the cells were consecutively rinsed five times
with serum-free medium, (1 x 30 s, 1 x 45 sand 3 x 60 s rinses), and
incubated at 37 QC overnight in ordinary media. The cells were then
trypsinised and re-plated at 1x106 per 10 cm dish. After 72 hrs Hygromycin B
or G418 selection at a suitable predetermined concentration (see Table 2.3)
was added to the plates. The selection medium was changed twice weekly
and colony formation monitored. A schematic of this procedure is shown in
Figure 2.2.
2.1.6) Assay for endogenous fl-galactosidase activity
Adhered cells were rinsed twice with PBS, and fixed by incubating in 3% (v/v)
formaldehyde in PBS for 5 min at RT. The cells were then twice rinsed again
with PBS. 5 ml of X-gal staining solution (50 mM MES, 150 mM NaGI, 2mM
MgCI2, 5mM ~Fe(GNkH20 (potassium ferrocyanide), 5mM I<:3Fe(CN6)
(potassium ferricyanide) and 1mg/ml X-Gal) at pH 6 was added to each 10 cm
plate. The dishes were incubated in a humid box for 16 hr at 37 QG.
Following this incubation the cells were rinsed with mQH20 and assessed
histochemically for blue staining.
2.1.7) Rhodamine Stain for Keratinocytes
Adherent cells were first washed with PBS and then overlaid with 10%
Formaldehyde/PBS and agitated on a shaker for 10 min. Following this the
cells were washed once with PBS and overlaid with 1% Rhodamine B stain
and agitated for 30 min on a shaker. The cells were then rinsed with tap
water until all surplus stain was removed, air dried and observed under a low
power microscope
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Figure 2.2. Microcell-mediated
monochromosome transfer technique
For description of experimental procedure see Section 2.1.5.
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2.1.8) Glemsa Stain
Cells were washed twice with PBS and fixed in 10% Formaldehyde/PBS and
fixed for 30 min. Following fixation cells were washed in H20 and then
stained with 10% Giemsa's/H20 for 30 min. Following stain cells were
washed in H20 and air-dried. Cells were observed under a low power
microscope.
2.1.9) Determination of population doublings
The number of mean population doublings (MPD) that hybrids from MMCT
and Transfections had achieved was calculated at each passage according to
the formula of Paul et al., 1975.
PO = (log Nb- log Na) x 3.32
where Na = initial cell number
Nb = final cell number
2.1.10) Metaphase Spreads
Cells were seeded and cultured to approximately 70% confluence and
Demecolcine added to a final concentration of 100ng/ml and incubated at
3t>C for 1 hr. The cells were then trypsinised as normal, pelleted and
resuspended in a small amount of media by tapping. Through dropwise
addition, over a gentle vortex, 10ml of prewarmed (37°C) 75mM KCI was
added to the cell suspension and then the mixture incubated for 15 min at
3]oC. Following this 1ml of ice-cold fix (80% methanol, 20% acetic acid) was
added to the suspension, incubated on ice for 5min and centrifuged at 1000-
2000 rpm for 10 min. Remove supernatant carefully and add dropwise 10ml
ice cold fix, incubate on ice for 5 min and centrifuge remove supernatant and
repeat. Metaphases were dropped onto ice-cold slides and washed with 1ml
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ice-cold fix and allowed to air dry. Metaphase spreads were carried out by Mrs
H. Ireland, BICR.
2.1.11) Production of Retrovirus by Transient Infection
Pheonix A cells were seeded at a density of 2 X 10s/Scm dish 24 hours prior
to transfection. The cells were medium changed 5min before transfection and
replaced with medium containing 25~M chloroquinine. During this incubation
the transfection mixture was prepared by combining 8f.-lgDNA, 300mM CaCI2
and H20 to 500ml. A further 500ml 2 X HBS (50mM HEPES pH 7.05, 10mM
KCL, 12mM Dextrose, 280mM NaGI, 1.5mM Na2HP04·2H20, pH 7.05) was
added and the whole solution bubbled for 15sec to mix thoroughly. This
mixture was then immediately added to the cells and incubated at 37°G for 8.5
hrs after which time the cells were medium changed and again after a further
24 hrs. Supernatant was collected 50 hrs post-transfection and filtered once
through a 0.45f.-lmmembrane prior to freezing and titrating.
2.1.12) Viral Titre Assessment
NIH3T3 cells were seeded at a density of 105 cells/Scm dish 24hrs prior to
transfection. l00~1 virus was serially diluted (10-2, 10-3, 10-4, 10-5) and added
to sterile 4~/ml polybrene containing 10% DeS to a total volume of 4ml.
Dishes of NIH3T3 were infected with 1.5ml of appropriate dilutions; controls
contained no virus, and incubated for 4 hrs at 37°C. After this time
10%DCS/DMEM was added to bring the volume to 5ml and left overnight.
Dishes were then medium changed and following 24 hrs incubation this was
replaced with 1mg/ml G418 selection. Selection was performed for 10 days
followed by staining with Giemsa and titre calculated.
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2.1.13) Viral Infection of Keratinocytes
Cells to be infected were seeded at a density of 105 cells/6cm dish 72hrs prior
to infection. Viral supernatant was added to 8mg/ml polybrene in 10H to a
total volume of 5ml containing at least 1.35 X 104 viral particles and incubated
at 37°C for 4 hrs. Following the incubation the media was replaced with fresh
10H and the cells left overnight to recover. The cells were then split and
seeded at a density of 3 X 105/9cm dish allowed to recover for a further 72 hrs
and then placed under appropriate selection until resistant colonies had
appeared. Following selection the resistant colonies were pooled and stored
in liquid nitrogen for further use.
2.2) Immunocytochemistry
2.2.1) Immunofluorescence
Cells were plated into 8-well chamber slides at a density of 280 cells per well
and incubated for an appropriate time Le. 6 hrs or 6 weeks. The cells were
then washed briefly with PBS, and fixed for 5 min in precooled -10°C
methanol and allowed to air dry. All incubations were carried out at room
temperature in a humidified chamber. Once air-dried the cells were
permeablized with 0.1% NP-40 for 20min followed by blocking with 10% goat
serum for 20 min to suppress non-specific binding of immunoglobin. The cells
were then washed twice with PBS and incubated with the primary antibody (in
2% BSNPBS) for 1 hr. Following the primary antibody incubation the cells
were washed three times with PBS and incubated with the directly conjugated
secondary antibody (11-l9/mlFluorescein!Texas Red~. The cells were then
washed five times with PBS; gaskets removed, blotted dry and mounted in
Vectashield with OAPI. Mounted cells were sealed with coverslips and clear
nail varnish and stored at 4°C for future viewing.
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2.2.2) 5-Bromo-2'-deoxy-uridine Incorporation Analysis
5-Bromo-2'-deoxy-uridine (BrdU) incorporation analysis was undertaken using
the 5-8romo-2' -deoxy-uridine Labelling and Detection Kit 1 (Boehringer
Mannheim). Reagents were supplied as kit components. Cells were plated in
8 chamber slides at minimal density (280 cells/chamber) and maintained in
media for an appropriate time Le. 6 days or 6 weeks). BrdU labelling reagent
was added to the sample at a final concentration of 10 urnol/ml diluted in
sterile cell culture medium. The cells were then incubated for an appropriate
period of time (1hr, 4hrs, or 48hrs) at 37°C in a 5% incubator. After this
incubation the slides were washed three times with PBS and then fixed with
70% Ethanol (in 50mM Glycine buffer, pH2.0) for at least 20 min at -20°C.
The slides were then washed again with PBS as described above before
covering the cells with anti-BrdU (mouse monoclonal antibody containing
nucleases, in PBS/glycerine) diluted in Incubation Buffer (66mM Tris-buffer,
0.66mM MgCI2, and 1mM 2-mercaptoethanol) and incubating for 30 min at
3r'C. Following on from this incubation the slides were again washed as
above and then covered with anti-mouse-Ig-flourescein and incubated for 30
min at 3r'C. Slides were then washed as above, dried, and gaskets removed
followed by mounting in Vectashield/DAPI. Slides were sealed using clear
nail varnish and coverslips and stored at 4°C for future viewing
2.2.3) TUNEL Analysis
TUNEL analysis was undertaken using the Apoptag® Fluorescein Direct In
Situ Apoptosis Detection Kit (Intergen Company). Reagents were supplied as
kit components. Cells were plated in 8 chamber slides at minimal density
(280 cells/chamber) and maintained in media for an appropriate time i.e. 6
days or 6 weeks). Fixation of cells was undertaken using 1%
Paraformaldehyde in PBS, pH7.4, for 10 min at room temperature followed by
2x 5 min washes in PBS. Cells were then post-fixed in precooled
Ethanol/Acetic Acid for 5 min at -20°C, drained, and washed as above.
Excess liquid was then removed and 75f.l1Equilibration Buffer added directly
into each chamber and incubated for at least 10sec. Following this incubation
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and aspiration of the Equilibration Buffer 55~1 of Working Strength TdT
Enzyme (70% Reaction Buffer/30% TdT Enzyme) was added to each
specimen and incubated for 1hr at 37°C in a humidified chamber. To stop the
reaction the slides were placed in a coplin jar containing Working Strength
Stop/Wash Buffer (3% Stop/Wash Buffer/97% Distilled H20) and agitated for
15 s followed by 10 min incubation at room temperature. Slides were then
dried, gaskets removed, followed by mounting in Vectashield/DAPI. Slides
were sealed using clear nail varnish and coverslips and stored at 4°C for
future viewing.
2.2.4) Chromosome Painting
The previously prepared metaphase spread slides were immersed in 2 X SSC
at 3~C for 20min and then briefly in H20. The slides were then rapidly
denatured for 1min exactly in 0.4M NaOH / 0.6M NaCI and then quickly
washed 3 times in neutralization solution (1M NaCI / 0.5M Tris-HCI pH7.2)
agitating whilst washing. 3 X 1min washes in neutralization solution whilst
moving continuously followed this. Slides were treated with 30~g/ml pepsin in
1mM Hel for 5 min and then washed in 4 X sse for 3min followed by 1 X
PBS for 3 min. Metaphases were then serially dehydrated in increasing
concentrations of ethanol (70%, 90%, absolute) for 3 min per dilution and air
dried prior to denaturation. Spreads were denatured in 70% formam ide in 2 X
SST for exactly 90 s at 68°e in a coplin jar and then transferred into ice-cold
70% ethanol for 3 min, serially dehydrated as above and allowed to air dry.
Prior to the above step the probe was denatured at 70-72°C for 10 min and
then maintained at 37°C for 30min whilst denaturing the metaphase spread.
Hybridise 15~1probe to metaphase slide, seal with evostick and incubate for
48-72 hrs at 37°C in the dark. The probe consisted of 1~I of each paint, 1~I
Cot1 DNA and hybridisation buffer (50% deionised formamide, 10% dextran
sulphate, 10% 20 X sse, 8% 0.5M Na2HP04, 1% sos, 1% 100xDenhardt's,
and 10% H20 to 15~1total volume. To visualize slides, they were washed for
S min in prewarmed (37°C) 2 X sse for 5 min and coverslips removed
followed by washes at 4SoC (2 x 50% formamide, 1 X sse, and 2 x 0.1xSSC)
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of Smin each. Slides are then washed 4 X SST, 3 min per wash. Block slides
using 100lli 3 X BSA in 4 X SST, cover with paraffin slip and incubate at 37°C
for 20 min in humidified chamber, followed by a 3 min wash in 4 X SST and
paraffin removal. Appropriate antibody dilution's prepared in 4 X SST, to 100ll
I, used to cover metaphase areas and incubated at 37°C. Once complete
wash twice in 4 X SST add DAPI mountant, coverslip and seal with nail
varnish. Slides must be kept in the dark as much as possible through the
denaturation and detection procedures. Dr. S. Dowens (Dept. of Pathology,
University of Cambridge) and Mrs Hazel Ireland (BICR) carried out
chromosome Painting.
2.2.5) Visualization by Fluorescence Microscopy
Visualization of slides was undertaken using a Zeiss Axioskop Fluorescent
Microscope using the appropriate filters for colour detection. Images were
captured using a CCD Camera System (Princeton Instruments) and analysed
using IPLab Spectrum 10, Version 3.0 (Signal Analyticals).
2.3) Extraction, Synthesis and Quantitation of Nucleic Acids
2.3.1) Extraction of Genomic DNA from Mammalian Cell Lines
Genomic DNA was extracted from mammalian cell lines and hybrids using the
QIAamp® DNA Mini Kit (QIAGEN). All reagents and plasticware were
supplied as kit components. Cells were first harvested by trypsinisation,
pelleted and washed twice in PBS followed by resuspension in 200lli PBS.
Lysis of cells was performed by first adding 1/10 volume Proteinase K
followed by an equal volume Buffer AL, vortexing the sample for 1Ssec and
incubating for 10 min at 5SoC. Following incubation % volume Ethanol was
added to the sample, vortexed again for 15sec, transferred into a QIAamp
spin column and centrifuged at 15300rpm for 1min. The flowthrough was
discarded and the column was first washed with SOOIlIBuffer AW1 and then
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with 500!!1of BufferAW2, both wash steps are centrifuged as above. Eluting
with an appropriate volume of Buffer AE eluted the DNA from the column.
2.3.2) Extraction of Total RNA from Mammalian Cell Lines
Total RNA was extracted from mammalian cell lines and hybrids using the
Rneasy® Mini Kit (QIAGEN). All reagents and plasticware were supplied as
kit components. Cultured cells were first trypsinised and pelleted at 300 x g
and lysed by addition of an appropriate volume of Buffer RLT (containing 13-
Mercaptoethanol), vortexed to mix, and the lysate transferred onto a
QIAshredder column followed by centrifugation at 15300rpm for 2 min. The
homogenized lysate was mixed with an equal volume of 70% Ethanol and
applied onto an Rneasy mini spin column and centrifuged for 15 s at 8000 X
g. The column was then washed first with Buffer RW1 and then Buffer RPE
with the flowthrough being discarded at each step, centrifugation carried out
at 8000 X g for 15 s. The final wash step used Buffer RPE at 15300rpm for 2
min before elution, into a 1.5ml collection tube, with an appropriate volume of
Rnase-free H20 using centrifugation at 8000 X g for 1 min.
2.3.3) Synthesis of Oligonucleotides
Oligonucleotides were synthesized at the BICR as a core service on a 394
RNA/DNA synthesizer (Applied Biosystems) using Cruachem reagents.
Oligonucleotides were deprotected and lyophilized using the Hybaid Proligo
system and supplied in this form. The supplied oligonucleotide was
resuspended in 500",,1of mQH20 and the concentration determined as
described below.
2.3.4) Quantitation of Nucleic Acid Concentrations
Nucleic acid was quantified by spectrophotometric determination of its UV
light absorbency. 5 ml of sample was added to 495 m1 of de-ionised water
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and the absorbency of the solution measured at 260 nm and 280 nm in a
quartz cuvette, using dH20 as a blank. The concentration of the solution was
calculated using de Beer's law on the basis that an optical density of 1.0 at
260 nm corresponds to a concentration of 50ngll-'" for double-stranded DNA,
40ng/J.tIfor total RNA, and 30ng/!-l1for single-stranded oligonucleotides. Pure
preparations of DNA and RNA have a ratio of A2601A28oreadings between 1.5
and 1.9.
2.4) peR and analysis of amplification products
2.4.1) peR
Standard PCR was generally undertaken using 100ng Template DNA, 10!-lM
Forward Primer, 10!-lM Reverse Primer, 1x Reaction Buffer II (Perkin-Elmer),
25mM MgCI2.2mM each dNTP, 0.04U Amplitaq Polymerase (Perkin-Elmer),
and mQH20 to a total volume of 23f.d. Occasional slight alterations to the
annealing temperature or concentration of magnesium ions were required for
optimal results. The PCR conditions consisted of a 3min denaturation at
95°C, followed by 30 rounds of 30 s denaturation at 94°C, 30 s annealing at
60°C, and 1 min extension at 72 "C, finally the reactions were held for a final
7 min extension at 72°C before ramping down to 4°C. Occasional alterations
were made to the annealing temperatures or to the extension time to optimise
PCR conditions. Reactions were carried out using a GeneAMP 9600 (Perkin-
Elmer Cetus). Prior to sequencing or quantification (see below) PCR product
was purified using the QIAquick PCR Purification Kit (QIAgen). A full list of all
primers used is outlined in Appendix 1.
2.4.2) peR Product Purification
This was undertaken using the QIAquick PCR Purification following the
manufacturers protocol as briefly described. Add 5 volumes of Buffer PB to 1
volume of PCR reaction mix and apply mixture to QIAquick spin column in a
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2ml collection tube and centrifuge at 10,000rpm for 60 s. Following this
discard flow-through and wash column by adding 0.75ml Buffer PE and
centrifuging as above, discard eluant and spin again as above. To elute
purified PCR product 30111elution buffer was applied to the column and
incubated at room temperature for 1 min and centrifuged as above. The
manufacturer as part of the kit supplied all reagents and plasticware.
Centrifugation was performed on a conventional tabletop microcentrifuge.
The concentration of the sample was determined by running 10% of total
volume against an appropriate DNA ladder, for example the 1kb ladder
(GibcoBRL).
2.4.3) Sequencing
Completed sequencing reactions were ran out in-house at the BICR on an
ABI 373 sequencer (Applied Biosystems). Prior to this 40-80ng of purified
PCR product and 3.2pmol primer oligonucleotide was added to BigDye
Terminator cycle sequencing reagents (Perkin-Elmer Applied Biosystems).
Reactions were performed on a PCT-100 thermal cycler (Genetic Research
Instrumentation Ltd) using 25 cycles of 10 s at 95°C, 5 s at 55°C, and 4 min at
60°C. Completed sequencing reactions were analysed using DNAStar
software. A full list of primers is outlined in Appendix 2.
2.4.3) Real-Time Quantitative peR
All two-step Real Time-QPCR reactions were carried out using 96-well
reaction plates. 50ng of total cell RNA was added to Reverse Transcription
reaction mix comprising 1xTaqman RT Buffer, 5.5mM MgCI2, 500r.-tMof each
dNTP, 2.5r.-tM Random Hexamer, 0.4 U/r.-tl Rnase Inhibitor, 1.25 U/r.-tl
Multiscribe Reverse Transcriptase. The total reaction volume was made up to
Sill with Rnase-free H20. The cycling parameters for the Real Time-PCR step
were 10 min Incubation Hold at 25°C, 30 min Reverse Transcription at 48°C,
followed by a S min Reverse Transcriptase Inactivation at 9SoC. Transfer 20111
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of PCR reaction mix into each tube; comprising 1x Taqman Buffer A, 5.5 mM
MgCI2, 200~M deoxyATP, 200~M deoxyCTP, 200~M deoxyGTP, 400""M
deoxyUTP, 100nM MyoD1 Fluorigenic Probe, 200nM MyoD1 Forward Primer,
200nM Myod1 Reverse Primer, 0.01 U/""I, and 0.025 U/""I Amplitaq Gold DNA
Polymerase. The PCR reaction mix volume was made up to 20",,1using
Rnase-free H20. Cycling steps for the PCR step were 2 min UNG Incubation
at 50°C, 10 min Amplitaq Gold Activation at 95°C, and 40 cycles of a 15 s
denature at 95°C and 1min Anneal/Extend at 60°C. Reactions and product
analysis were carried out upon an ABI PRISM 7700 Sequence Detection
System. Primers designed using Primer Express™ software (see Table 2.5.),
MyoD1 intron/exon structure obtained from Zingg et ai, 1991.
2.4.4) peR Analysis of Microsatellites
Microsatellite Analysis was undertaken using 40ng of genomic template DNA
extracted from matched HNSCC fibroblasts and tumour lines and hybrids
resulting from the MMCT procedure. Total PCR Reaction Mix comprised
40ng DNA, 1x Buffer 1 (Perkin-Elmer), 200~M dNTP's, 10% DMSO, 1""M
Forward Primer, 1""M Reverse Primer, 10kBq a-32P-dCTP, and 0.5U Taq
Polymerase. Cycling steps comprised 3 min at 95°C, followed by 30 cycles of
(30 s at 94°C, 30 s at 55°C, and 30 s at 72°C), and finally 7 min at 72°C. The
Microsatellite markers were derived from Genethon, a full list of polymorphic
marker specific primers is described in Appendix 3. Radiolabelled
Microsatellite PCR products were visualized using Denaturing Polyacrylamide
Gel Electrophoresis.
2.4.5) Denaturing Polyacrylamide Gel Electrophoresis
The radiolabelled PCR products of polymorphic markers were resolved on a
range of polyacrylamide gels under denaturing conditions. This range was
dependent on the length of the PCR product; see Table 2.6. A gel solution
was prepared from Sequagel stock solutions using 7.5M Urea (Sequagel
Diluent), 25% "I,Acrylamide solution 19:1 Acryl:Bisacryl and 7.5M Urea
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Table 2.5. MyoD1 primers used in Real Time-
QPCR
See Section 2.4.3 for description of technique and description of primer
construction.
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Length Tm %GC Primer
Forward 19 59 63 ACAGTGGCGACTCAGACGC
Primer
Taqman 20 69 70 CAGCCCGCGCTCCAACTGCT
Probe
Reverse 22 59 45 GCTGTAATCCATCATGCCATCA
Primer
Amplicon 65 84 60
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Table 2.6. Microsatellite peR product size and
appropriate gel acrylamide concentration
Concentration of acrylamide was optimised to PCR product size to ensure
seperation of differing microsatellite bands by gel migration.
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Product Size Gel
100-130bp 8%
130-170bp 7%
170-220bp 6%
220-300bp 5%
300-500bp 4%
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(Sequagel Concentrate), and Sequagel Buffer comprising 7.5M Urea, 1M Tris-
Borate and 20mM EDTA pH8.3. The solution was polymerised by the
addition of 650ml of 10% "t, ammonium persulphate and 100ml of TEMED
per 100ml of gel solution. This solution was then poured between glass
plates separated by 0.4 mm spacers and allowed to set at room temperature
for approximately 1 hr. Gels were pre-run at 60W for 45 min in 1 x TBE (90
mM Tris-borate and 2 mM EDTA pH 8.0) to warm the gels to approximately
50 QCbefore the loading of samples. Denaturing Gel Loading Buffer (98% v/v
Formamide, 10mM EDTA pH 8.0, 0.1% "I, Xylene Cyanol and 0.1% "l,
Bromophenol Blue) was added to the completed PCR reactions (Sill added to
10111reaction) and this mixture denatured by heating at 95°C for 5 min and
immediately quenched on ice. 5ml of this mixture was subjected to
electrophoresis at 50W for approximately 4 hr depending upon the size of the
PCR product. The gel was then transferred to a sheet of Whatman 3M paper
and dried under vacuum at 80°C for 45 min. The PCR products were
detected by autoradiography using X-ray film.
2.4.6) Agarose gel electrophoresis of unlabelled peR products
Non-radioactive PCR products were separated on non-denaturing agarose
gels and visualized by staining with Ethidium bromide and UV
transillumination. Gels were prepared by dissolving electrophoresis grade
agarose in I X TAE (40 mM Tris-acetate and 2 mM EDTA pH 8) through
microwaving on a medium heat setting for 2-3min. Ethidium Bromide to a
final concentration of 0.5Ilg/ml was added to the dissolved agarose before
being poured into an appropriate gel former and left to set for approximately
20 min. Once solid, gels were placed into electrophoresis tanks containing I x
TAE. Samples to run were combined with 1/5 volume Running Buffer (50%
Glycerol, 100mM EDTA, 1x TAE, 0.1% Bromophenol Blue) and loaded into
the appropriate well. Electrophoresis was performed for 1 hr at 100V to
ensure separation of bands. In order to estimate the size of fragments
resolved by electrophoresis, samples were run alongside known molecular
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weight markers, such as a 1kb ladder. DNA was visualized by UV
transillumination and the gel analysed using Biorad software.
2.5)Microbiological techniques
2.5.1) Plasmid DNA Extraction
Plasmid DNA was extracted using the OIAGEN Midi Kit. A single colony was
picked from a selective plate (see Section 2.5.2) and used to inoculate a 5ml
starter culture of LB medium containing 100t-tg/mlAmpicillin. The culture was
incubated for 8 hrs at 37°C in a shaker, diluted 1/1000 into selective LB
medium and incubated for a further 16 hrs at 37°C in a shaker. The bacterial
cells were harvested by centrifugation at 6000 X g for 15 min, all supernatant
removed and resuspended completely in 10ml Buffer P1. An equal volume of
Buffer P2 was added and gently mixed by inversion followed by incubation at
room temperature for 5 min. A further incubation of 20 min on ice followed the
addition of 10ml Buffer P3 (chilled). Centrifugation at 20,000 X g for 30 min at
4°C separated the plasmid DNA from cell debris, the supernatant from this
spin was removed promptly and respun at 20,000 X g for 15 min at 4°C.
Whilst the final spin was underway applying 10ml Buffer OBT and allowing it
to empty by gravity flow equilibrated a OIAGEN-tip 500. On completion of the
spin the supernatant was removed and applied to the QIAGEN-tip and
allowed to enter the resin by gravity flow. The QIAGEN-tip was washed twice
with 30mI Buffer OC allowing gravity flow to move the buffer in both cases.
Elution of DNA from the resin was done with 15ml Buffer OF and collected in
a 30ml tube followed by precipitation by adding 0.7 volumes of Isopropanol to
the eluted DNA. This mixture was then centrifuged at 15,000 X g for 30 min
at 4°C and the supernatant decanted leaving the DNA pellet in the tube. The
DNA pellet was washed with 5ml of 70% Ethanol by centrifugation at 15,000 X
g for 10 min and the supernatant again decanted leaving the DNA precipitate.
The pellet was then air-dried for 10 min and resuspended in TE, pHS.O.
Plasmid DNA concentration was determined as described for genomic DNA
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2.5.2) Transformation of bacteria with plasmid DNA
DHSacompetent strain of E.coli was thawed on ice and 20~,tItransferred into a
prechilled 1.Sml microcentrifuge tube. Plasmid DNA diluted to a final
concentration of 1Ong/~,d-20ng/lllwas added to the DHSa cells, mixed and
incubated on ice for 30 min. The cells were then heat-shocked for 40 s in a
42°C water bath and then placed on ice for 2min. BOlli S.O.C Medium
(GibcoBRL) was added to the microcentrifuge tube and agitated in a shaker at
22Srpm at 1hr at 370C. All of the cells were then spread on LB medium
(Luria-Bertani Medium; 10g bacto-tryptone, Sg bacto-yeast extract, 10g NaCI
in 11trdeionised H20 pH7.0. LB Medium prepared in-house at the BICR)
plates containing 1.S% (w/v) agar supplemented with the appropriate
antibiotic and poured in advance. Plates were incubated in an inverted
position at 37 "C, and colonies transferred into LB medium the following day.
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Chapter 3
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3.1) Combined Analysis Suggest Areas of Deletion on
Chromosome 4
The ability to inactivate tumour suppressor genes through loss of a
copy of an endogenous chromosome accompanied by mutation on the
remaining gene copy has been proposed as an important mechanism in the
development of carcinogenesis. This manifestation of allelic loss has been
termed Loss of Heterozygosity (LOH) and has been implicated in a variety of
tumour types. Defects in components of the mitotic machinery have been
implicated in the development of this chromosomal instability allowing
aneuploidy to develop (Pihan et al., 1999). The study of LOH is based on the
PCR amplification of highly polymorphic, ubiquitous, and abundant
endogenous microsatellite repeats (Weber and May, 1989; Loius et al., 1992;
Weissenbach et al., 1992; Gyapay et al., 1994) and resolving the two alleles
using gel electrophoresis. Microsatellites themselves consist of repeating
units of 1-6bp that are highly polymorphic due to their high mutation rate (10.3-
10-4per generation) (Weber and Wong, 1993). In this manner it can be clear
if the tumour has lost an allele copy as compared to the matched normal
tissue. The polymorphic markers are continuously placed in order at both
Genemap 2000 and Marshfield (Broman et al., 1998), see list of websites for
more details.
Chromosome 4 LOH has been observed in multiple tumour types
although the tsg's undergoing inactivation have yet to be cloned or identified.
Indeed the LOH observed occurs on both the short p arm and the long q arm
identifying several potential tsg sites on this chromosome. An illustration of
the findings of these studies is outlined below.
An allelotypic study in bladder cancer revealed LOH on 4p in 22%
(13/60) of samples analysed although no LOH on 4q was observed (Knowles
et al., 1994). Using a large number of primary bladder carcinoma samples
two common regions of lost were identified (Polascik et al., 1995). These
regions were localised to a 3.9cM region on 4p15 (29%, 82/282) and a 12cM
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region on 4q34 (24.1%, 68/282) and correlated well with an advanced tumour
stage.
Breast cancer studies have also implicated LOH on chromosome 4 as
important for tumour progression. A GGH study on 39 invasive ductal breast
carcinomas found loss of material on 4q in 51% (20/39) of samples analysed
making it the second most frequent loss seen (Schwendel et al., 1998),
whereas a further allelotyping of breast carcinomas revealed four regions of
common loss (Shivapurkar et al., 1999). These regions comprised two from
both the p and q arms, namely, a locus on 4p15.1-p15.3 of 3cM length (63%,
26/41), a locus on 4p16.3 of 750-kb long (58%, 22/38), a locus on 4q33-q34
of 14cM length (79%,27/34), and a locus on 4q25-q26 (67%, 26/39).
A study utilising GGH in consecutive stages of colorectal
carcinogenesis found that chromosome 4 was lost in 31% (5/16) of colorectal
carcinomas (Ried et al., 1996). A chromosome 4 copy number reduction was
not seen in either low-grade adenomas or high-grade adenomas suggesting
the reduction was a late event. GGH studies in colon cancer found increasing
frequency of losses at 4p16 were present in metastases as compared to
primary tumours (Paredes-Zaglul et al., 1998). This suggests that although
not sufficient the loss of 4p16 may in this instance be advantageous to
malignant development.
Gynaecological carcinosarcoma cases studied revealed 4q losses to
be the fourth most frequent site of LOH (29.4%, 5/17) after 17p (P53), 9p
(P16), and 13q (PRB) although no specific locus was identified (Fujii et al.,
2000). GGs studied allelotypically revealed LOH on 4q (46%) that specifically
mapped to the 4q21-q23 region (Mitra et al., 1994), although this study did not
define any specific locus. A semi-automated fluorescence-based LOH
detection system was used to identify two preliminary regions (Hampton et al.,
1996). These regions mapped to a 63cM region distal to 04S1627 on 4p and
a 67cM region distal to 04S1625 on 4q. GIN demonstrated LOH on both 4p
and 4q and identified a 24.4cM region at the telomeric end of 4p and a 1.1 cM
region at the telomeric end of 4q (Larson et al., 1997).
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HN8CC cases studied have also been shown to demonstrate LOH on
chromosome 4. Importantly findings would indicate that LOH at 4q is a later
event in HN8CC tumourigenesis in agreement with the work described
previously (Califano et al., 1996; Koch and McQuone, 1997; Rosin et al.,
2000). Allelotypic analysis of advanced HNSCC demonstrated loss of both
chromosome 4 arms without specifying any definite locus (Nawroz et al.,
1994). This study showed 4p loss in 38% (8/21) and 4q loss in 37% (9/24) of
samples analysed, whilst a further study utilised CGH to show frequent losses
of the chromosome in approximately 50% of samples from a panel of 133
primary HNSCC (Bockmuhl et al., 2000). A study using immortal HNSCC
derived cell lines implicated a locus at 4q32-q34 between 04S1535 and
D4S408 where 75% (6/8) of samples showed losses (Loughran et al., 1997,
Parkinson et al., 1997). This correlated well with an earlier study where losses
were seen on 4q and not on 4p although a lack of informativity prevented
locus definition (Loughran et al., 1994). However a similar study found LOH
on 4q in 81% (22/27) and 4p in 41% (11/27) of HNSCC tumours analysed
(Pershouse et al., 1997). This implicated a small region on 4q21 between
D48400 and 048423. a region on 4q25 between 0481616 and 048407, and
a third region on 4p11-p12 of 7cM.
An early study using a panel of RFLPs against hepatocellular
carCinoma (HCC) samples found evidence of 4q allele loss in 58% (7/12) of
cases which localised to 4q11-q25 (Buetow et al., 1989). Further use of
RFLP showed LOH on chromosome 4 in 28% (4/14) of cases (Fujimoto et al.,
1994). In hyperploid HCC LOH of 4q was observed in 42% (20/48) of
samples suggestive of an alternative mechanism in the tumour progression
(Legoix et al., 1999) although no specific locus was identified in this study.
Three minimally lost regions were identified in 15 HCCs analysed by LOH on
4q26-q27 of 7cM (67%, 10/15), 14cM (67%, 10/15), and 6cM (73%, 11/15)
although there was no data to distinguish between these areas (Chou et al.,
1998). Seven regions on 4q were demonstrated to have undergone a high
frequency of LOH in HCCs in an additional study (Piao et ai, 1998). These
were 1) 7cM region centred on 4q25 at 04S 1615 (47%, 16/34), 2) 5cM
centred on 4q31 at 04S 1598 (50%. 17/34), 3) 3cM centred on 4q31 at
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048620 (59%, 20/34), 4) 5cM on 4q31 between 0481566 and 0482979
(56%, 19/34), 5) 4cM on 4q32 defined by 04S1545 and 04S1617 (47%,
16/34), 6) 2cM on 4q33 defined by 04S1537 (56%, 19/34), and 7) 7cM on
4q34 between 0483041 and 0481535 (62%, 21/34). A separate study
identified two regions of LOH centred on 4q12-q21 and 4q22-q24 which were
lost in 50% (12/24) of HCCs with informative alleles (Rashid et ai, 1999). The
4q21 lost was region defined to a deleted region of 1cM on 4q21-q22 based
on common LOH in 48% (12/25) of HCCs analysed and delineated by
0481534 and 04S2929 (Bando et al., 1999).
8CLC has been shown to undergo a high incidence of deletions on 4q.
Using the CGH technique losses were seen on 4q in 55% (10/18) at 4q24-q26
(Levin et al., 1994), and 86% (19/22) of SCLCs examined with two common
regions lost at 4q11-q23 and 4q32 (Petersen et al., 1997). CGH analyses of
primary 8CLC and their metastases found over 60% of cases showed losses
on chromosome 4 with deletions at 4q11-q23 and 4q32 present (Schwendel
et al., 1997), however no single aberration was shown to be significantly
associated with metastatic phenotype. A further CGH study in clonal
evolution of metastatic 8CLC of the lung found that 4p and 4q losses were
present in over 50% of samples however a deletion at 4p15-p16 occurred
more frequently in the metastatic stage (Petersen et al., 2000).
CGH analyses of both adenocarcinoma and 8CC of the lung showed
frequent losses of 4q were seen in both entities (Petersen et al., 1997). This
indicates that although both tumours have distinct originating tissues they can
be characterised by common genetiC losses suggestive of common pathways
being deregulated.
The findings in epithelial hyperplasia and low-grade dysplasia which
demonstrated progression showed LOH on 4q in 30% (8/27) of cases
whereas those with no progression showed LOH on 4q in 5% (4/79) (Rosin et
al., 2000) suggesting that LOH on 4q may be advantageous for tumour
progression. A localization study in osee revealed a frequency of LOH on
the q arm of 66% (21/32) compared to 25% (8132) on the shorter p arm
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however the common region of loss was centred at 04S1573 on 4q25 with a
minimal distance of 4cM lost (Wang et al., 1999). Allelotypic analysis in EA
revealed an involvement of 4q losses, although no specific locus was
identified in this study, with 54.5% (12/22) of samples showing long arm loss
(Hammaud et al., 1996). Further examination found LOH on 4q in EA at three
regions of common loss (Rumpel et al., 1999). These were centred on
04S1534 at 4q21.1-q22 (56%,13/23), on 04S620 at 4q32-q33 (48%,13/27),
and on 04S426 at 4q35 (62%, 16/26). A genome wide screen in ESCC found
LOH on 4p in 65% (24/37) and 4q in 67% (62/93) of cases studied (Hu et al.,
2000). In this same study three regions with a very high frequency of LOH
were identified at 4p16 with 04S2366 (78%, 7/9), 4p 12-p14 with 04S2632
(90%, 9/10), and 4q21.3-q22 with D4S2361 (100%, 7/7) although the size of
the regions are all approximately 20cM due to density of microsatellite
markers used in the screen.
Representational difference analysis (RDA) in osteosarcomas, where
normal DNA acted as the tester and tumour ONA as the driver therefore
highlighting any deleted sequences, identified a region from 4q32-qtel of
approximately 26.2cM although a preliminary known gene screen did not
identify any suitable candidates (Simons et al., 1999). LOH analysis in
dedifferentiated chondrosarcoma demonstrated that deletion of a
chromosome 4 allele had occurred in both the anaplastic sarcoma and the
low-grade malignant cartilage-forming tumour (Bovee et al., 1999).
Furthermore the chromosome 4 losses had occurred as separate events in
each component as both had lost a different copy indicative of separate
deleterious events.
CGH studies revealed that 4q losses were also present in RCCs with
50% (6/12) showing 4q deletions (Jiang et al., 1998). The minimal region of
overlap in this study was suggestive of minimal loss locus on 4q28 although
no further definition of the region was reported.
There has also been an implication in other non-cancerous disease
states that LOH on chromosome 4 is important for their progression. Linkage
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studies on mixed families suffering from forms of IBO identified a locus
centred on 0481647 and 0482623 (Mlod 1.71, P = 2.5 X 10-3) at 4q23 (Cho
et al., 1998). The human autosomal polycystic kidney disease (AOPKO) has
at least three loci that account for the disease, one of these is localised to
4q21 where 10% (3/30) of samples showed LOH whilst a further 27% (8/30)
demonstrated somatic mutations (Torra et al., 1999). A further linkage study
involved in identifying the gene responsible for an autosomal dominant
scleroatrophic syndrome which also predisposes to aggressive early onset
sec identified a locus on 4q21 centred on 04S2380 (Mlod 8.69) of
approximately 3.1cM (Lee et al., 2000).
3.2) LOH Analysis Reveals Three Regions of Loss in Immortal
HNSCC Lines
Given the wide variety of informative LOH from the large variety of
different tumour types it is clear that there are a number of different regions
being identified as sites for potential tsg's. An unbiased view at the available
discrete data sources reveals that there are probably 9 different common
regions of LOH on chromosome 4 shared to differing degrees between
tumour types (see Figure 3.1). Given the varying nature of these studies we
decided to further our interest in HNSCC by carrying out an initial LOH screen
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Figure 3.1. Regions of chromosome 4 LOH
identified in previous studies
Numerous regions of LOH have been identified and published as putative
sites of tsg localisation. Figure 3.1 illustrates these identified regions (grey
boxes) and the tumour type or disease of origin (listed along the top of the
diagram). The representation of chromosome 4 on the left hand side delivers
an approximation of the chromosomal position of the identified regions. The
areas boxed in red illustrate the regions of LOH identified in Figure 3.3 from
the panel of 10 immortal HNSCC lines.
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across chromosome 4 using an approximate 10cM microsatellite repeat
spacing which spanned both arms of the chromosome, all microsatellite
details are described in Appendix 1. The ordering of the markers were
verified using the CEPH/Genethon chromosome 4 linkage map, the
Marshfield chromosome 4 sex averaged linkage map, and the Stanford
Human Genome Centre YAC ST8-content map. For this study we analysed
normal DNA and matched tumour DNA from a panel of 10 immortal HNSCC
derived cell lines as described in Chapter 2. The study was performed using
the microsatellite PCR and gel electrophoresis methods described in Chapter
2. Representative gel images illustrating LOH and ROH are shown in Figure
3.2.
The results of our broad screen across the chromosome identified
three regions of common LOH seen across our lines (Figure 3.2). The first
(R1) of these spanned 4q12-4q23 and was defined by retentions of
heterozygosity (ROH) proximally in BICR31 at 04S409 and distally in BICR18
at 0481089 and BICR22 at 048423. This region of LOH spanned an
approximate distance of 30cM. The second (R2) and largest region of LOH
identified was approximately 36cM in length on 4q22-q28. This region was
defined by ROH in BICR18 at 0481570 and BICR22 at 0482981. The third
region (R3) was on 4q34-q35 of approximately 9cM length. This region was
defined by ROH in BICR68 at 0483032 and in BICR68 at 0482930.
From the analysis of our lines we observed complete ROH of
chromosome 4 in 30% (3/10) of cases, BICR3, BICR19, and BICR63. In the
immortal keratinocyte lines studied 70% (7/10) showed some degree of LOH
on the endogenous chromosome copy. Of these lines 50% (5/10) showed
LOH of R1, showed LOH of R2, and 60% (6/10) showed LOH of R3. There
were no observable discrete areas of LOH on 4p with 30% (3/10) lines
Showing losses. In every case of 4p loss the entire 4q arm was also lost
whereas 40% (4/10) lines with an intact p arm had deletions on the q arm.
From our analysis then we had identified three regions of LOH on our
lines however we had no basis on which to distinguish which area was likely
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Figure 3.2. Microsatellite marker 045409
illustrates both ROH and LOH
The image of 04S409 microsatellite PCR products following seperation on a
5% denaturing polyacrylamide gel (see Chapter 2, Section 2.4.5) serves to
illustrate LOH and ROH. 04S409 delineates the upper margin of Region 1
through ROH of BICR 18 and BICR31. For each cell line the left hand band
indicates normal patient fibroblast DNA whilst the right hand band indicates
patient tumour DNA.
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Figure 3.3. LOH analysis of immortal HNSCC
lines reveals three regions of loss
Microsatellite analysis of 10 immortal HNSCC-derived keratinocyte cell lines
illustrates 3 common regions of loss (red boxes). Endogenous chromosome
lOH is shown where it occurs for each immortal cell line (grey box). The
microsatellite markers used, their approximate positioning (eM), and cytogenic
Positioning on a chromosome 4 ideogram are shown to the left of the LOH
cartoon.
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to be a good candidate for an intensive screen to identify any potential novel
tsg on chromosome 4. Indeed our three identified regions agreed with every
region previously identified in the studies described above. The more
advanced a tumour the greater likelihood of observing increasing regions of
loss through genomic instability. This instability would be reflected in random
losses throughout the genome however in the regions, which we have
identified, there is a repetitive loss occurring in a number of different tumour
types increasing confidence in the identified regions. LOH analysis has been
described as a useful source of circumstantial evidence whilst providing no
formal proof for the presence of a tsg (Casey et al., 1993). To extend our
study then we decided to carry out MMCT experiments to identify both the
phenotype and the location of the gene through segregation events.
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Chapter 4
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4.1) MMCT of Exogenous Chromosome 4 Induces Growth
Arrest in Lines Exhibiting LOH on the Endogenous Copy
From the LOH study, which we undertook on our 10 HNSCC immortal
keratinocyte lines, we were able to identify three regions on the endogenous
chromosome as potential tsg sites. These regions also agreed with that
previously discussed in the literature (see Chapter 3) so clearly we needed to
select between our regions before launching a focused gene hunt. These
identified regions also concur with observations previously made in the
literature although without any bias towards any favoured locus. To
distinguish between these three regions of LOH we used MMCT to ascertain
whether any functional complementation would occur followed by the
development of truncated chromosomes through XMMCT to determine where
the complementing locus lay. We also hoped to develop loss maps from
resultant hybrids to confirm our regional findings from above.
MMCT has been previously demonstrated to be of use in identifying
genes lost in tumour progression in a number of studies through functional
complementation of an inactivated copy on the endogenous chromosome by
the introduced exogenous copy. This technique has been used to identify
potential tsg's on Chromosome 1 (yamada et al., 1990; Sasaki et al., 1994;
Miele et al., 1996), tq (Hensler et al., 1994, Karlsson et al., 1996),2 (Uejima
et al., 1995), 2p22-p25 (Mashimo et al., 2000), 3p (Rimessi et al., 1994,
Tanaka et al., 1998), 3p21-p22 (Killary et al., 1992), 4 (Ning et al., 1991), 6
(Yamada et al., 1990; Welch et al., 1994; Miele et al., 1996)), 6q (Sandhu et
al., 1994), 6q14-q21 (Sandhu et al., 1996), 6q16.3-q23 (Miele et al., 2000), 7q
(Ogata et al., 1993), 8 (Gustafson et al., 1996), 9 (yamada et al., 1990b).
9p21 (England et al., 1996), 11 (Weissman et al., 1987; Oshimura et al.,
1990), 11P15 (Dowdy et al.. 1990, Koi et al., 1993), 17 (Casey et al., 1993).
18 (Sasaki et al., 1994). and X (Klein et al., 1991, Wang et al., 1992, Trott et
al., 1995).
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The first evidence of a link between chromosome 4 and tumourigenicity
was provided by cell-cell fusions between a fibrosarcoma cell line and normal
fibroblasts (Benedict et al., 1984) followed by injection into athymic mice. The
reappearance of tumourigenicity in the mice correlated with the loss of
chromosome 4. This was suggestive of chromosome 4 carrying a gene
whose loss is beneficial to the progression of tumourigenesis. Further
evidence was provided by the MMCT of chromosome 4 into a subset of cells
(HeLa, J82, and T98G) causing the reversion of the immortal phenotype to a
phenotype characteristic of replicative senescence (Ning et al., 1991). This
demonstrated that the functional complementation that was occurring was
likely replacing a component in a commonly lost pathway enhancing the
tumourigenic potential.
We used MMCT (see Chapter 2, Section 2.1.5) to introduce an
exogenous copy of chromosome 4, which was resistant to both neomycin and
hygromycin (McNeill and Brown, 1980; Santerre et al., 1984; Saxon et al.,
1985; Ning et aI, 1991; Cuthbert et aI, 1995) into a preselected panel of our
cell lines (see Table 4.1). Chromosome painting of the A92 donor murine line
and the A9HYTK4 line with a single copy of chromosome 4 is shown in Figure
4.1. Dr. S. Dowen, Dept. of Pathology, University of Cambridge, and Mrs H
Ireland, BICR undertook all chromosome painting described throughout. The
exogenous chromosome 4 was tagged using an amphotropic pseudotype of
the replication-defective retrovirus vector tgLS(+)HYTK, the HYTK is a fusion
gene from the bacterial hph (conferring resistance to Hygromycin B,
hygromycin phosphotransferase) and herpes simplex virus thymidine kinase
(Lupton et al., 1991, Trott et al., 1995), followed by secondary tagging using
LN(neo) retroviral infection (Newbold and Cuthbert, 1996). For our purposes
in this instance we utilised the Hygromycin resistance marker for hybrid
selection. The selected cell lines were matched for a number of
characteristics genetically (see Table 4.1) but differed critically in whether they
showed LOH (BICR6, BICR31) or ROH (BICR3, BICR19) of the endogenous
chromosome 4 copy. We found that we observed a growth arrest like
phenotype in BICR6 (39%, 24/62)) and additionally in the second
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Table 4.1. Characteristics of cell lines used for
MMCT
The criteria used for cell line selection are tabulated overleaf. These criteria
are defined as the absence of ras mutations, the inactivation of p161NK4A,the
mutation of p53, consistent levels of EGFR number per cell, positive hTERT
expression, LOH on 3p, and the presence or absence of LOH on 4q.
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Cell Line BleR3 BleR6 BleR19 BleR31
Characteristic
Harvey ras No No No No
mutation
(Clark et al., 1993)
p161NK4A Mutated Deleted Mutated Deleted
(Loughran et al.,
1994)
p 14ARF (Munro et Yes No Yes No
al.,1999)
p53 Mutated Mutated Exon 10 Mutated
(Burns et al., 1993) Deleted
EGFR number/cell 1.4 X 106 1.8 X 106 0.2 X 106 1.2 X 10
6
(Stanton et aI., 1994)
Telomerase Positive Positive Positive Positive
(Loughran et al.,
1994)
LOH on 3p Yes Yes Yes Yes
(Loughran et al.,
1997)
LOH on 4q No Yes No Yes
(This Study)
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Figure 4.1. Chromosome painting images
Metaphase spreads of murine line A92 (a) which does not show hybridisation
to human chromosome 4-specific paint, smaller red specks in this image are
background staining rather than non-specific annealing. Metaphase spread of
A9HYTK4 murine donor line with a single human chromosome 4 (b) illustrated
by the annealing of the paint to the introduced contigous chromosomal
element.
143
Ca)
Cb)
144
cell line BICR31 (27%,3/11). We did not observe any form of growth arrest in
either BICR3 (0%, 0/13) or BICR19 (0%, 0/6). These results suggested
primarily that in agreement with the findings of Ning et al. (1991) we could
ascribe a phenotype associated with chromosome 4 that was capable of
reversing an immortal phenotype. These results are shown in tabular format
in Table 4.2. We had also shown that that the chromosome 4-associated
growth arrest phenotype did not occur in those lines with no LOH on the
endogenous copy suggestive of a novel functional complementation occurring
in those lines with LOH on 4q.
To determine the specificity of the phenotype we used MMGT to
transfer a panel of chromosomes into the recipient cell lines BIGR3, BIGR6
and BIGR31. We introduced chromosome 6 into BIGR3 and BIGR6, BIGR19
and BICR31 were not suitable recipients as both display LOH on the
endogenous chromosome 6 copy suggesting deletion of a gene
advantageous to tumourigenesis. Transfer of chromosome 6 into BIGR3 (0%,
0/1) and BICR6 (0%,0/32, work also carried out by Dr. S. Fitzsimmons, BICR)
resulted in no reversion of immortality demonstrating that the growth-arrest
phenotype was specific to chromosome 4 and was not due to a non-specific
drug-resistance effect. The low hybrid yield observed with BICR3 was
indicative of the lines poor hybrid forming ability in agreement with the
chromosome 4 transfers rather than a reduction in hybrid forming ability due
to the donor chromosome. The further transfer of chromosomes 11 (0%,0/4)
and 15 (0%, 0/33, work also carried out by Dr. S. Fitzsimmons, BICR) into
BICR6 resulted in no observable growth arrest further demonstrating the
specificity of the phenotype to the donor chromosome 4 in complementing the
loss on the endogenous 4q in BIGR6. Transfer of chromosome 11 into
BICR31 resulted in no observable growth-arrest demonstrating a specificity of
phenotype to abrogated pathways. Transfer of chromosome 15 into BIGR19
(0%, 0/1) and BIGR31 (10%, 1/10) demonstrated a further growth arrest
pathway potentially inactivated in BIGR31 tumourigenesis but out-with the
scope of this investigation. These results are shown in tabular format in Table
4.3.
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Table 4.2. Transfer of Chromosome 4 into
immortal HNSCC keratinocyte cell lines
The introduction of chromosome 4 into our preselected panel of immortal
keratinocyte lines (see Table 4.1) demonstrates a specific growth-arrest
phenotype related to a display of LOH on the endogenous 4q arm (BleRG and
BICR31). Immortal lines with apparently intact endogenous 4q arms do not
display a phenotype (BICR3 and BICR19). The observed growth-arrest
Occurredin 27% and 39% of hybrids from BleRG and BleR31 respectively.
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Chromosome Line LOH on 4q Growth- Total
Arrested Growth-
Hybrids Arrested
Hybrids (%)
A9HYTK4 BICR3 No 0/13 0%
A9HYTK4 BICR6 Yes 24/62 39%
A9HYTK4 BICR19 No 0/6 0%
A9HYTK4 BICR31 Yes 3/11 27%
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Table 4.3. Transfer of control chromosomes into
immortal HNSCC keratinocyte cell lines
Experimental controls to ascertain the specificity of the growth-arrest
observed following introduction of an exogenous chromosome 4 in specific
lines. Introduction of chromosomes 6, 11, and 15 does not illicit a growth-
arrest response in BleR6 demonstrating the specificity orf the phenotype to
chromosome 4 introduction. N.d.= Not defined.
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Chromosome Line LOH on Growth- Total
recipient Arrested Growth-
chromosome Hybrids Arrested
Hybrids
(%)
A9HYTK6 BleR6 No 0/32 0%
A9HYTK6 BleR3 No 0/1 0%
A9HYTK11 BleR6 N.d. 0/4 0%
A9HYTK 15 BleR6 N.d. 0/33 0%
A9HYTK11 BleR31 N.d. 1/10 10%
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4.2) XMMCT Generates Chromosomal Fragments Which
Definea Phenotypic Locus
The principle employed in with XMMGT is the same as in MMGT with
the exceptions being that the microcells are treated with low doses of X-
irradiation before being fused back onto a suitable donor background (i.e.
A92) (Dowdy et al., 1990) (see Figure 4.2). The truncated chromosomes can
then be characterised quickly using human specific microsatellite marker
sequences and those suitable for transfer selected and introduced into the
appropriate recipient using MMGT. This technique has been used
Successfully to identify the position of a metastasis suppressor on 2p22-p25
(Mashimo et al., 2000), a telomerase repressor on 3p14.2-p21.1 (Tanaka et
al., 1998), a metastasis suppressor on 8p12-p21 (Nihei et al., 1996) and a
rhabdomyosarcoma specific senescent growth arrest to 11p15 (Koi et al.,
1993).
To generate truncated chromosome 4 copies we used a dose exposure
range of 50 - 200 rads. Previous attempts using higher doses (300-600 rads)
resulted in a shattering of the human chromosome 4 suggesting a lower dose
requirement. From the panel of truncated hybrids wide ranges of deletions
were observed ranging from small interstitial deletions to whole chromosome
arm losses. The hybrids were screened using microsatellite markers by Dr. s.
Bryce, BICR, and the results are shown in Figure 4.3. In this panel there were
four hybrids that would allow us to determine which of our characterised
regions were responsible for the phenotype. These fragments are shown in
Figure 4.4. MMCT of fragment A92i24 into BICR6 would rule out any locus on
4p. Fragment A92i30 would rule out Regions 2 and 3 if we observed a
phenotype following transfer into BIGR6, if not it would rule out Region 1. No
phenotype following transfer with A92i32 into BIGR6 would rule out Regions 1
and 2 whilst ruling in Region 3. The smallest selected fragment, A92i33, with
retention of activity would rule out Region 3 and the telomeric end of Region 2
whilst ruling in the remaining regions. Chromosome fragment painting was
performed by Dr. S. Dowen to confirm the fragments were not recombined
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Figure 4.2. X-Irradiated microcell-mediated
monochromosome transfer
In XMMCT the microcells are generated in the manner described previously
(Chapter 2, Section 2.1.5). Prior to fusion back onto the mouse background
(A92) the microcells are treated with low doses of radiation to induce double-
strand breaks and truncated chromosomes.
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Figure 4.3. Panel of irradiated hybrids generated
byXMMCT
Illustration of the range of truncated chromosome 4 copies generated by the
XMMCT technique (see Figure 4.2). Regions lost are shown in grey boxes,
regions identified in Chapter 3 are shown in red boxes. The microsatellite
markers used, their approximate positioning (cM), and cytogenic positioning
on a chromosome 4 ideogram are shown to the left of the LOH cartoon.
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Figure 4.4. Selected A92HYTK4 irradiated clones
(0.25 - 2.0 Gy)
From the panel of truncated hybrids illustrated in Figure 4.3 we were able to
select four which would functionally determine which one of our three
identified regions (red boxes) (see Chapter 3, Figure 3.3) was correct. The
areas of chromosome 4 loss are shown by grey boxes the legend at the
bottom of the page indicates that all four hybrids caused a growth-arrest
phenotype following transfer. As all four hybrids shared a common region
defined by microsatellite markers 0482978 and 048423 the growth-arrest
locus should lie in this region. The microsatellite markers used, their
approximate positioning (cM), and cytogenic positioning on a chromosome 4
ideogram are shown to the left of the LOH cartoon.
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with mouse material (see Chapter 2, Section 2.2.4 for method). This revealed
that with the exception of A92i32 all truncated copies of chromosome 4 were
maintained stably on the murine background, A92i32 had recombined with
mouse material. The painting is shown in Figure 4.5 and Figure 4.6.
Transfer of our selected panel of truncated chromosomes was
performed with the recipient BICR6. The results of this series of transfers are
displayed in Table 4.4. Every fragment tested demonstrated a growth-
arrested phenotype, at a similar ratio of 33%-50% of hybrids, and due to a
shared minimal common region this enabled us to define our minimal region.
In each instance an intact chromosome 4 was introduced simultaneously into
a separate recipient and the growth arrest ratios were observed to be similar
to the fragments. The result with A92i32 supports the conclusion drawn from
the other fragments although due to the presence of fused mouse material
caution should be exercised in interpretation. The phenotype will be
examined in detail in Chapter 5. The common region shared by all our
fragments was found within Region 1 and encompasses a 22cM region on
4q21 defined by D4S409 and D4S423. This region is in agreement with LOH
studies carried out on EA (Rumpel et al., 1999), ESCC (Rumpel et al., 1999),
HCC (Rashid et al., 1999, Banda et al., 1999), HNSCC (Pershouse et al.,
1997), SCLC (Petersen et al., 2000), and sclerotylosis (Lee et al., 2000).
4.3) Allelic Pattern Loss in Immortal Segregant Hybrids Define
Minimal Region Centred on D4S423
A recognized feature of the MMCT technique is the generation of deleted or
rearranged exogenous chromosomes (Leach et al., 1989; Newbold and
Cuthbert, 1996; Zhu et al., 1998). In monochromosome hybrids which do not
demonstrate the functionally complementated phenotype these segregated
hybrids can be used to map which regions of the exogenous chromosome are
missing and therefore where the complementing locus may
157
Figure 4.5. Chromosome painting of XMMCT
generated truncated fragments A9i24 and
A9i30
Metaphase spreads of A9i24 (a) and A9i30 (b) were hybridised to a human
chromosome 4-specific paint to highlight the presence of independent,
contiguous chromosomal elements. Figure 4.5 (b) has some degree of
background hybridisation although this does not correspond to DAPI stained
regions and is not therefore chromosomal material. In each instance the
arrows indicate the truncated human chromosome 4 in the DAPI and painted
image.
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Figure 4.6. Chromosome painting of XMMCT
generated truncated fragments A9i32 and
A9i33
Metaphase spreads of A9i32 (a) and A9i33 (b) were hybridised to a human
chromosome 4-specific paint to highlight the presence of independent,
contiguous chromosomal elements. Figure 4.6 (a) illustrates that the human
chromosome 4 fragment has recombined with a mouse telomere. In each
instance the arrows indicate the truncated human chromosome 4 in the DAPI
and painted image.
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Table 4.4. Results from chromosome 4 fragment
MMCT experiments
Transfer of the panel of truncated chromosomes identified in Figure 4.4
demonstrates retention of the growth-arrest phenotype in all instances. This
indicates that the region of common retention spanning D4S2978 to D4S423
retains the growth-arrest phenotype. The observed phenotype occurs in the
range of 33%-50%, this similar value to that seen in Table 4.2 suggests the
growth-arrest mechanisms are the same.
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Fragment Recipient Hybrids Growth-Arrested Total
Hybrids Growth-
Arrested
Hybrids (%)
A9i32 BICR6 17 7 41.2%
Control BICR6 16 6 37.5%
A9i24 BICR6 30 15 50%
Control BICR6 26 7 27%
A9i33 BICR6 22 9 40.9
Control BICR6 33 13 39.3%
A9i30 BICR6 30 10 33%
Control BleR6 41 8 19.5%
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lie. This approach has led to the successful confirmation of p161NK4Aat 9p21
(England et aI, 1996). SURF1 at 9p34 (Zhu et al., 1998). a potential tsg on 3p
(Rimessi et al., 1994). a genetic locus at 3p21-p22 involved in tumour
suppression (Killary et al., 1992). a senescence-associated gene on 6q14-q21
(Sandhu et al., 1996). a metastasis suppressor on 6q16.3-q23 (Miele et al.,
2000). a metastasis suppressor on 8p12-p21 (Nihei et al., 1996) and a tsg on
8p22-p23 (Gustafson et al., 1996).
To take advantage of this feature of the MMCT technique we opted to
analyse the segregants from which we had recovered genomic DNA using the
panel of polymorphic microsatellite markers described in Chapter 2 to give a
general 10cM spacing across the whole chromosome span. In BICR6 where
we had lost an entire chromosome copy we would expect a high proportion of
markers to be informative due to the homozygous nature of the endogenous
copy. In each instance we PCR amplified the microsatellite in the A92 murine
line (Cuthbert et al., 1995). the A9HYTK4 donor line (Lupton et al., 1991.
Cuthbert et al., 1995). the respective BICR line. and H20 as a blank. The
microsatellite PCR methodology is described in Chapter 2. Section 2.4.4.
Completed reactions were loaded onto and run on polyacrylamide gels until
the bands resolved: they were then visualized using autoradiography (see
Chapter 2. Section 2.4.5).
To determine which hybrids were segregants. hybrids which
demonstrated partial exogenous allele loss. we carried out a microsatellite
screen across this minimal region in hybrids resulting from transfers with
A92i24. i32. and i33 using the markers 04S2978. 04S409. 04S2964.
04S423. and 04S1570. The Microsatellite PCR and gel electrophoresis used
to resolve the polymorphic alleles are described in Chapter 2. The hybrids
resulting from the smallest fragment transfer. BICR6/4i33 showed that intact
hybrids accounted for 11% (2/19) of the total whilst 63% (12/19) of hybrids
had deleted all exogenous material. 26% (5/19) displayed segregation of the
introduced chromosome fragment in the minimal region tested. Hybrids
resulting from transfers with A92i24 demonstrated 73% (16/22) of all hybrids
were intact. 5% (1/22) had deleted all material and the remaining 22% (5/22)
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had segregated exogenous material. From this screen we determined that
64% (9/14) of BICR6/4i32 hybrids had retained all exogenous material across
this region, 21% (3/14) of hybrids had deleted all material with a remaining
15% (2/14) displaying segregation of exogenous material in the minimal
region. Characteristically, the larger fragments displayed a greater propensity
to remain intact (A92i24) than the smaller fragments (A92i33), which is a likely
reflection of chromosomal stability through the transfer procedure. The
segregated hybrids are shown in Figure 4.7. A strikingly high percentage of
these segregants had lost D4S423 as shown in Figure 4.8, which is
suggestive of a locus in this area.
Analysis of BICR6/Chromosome 4 immortal hybrids revealed that 23%
(8/35) had lost all exogenous material with the exception of the Hygromycin
resistance marker. A further 46% (16/35) of immortal hybrids revealed a
completely intact exogenous chromosome 4 copy, however when a panel of
these were cultured without the lethally irradiated feeder (see Chapter 2) 86%
(6/7) underwent growth arrest contrasted with 0% (0/5) immortal segregants
cultured under the same conditions (Figure 4.9). This indicates that the
minimal requirement for the growth-arrest phenotype is an intact exogenous
chromosome 4 although the growth-arrest phenotype can be overcome by
other mechanisms, which could be related to culture conditions or epigenetic
mechanisms such as promoter methylation. Chromosome painting of a
BleR6/Chromosome 4 hybrid with an intact exogenous chromosome as
judged by microsatellite analysis was demonstrated to have an intact solitary
extra copy of Chromosome 4 through painting on metaphase spreads, as
shown in Figure 4.10. This was suggestive of a favourable culture system
enabling epigenetic silencing of the locus responsible for the growth arrest. A
total of 31.5% (11/35) of immortal hybrids revealed under microsatellite
analysis that they had segregated exogenous chromosome 4 material, either
in situ or as an artefact of the experimental system. These segregants are
shown diagrammatically in Figure 4.11 where for added clarity the three
regions previously identified in our LOH study are shown. The ratio of marker
loss in the minimally identified region for all BICR6/chromosome 4 hybrids is
shown in Figure 4.12. Observable losses are not as high as those seen with
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Figure 4.7. Microsatellite analysis of fragment
segregants
Microsatellite analysis of immortal segregants arising from MMCT of truncated
fragments into BICRS (see Table 4.4). The minimal region of functional
complementation identified in Figure 4.4 demonstrates a high frequency of
loss at D45423. The red box indicates Region 1, identified in Chapter 3,
which is the minimal region of functional complementation. Grey boxes
indicate regions of exogenous chromosome loss. Microsatellite marker
D45409 displays retention in 100% of segregants analysed indicating its
proximity to the exogenous chromosome Hygromycin resistance cassette.
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Figure 4.8. Microsatellite marker loss suggests
locus close to 045423
The frequency of microsatellite losses seen in the immortal segregants
described in Figure 4.7 show a peak at 048423. Over 90% of segregants
have lost the marker 048423 whereas the flanking markers 0482964 and
0481570 are lost in 50% of cases. The x-axis displays the microsatellite
marker name, the y-axis indicates the percentage of hybrids which have lost
the marker.
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Figure 4.9. Growth-arrest phenotype requires
the presence of the intact exogenous
chromosome
Following on from MMCT of intact chromosome 4 a panel of colonies, which
were selected on a feeder background, were ring cloned and split into equal
amounts onto feeder free and feeder backgrounds. From this we found; 1)
colonies which underwent growth-arrest on both backgrounds possessed an
extra intact copy of chromosome 4, 2) Colonies which underwent growth-
arrest initially on both backgrounds frequently gave rise to immortal variants
on the feeder background, these hybrids retained an intact extra chromosome
4 copy, and 3) Colonies which formed immortal variants had either lost the
entire exogenous chromosome 4, had undergone segregation of the
exogenous chromosome 4 material, or in some instances had also retained
an intact exogenous chromosome 4 copy. This is suggestive of an ability to
silence the locus responsible for the growth-arrest phenotype on the feeder
background but not in the absence of the feeder layer. This indicates a
likelihood of a complex mechanism behind the observed phenotype
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Figure 4.10. Chromosome painting reveals an
intact extra copy of chromosome 4 in
BICR6/chromosome 4 hybrid
(a) Metaphase spreads of the immortal BICR6 cell line hybridised with a
chromosome 4-specific paint illustrate the presence of two endogenous
chromosome 4 copies. The unspread nuclei in the bottom right hand of the
diagram also indicates what may be two endogenous copies of chromosome
4. (b) The metaphase spread of a BICR6/Chromosome 4 hybrid displays an
extra copy of chromosome 4, this was also confirmed using microsatellite
marker analysis (data not shown). Arrows indicate chromosome 4 copies in
both painted and OAPI metaphase images.
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Figure 4.11. Exogenous material loss in
BleR6/chromosome 4 segregants
Microsatellite analysis of segregants arising from MMCT of chromosome 4
into BICR6, show losses across the whole exogenous chromosome. Losses
of exogenous chromosomal material (grey boxes) occur in all three regions
identified in Chapter 3 (red boxes). Hybrid number is listed along the top axis.
The microsatellite markers used, their approximate positioning (cM), and
cytogenic positioning on a chromosome 4 ideogram are shown to the left of
the LOH cartoon.
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Figure 4.12. Minimal region microsatellite
marker loss frequencies suggest region
spanning 045423 and 0451570
The minimal region of functional complementation, (identified in Figure 4.4)
show losses of 50% for 04S423 and 04S1570 in BICR6/Chromosome 4
immortal segregants. Microsatellite markers centromeric to 04S423 show
losses in approximately 25% of hybrids. This suggests a greater likelihood of
the locus lying in the proximity of 04S423 than 04S2964.
176
Minimal Region Microsatellite Marker Loss Frequency In
BICR6/Chromosome 4 Immortal Segregants
- 60% .---------------------------------------------------------~~; 50% +-------------------------------------~--~------._--_r--~
~ 40% +-------------------------------------1
....JE 30% +-------------------------------------~
lIS
g' 20%
C, 10%
Cl)~ 0% +-~~ __~ __~~----L-~---L--~~~--~--~---r--~~-L--~
04S2978 04S409 04S2964
Marker Name
04S423 04S1570
177
the fragment hybrids in the minimal region although this does not rule out
microdeletions or gene silencing though other epigenetic mechanisms.
Consequently we examined the BICR31/chromosome 4 hybrids to
determine whether their status matched that seen previously in Chapter 4 and
that seen in the BICR6/chromosome 4 hybrid panel. BICR31, as was shown
in Chapter 3, has ROH on the short p arm whilst showing LOH on the majority
of the long q arm from 045409 at 4q13 to 0452930 at the telomeric end of
4q35. Unlike the BICR6/chromosome 4 examination none of the
BICR31/chromosome 4 hybrids had lost all of the exogenous material whilst
retaining the hygromycin B resistance gene alone and 9% (1/11) of
BICR31/chromosome 4 hybrids had retained all exogenous material
(compared with 23% and 46% respectively on the BICR6 background). This
is suggestive of different levels of stable exogenous material maintenance
depending on the background into which it is introduced. The reciprocal of
this was seen in Chapter 4 where the introduced truncated chromosome 4
copies showed differing stability on the same background. Interestingly the
most commonly lost alleles in BICR31/chromosome 4 hybrids were on 4p14-
15 at 0453022 (80%, 8/10) and 0452912 (80%, 8/10). The highest ratio of
long arm losses was on 4q33 at 0453028 (70%, 7/10) and 4q34 at 0453032
(70%, 7/10). However, the majority of the BICR31/chromosome 4 hybrids
showed losses at the D4S423 (60%, 6/10) locus, which has been suggested
through BICR6 segregant analysis. Furthermore as BICR31 does not display
LOH on the 4p arm this would argue against the gene responsible for the
Similar phenotypes being located on that chromosomal arm. Truncated
chromosome transfers into BICR6 excluded the chromosomal regions 4pcen-
16 and 4q25-35, and as both cell lines display a similar phenotype (see
Chapter 5) it is likely that the identified locus is the same for both cell lines.
The BICR31 hybrids also display complex break patterns, which can provide
misleading information when presented in the absence of complementary
functional data. The stability of exogenous chromosomes has been shown to
vary depending on the recipient line following MMCT and may simply reflect a
difference in toleration of such material (Dr. S. Bryce, BICR, personal
communication). The deletion map of all BICR31/Chromosome 4 segregants
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is shown in Figure 4.13. The ratio of marker loss in the minimally identified
region in BICR31/4 hybrids is shown in Figure 4.14. A substitute informative
polymorphic marker for 045409 was not identified for BICR31 and therefore
no loss ratio is present in this column, although a low loss ratio would be
expected through retention of the hygromycin resistance cassette.
The immortal hybrids resulting from monochromosome transfer into
recipients BICR3 and BICR19, which had both displayed full ROH on the
endogenous chromosome 4 copies, were examined to ascertain the loss
patterns on the introduced chromosome in this unreactive background. In the
BICR19/chromosome 4 hybrids 67% (4/6) had retained a completely intact
exogenous chromosome 4 copy when tested with microsatellite markers at a
20cM spacing. There were two hybrids with deletions of material in the panel,
one of these had deleted all exogenous material (17%, 1/6), whilst the other
had deleted all but from 4q32-tel (17%, 1/6). The BICR3/chromosome 4
hybrids examined had deleted all exogenous material transferred (100%, 5/5)
with no microsatellite markers present in a 20cM screen. This corroborates
the findings with BICR6 and BICR31 where different stability of exogenous
material was dependent on the recipient background.
A study of hybrids resulting from preliminary chromosome 4 transfers
into lines BICR18 and BICR56 revealed that 100% (1/1) and 100% (1/1)
respectively had retained all markers tested however as stated previously due
to the low hybrid yield this result can not be used to discriminate between our
identified regions.
Given the strikingly high ratio of 045423 loss (92%) in the hybrids
resulting from the fragmented chromosome transfers the lower ratios
observed with the intact chromosome transfers (BICR6/Chromosome 4,50%,
and BICR31/Chromosome 4,40%) suggest that the loss map data alone can
be misleading and requires complementation by other techniques such as
XMMCT. However total losses of the minimal region in the fragment
experiments as described are 51% (28/55), whilst BICR6 hybrids show 52%
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Figure 4.13. Exogenous material loss in
BICR31/chromosome 4 segregants
Microsatellite analysis of segregants arising from MMCT of chromosome 4
into BICR31, show losses across the whole exogenous chromosome. Losses
of exogenous chromosomal material (grey boxes) occur in all three regions
identified in Chapter 3 (red boxes). Hybrid number is listed along the top axis.
The microsatellite markers used, their approximate positioning (eM), and
cytogenic positioninq on a chromosome 4 ideogram are shown to the left of
the LOH cartoon.
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Figure 4.14. Minimal region microsatellite
marker loss frequencies suggest equivalence
across 4q21
Microsatellite analysis of segregants arising from MMGT of chromosome 4
into BIGR31 show losses of approximately 40-50% across the minimal area of
functional complementation identified in BIGR6. This is a likely reflection of a
less stable exogenous chromosome 4 on the BIGR31 background than that
seen with BIGR6. No data was available for 048409 do to a lack of
informative alleles, no surrogate marker was identified.
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(15/29) and BICR31 hybrids show 50% (6/12). This demonstrates a similar
frequency of loss of the minimal region in all lines of evidence. Furthermore
Table 4.5. shows the losses in the minimal region at 04S423 are most
statistically significant as compared to the other markers in the region by both
Fishers Exact Test and Chi Squared (X2).
With an initial degree of caution we have successfully defined the
region of chromosome 4 responsible for the observed growth-arrest
phenotype. The region identified correlates with our initially identified Region
1 however we are able to define the region further with two lines of data.
Firstly the finely mapped breakpoint in A92i30 lies at BIR0101 which itself is
distal to 04S423, although both lie approximately at the same locus.
Secondly the segregant analysis positions the upper boundary of the minimal
region at 04S2964. Our minimal region by three lines of evidence; LOH,
deletion mapping and functional complementation is defined as a 12.1 cM
region on 4q21 between 04S2964 and BIR0101.
Through use of the alignment algorithm programme 'OOGreedy' Or. S
Bryce, BICR, constructed a correctly ordered map of the minimal region,
Which we had identified previously. The alignment algorithm programme
OOGreedy represents an automated system product sequence contig builder
from draft sequence data. Through this a contig spanning the minimal region
was constructed allowing definition of the physical map to parallel that of the
previously defined genetic map (Genethon, 1996). This map is shown in
Figure 4. 15.
Microsatellite analysis of a panel of our segregants from both our intact
chromosome 4 transfers and the fragmented chromosome transfer
experiments is shown in Figure 4.16. From this data we can demonstrate a
preferentially lost locus at 04S3037 and 04S2404 on 4q21-q23 with 94% of
segregants analysed having lost these markers (Figure 4.17). This loss
defines a minimal region on the long arm of chromosome 4 of approximately
1.5Mb bordered by the markers 04S423 and BIR0101. This minimal region
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Table 4.5. Statistical relevance of losses in the
identified minimal region demonstrate
weighting towards 04S423
Statistical analysis using both Fishers Exact Test and Chi2 demonstrate that
the losses observed at 04S423 are the most statistically significant by both
tests. The Chi2 value shows the losses at 04S423 to be highly significant.
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Microsatellite Fishers Exact Test X2
Marker (ProbabilJM (ProbabillM_
04S2978 0.19 0.81
04S409 0.18 0.40
04S2964 0.19 0.65
04S423 0.10 0.04
04S1570 0.17 0.32
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Figure 4.15. Minimal region marker order and
locations
Illustration of the marker order and physical distance across the minimal
region identified from LOH analysis (Chapter 3), segregant exogenous
material loss analysis (this Chapter), and functional complementation (this
Chapter). The equivalence of the genetic and physical distances
(18Mb/18cM) suggests an area of low recombination. Figure produced by Dr.
S. Bryce
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Figure 4.16. Minimal region exogenous material
loss in BleR6/chromosome 4 segregants
Microsatellite analysis of segregants arising from MMCT of intact and
truncated copies of chromosome 4 into BICR6 show losses across the whole
minimally identified region on the exogenous chromosome (grey boxes). The
minimal region of loss is defined by microsatellite markers D48423 and
BIR0101, which is illustrated by the red box. Hybrid number is listed along the
top axis. The microsatellite markers used and their physical separation are
shown to the left of the LOH cartoon.
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Figure 4.17. Minimal region microsatellite
marker loss frequencies suggest region
spanning 045423 and BIR0101
The frequencies of exogenous chromosome 4 loss arising in segregants
reaches levels of greater than 90% across the region spanning D4S423 and
BIR0101 (Figure 4.16). This is suggestive of the gene responsible for the
observed growth-arrest phenotype lying within this locus.
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analysis was undertaken with the assistance of Or. N. Craig and, Or. V.
Morrison. Microsatellite markers, which serve to define the minimal locus, are
shown in Figure 4.18.
Through use of the MMCT and the adaptive XMMCT we were able to
reproducibly identify a growth-arrest phenotype following specifically transfer
with chromosome 4. The phenotype in question occurred on cell line
backgrounds with deregulated p53. p161NK4A. and positive telomerase
expression. This would suggest that the growth-arrest was not linked into the
replicative senescence arrest pathway although a complementation of the
repression of telomerase could not be dismissed at this point. We were
further able to define the region of chromosome 4 responsible for this
phenotype to 4cen-4q23 through minimal overlap of chromosome 4
phenotype-retaining fragments. The phenotypic analysis will be discussed in
Chapter 5. In this minimal region the centromeric and telomeric limits were
0482964 and 0481557 respectively. Through sequence assembly and
further microsatellite analysis we were able to define our locus to a region
spanning 048423 and BIR0101 centred on the microsatellite markers
0483037 and 0482404 and spanning approximately 1.5Mb. This identified
region has been implicated in a number of different tumours and disorders
such as CC, HN8CC. HCC. 8CLC. E8CC, 8clerotylosis, EA. and AOPKO.
However although implicated in the locus we previously described (0482964-
0481557) we know of no study, which has concisely identified a minimal
locus from this region. Given the size of the region we were able to identify a
limited number of candidates. these will be discussed in Chapter 6.
193
Figure 4.18. Microsatellite markers 045423 and
BIR0101 define the minimal locus.
Primary data representing the microsatellite markers loss pattern as described
in Figure 4.1S. Immortal hybrids BICRS/4.03 and BICRS/4i24.05 define the
upper boundary with retentions of D4S423. The lower boundary is defined by
retentions of BIR0101 in BICR6/4.29, BICRS/4i33.01, and BICRS/4i33.04. In
each instance where one boundary marker is retained the other is lost.
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5.1) Growth-Arrested Phenotype Has Characteristics Of Crisis
The functional evidence to suggest the presence of a tsg on
chromosome 4 was first provided with the demonstration that immortal
variants arising from cell-cell fusions between the fibrosarcoma line HT1080
and normal human fibroblasts correlated with the loss of chromosome 4
(Benedict et al., 1984). This was suggestive of the dominant suppression of
tumourigenicity provided by a gene(s} on chromosome 4 being selected
against allowing the development of the tumourigenic phenotype. Following
on from this study, on the basis of a subset of cells (GM2096SV9, T98G, J82)
identified to undergo growth-arrest resembling replicative senescence
following cell-cell fusion with the cervical carcinoma cell line HeLa (Pereira-
Smith and Smith, 1988), the introduction of an exogenous chromosome 4 by
MMCT into members of the same subset of cells and HeLa produced the
same growth-arrest features (Ning et el., 1991) therefore ascribing the
phenotype to the introduced chromosome. A further observation showed a
reduced colony forming ability in the murine A9 line however this report was
not investigated further (England et a/., 1996). The reported functional
evidence would suggest that the activity associated with chromosome 4 is
involved in the reversion of the immortal phenotype observed in tumour lines
to that of a growth-arrest resembling replicative senescence.
As stated in Chapter 4 we observed a growth-arrest phenotype in
hybrids resulting from transfer of chromosome 4 into the immortal keratinocyte
lines BICR6 and BICR31. The BICR6/Chromosome 4 hybrid growth-arrest
phenotype, which was reproducibly observed, is shown in Figure 5.1. The
BICR31/Chromosome 4 hybrid growth-arrest phenotype is shown in Figure
5.2. The observed growth-arrest displayed some clonal variety with a display
of phenotype occurring after 3 and 10 population doublings. Growth-arrested
hybrids from both lines are greatly enlarged with massive nuclei and
cytoplasmic regions both of which are recognised features of cellular
senescence. We next examined
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Figure 5.1. Immortal and growth-arrested BleR6
hybrids
(a) Phase contrast image of immortal keratinocyte line BICR6, (b) Growth-
arrested BICR6/Chromosome 4 hybrid showing characteristic features
described below, (c) Photomicroscopy image of SA-~Gal stained
BICR6/Chromosome 4 hybrid showing tightly packed keratinocytes with an
absence of specific nuclear staining, (d) SA-~Gal stained growth-arrested
BICR6/Chromosome 4 hybrid demonstrating flattened cells with massive
nuclei and a positive blue stain, (e) Multinucleate cells in image (b), (f)
Attempted cytokinesis which ultimately gives rise to multinucleate cell labelled
in (b). Scale= 100 microns
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Figure 5.2. Immortal and growth-arrested
BICR31 hybrids
(a) Phase microscopy image of immortal keratinocyte line BICR31, and, (b)
Image of growth-arrested BICR31/chromosome 4 hybrid displaying features
seen in Figure 5.1 of growth-arrested BICR6/chromosome 4 hybrids, (c)
Multinucleate cell as seen in Figure 5.1. Scale = 100 microns
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BICR6/Chromosome 4 hybrids for the presence of the biomarker of growth-
arrest, Senescence-Associated t3-galactosidase (SA-t3Gal) at pH 6, which has
been shown to be detectable histochemically in replicatively senescent and
crisis stage cells (Oimri et al., 1995). In BICR6/Chromosome 4 growth-
arrested hybrids we found a detectable SA-t3Gal activity that was localised
around the nuclear region (Figure 5.1 (d)). Although this is not indicative of
which form of growth-arrest is occurring (replicative senescence or crisis) it
does serve as an important biomarker of this induced phenotype.
A recognised definition of the senescent state is when less than 5% of
an uncrowded cell population incorporate a nucleic acid marker during a 24hr
period (Cristofalo and Sharf, 1973). With this approach the senescent growth-
arrest state is quantifiable in a biologically valid assay system rather than
utilisation of a non-specific histochemical marker. Cells in the replicative
senescent state undergo low levels of apoptosis as the cells maintain a
biologically viable state without actually undergoing cell division. Cells in
crisis however still incorporate nucleic acid markers, albeit at a lower level
than normal counterparts, but exhibit a higher level of apoptosis (Stein, 1985,
Hahn et al., 1999). Crisis cells are still in cycle but the levels of cell death
increase with a constant level of cell birth resulting in an apparent cessation of
population growth (Stein, 1985).
To define the form of growth arrest, which we were observing, we
therefore carried out BrdU incorporation staining and TUNEL staining to
determine the levels of both in mortal and immortal hybrids. Examples of
staining patterns are shown in Figure 5.3. The protocols for the BrdU
incorporation and the TUNEL staining techniques are outlined in Chapter 2,
Section 2.2.2 and 2.2.3 respectively. We analysed 12 immortal and 8 mortal
BICR6/Chromosome 4 hybrids to determine the rate of BrdU label
incorporation after 48hrs, BICR6 and BICR6/HYTK were included as labelling
controls, results are shown in Figure 5.4. We found that mortal
BICR6/Chromosome 4 hybrids had a mean labelling index after 48hrs of
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Figure 5.3. BrdU incorporation and TUNEL
staining in mortal and immortal BleR6
hybrids
(a) 48hr BrdU staining in mortal and immortal BICR6/Chromosome 4 hybrids
shows incorporation of the nucleic acid after 6 weeks in culture, (b), TUNEL
staining in mortal and immortal BICR6/Chromosome 4 hybrids shows an
elevation of apoptosis in mortal hybrids after 6 weeks in culture, (c)
MUlinucleate cell, (d) Apoptotic cell.
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Figure 5.4. BrdU staining of BleR6/chromosome
4 hybrids shows significantly lower levels of
incorporation in mortal hybrids
Incorporation of BrdU in mortal hybrids after a 48hr pulse is seen in
approximately 25% of cells following 6 weeks in culture without passage.
Immortal hybrids, BICR6 cell line and BICR6 carrying the Hygromycin
resistance cassette show incorporation in 45%-50% of cells following 6 weeks
in culture without passage.
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25.2% (Rank Test, t = >2.0 (versus BIGR6, BIGR6/HYTK, and immortal
hybrids), p = <0.05) whilst immortal hybrids had a mean labelling index after
48hrs of 46.6% (Rank Test, t = <1.0 (versus BIGR6 and BIGR6/HYTK), p =
>0.5). Both probabilities suggested that the result for the mortal hybrids were
statistically significant as compared to the immortal hybrids, probabilities are
shown in Table 5.1. We then analysed 15 immortal and 7 mortal
BICR6/Chromosome 4 hybrids to determine the level of apoptosis present in
both sets, results are shown in Figure 5.5. No population of less than 80 cells
as included in this analysis. Mortal hybrids showed a mean apoptotic rate of
2.5% (Rank Test t = /<2.52 (versus BIGR6, BIGR6/HYTK, and immortal
hybrids), p = <0.02) whilst immortal hybrids had a mean apoptotic rate of
0.6% (Rank Test t = <0.77 (versus BIGR6), p = >0.5) (see Table 5.2). These
figures demonstrate the rate of apoptosis of mortal BICR6/Chromosome 4
hybrids, as assayed by TUNEL, are highly statistically significant when
compared to both immortal BIGR6/Chromosome 4 hybrids and the parental
recipient line BICR6. The statistical significance of the apoptotic rate of mortal
hybrids compared to BIGR6/HYTK is less than expected although Figure 5.5
shows clearly that both variance values do not overlap and are strikingly
different. This reflects a problem in statistical analyses such that the low
apoptotic rate observed in the immortal cell lines and the zero values obtained
from some mortal hybrids generate values which when applied to Rank Tests
tend to skew the probabilities to a less significant value than that expected
from observed differences. The variation in apoptotic rate between immortal
hybrids and BIGR6 was not statistically significant although a similar situation
to that described previously existed for comparison of BICR6/HYTK and
immortal hybrids where the large number of zero score values skewed the
test to the levels of Significance whereas in Figure 5.5 both data sets visibly
overlap and fall within visible error bar values. Although the data sets present
some degree of statistical variance this is likely a reflection of a number of
factors. Keratinocytes are highly resistant to apoptotic cell death and those,
Which do undergo apoptosis do so relatively rapidly, the TUNEL assay can
only provide an indication of apoptotic death at that point in time and so does
not record earlier or later events. The hygromycin resistance gene induces
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Table 5.1. Statistical values for 48hr BrdU
staining
The non-parametric rank test displays the observed differences in BrdU
labelling between mortal and immortal hybrid populations to be statistically
significant to the p = <0.05 level. Differences in incorporation seen between
immortal populations are not statistically significant (p = >0.5). When p =
<0.05 this is taken as indicating a significant difference.
208
BICR6 Variants Rank Test (t) Probability
BICR6/HYTK and Mortal 2.19 <0.05
BICR6/Chromosome4 Hybrid
BICR6/Mortal 2.19 <0.05
BICR6/HYTK and Immortal 0.47 >0.8
BICR6/lmmortal 0.75 >0.5
Immortal/Mortal 2.08 <0.05
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Figure 5.5. TUNEL positive staining in mortal
BleR6/chromosome 4 hybrids is greatly
increased compared to immortal hybrids
The levels of apoptosis seen in mortal hybrid cells rise to approximately 2.5%
after 6 weeks in culture without passage. The levels of apoptosis seen in
immortal cells peaks at approximately 0.5% of cells after 6 weeks in culture
without passage. This is indicative of a greatly increased apoptotic rate in the
mortal hybrids.
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Table 5.2. Statistical values for TUNEL staining
The non-parametric rank test displays the observed differences in TUNEL
staining between mortal hybrids and the BICR6 cell line populations to be
statistically significant to the p = <0.05 level. Differences in staining seen
between immortal hybrids and BICR6 populations are not statistically
significant (p = >0.5). When p = <0.05 this is taken as indicating a significant
difference.
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BICR6 Variants Rank Test (t) Probability
BICR6/HYTK and Mortal 1.57 <0.2
BICR6/Chromosome4 Hybrid
BICR6/Mortal 2.21 <0.05
BICR6/HYTK and Immortal 1.97 <0.05
BICR6/lmmortal 0.77 >0.5
Immortal/Mortal 2.52 <0.02
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cell death through apoptotic mechanisms and therefore a minimal background
could be expected in both the immortal hybrids and the BICR6/HYTK cells as
shown in Figure 5.5. These factors will tend to mask the significance of
observations although the mortal hybrids do maintain a high level of statistical
relevance as compared to the controls.
From the previously cited definitions of growth arrest we could now
therefore increasingly define the form that we could repeatedly observe. We
had observed SA-f3Gal staining which is indicative of growth arrest along with
a lower rate of nucleotide incorporation and an increased rate of apoptosis.
From these three lines of evidence we have defined the growth arrest
occurring in the mortal hybrids as a form of crisis (M2 arrest).
Crisis is thought to occur by the shortening of telomeres to a critical
length where end-to-end chromosomal fusions occur leading to non-
disjunction of chromosomes, formation of anaphase bridges, incomplete
cytokinesis and resultant cell death (Counter et al., 1998) although there may
also be telomere-independent crisis mechanisms (Artandi and DePinho, 2000,
Zhu et al., 1999). To determine if critically short telomeres were responsible
for the observed crisis-like phenotype we measured the average telomere
lengths of a panel of BICR lines, Dr. K. Gordon, BICR, carried out this work
(data not shown). This showed that the telomeres of BICR6 were maintained
at a low level whereas the telomeres of BICR31 were maintained at a much
longer length. The two lines BICR6 and BICR31 had both reproducibly
demonstrated the crisis-like phenotype however both clearly had greatly
different telomere lengths, although this does not rule out a critically short
BICR31 telomere being masked by the presence of longer ones. The two
control lines BICR3 and BICR19 both also had differing telomere lengths. In
BICR3 they were maintained at a short length whereas in BICR19 had much
longer telomeres. This result would suggest that the crisis-like arrest might
not be telomere-dependant.
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The cells lines used in this study all demonstrated deregulated
telomerase activity detectable through standard detection kits and also
showed LOH on 3p (putative site of telomerase repressor). The determined
variation in MMCT target line telomere length was cautiously suggestive of a
telomere-independent crisis mechanism. The ends of telomeres are
regenerated and maintained stably by the telomerase complex. To determine
if the crisis-like growth arrest was due to blocking the effect of the telomerase
enzyme BICRS and BICR31 both underwent infection with a retrovirus
carrying an ectopic copy of the limiting catalytic component of the telomerase
enzyme (hTERT). Dr. E. K. Parkinson, BICR, carried out viral infections and
Dr. N. Barr, BICR, prepared viral titre (see Chapter 2, Section 2.1.11-13) for
methods). MMCT of Chromosome 4 into BICRS, BICRSneo (infected with the
retrovirus alone), BICRShTERT, BICR31, BICR31neo, and BICR31hTERT
were carried out to determine if there was a blocking of the phenotype by the
ectopic telomerase hTERT subunit. Results of these transfer experiments are
shown in Table 5.3. We were still able to observe the crisis-like phenotype in
both BICRShTERT and BICR31hTERT thus indicating that the observed
reversion to the mortal phenotype did not seem to be caused by any obvious
blocking of the endogenous telomerase enzyme. This interpretation is
supported by preliminary data from experiments in collaboration with Dr. K.
Gordon, BICR, where we showed the mortal BICRS/Chromosome 4 hybrids
still expressed TRAP activity (data not shown). Furthermore, the fact that the
telomeres of both BICRS and BICR31 were greatly extended by the ectopic
expression of hTERT, suggests that the chromosome 4 mortality effect does
not involve telomeric attrition either. This data along with the variation in
telomere length suggests that the locus responsible for the phenotype may be
operating without directly acting on the telomerase enzyme.
CpG island methylation has been shown to transcriptionally silence a
number of tsgs in cancers from all stages. Furthermore, the unknown
senescence gene(s) on chromosome X is known to be silenced by
methylation through several passages of the donor A9 cells (Klein et al., 1991;
Wang et al., 1992). As described in Chapter 4 we had observed on several
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Table 5.3. Transfer of chromosome 4 into stably
expressing hTERT BICR6 and BICR31 lines
Ectopic hTERT expressing BICRS and BICR31 both undergo growth-arrest
following MMCT of chromosome 4 into these recipient cell lines. This is
indicative of the observed growth-arrest phenotype not occurring through the
telomerase-based telomere maintenance pathway.
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Recipient Line Chromosome Growth-Arrested Total Growth-
Hybrids Arrested Hybrids (%)
BICR6 A9HYTK4 5/21 23.8%
BICR6neo A9HYTK4 4/26 15.4%
BICR6tert A9HYTK4 3/12 25%
BICR31neo A9HYTK4 0/2 0%
BICR31tert A9HYTK4 3/5 60%
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occasions that hybrids with a seemingly intact exogenous chromosome 4
underwent growth arrest when plated in minimal conditions whereas in
optimal conditions continued dividing indefinitely. To assess whether this
rescue was occurring through an epigenetic silencing of the mortality-
associated locus we treated our donor line A9HYTK4 with the demethylating
agent 5-aza-cytidine. To determine whether our line had been successfully
demethylated we performed real-time peR on RNA extracted from both
treated and untreated cells using primers that spanned an intron of the mouse
MyoD1 gene. MyoD1, a muscle differentiation gene, had been shown
previously to be silenced through methylation at an early stage of mouse
development. The ubiquitously expressed GAPDH gene was used as a
control to assess the relative values. From this we determined that although
GAPDH was expressed in both samples the MyoD1 gene had been
transcriptionally reactivated in the 5-aza-cytidine treated sample alone
suggesting that demethylation had occurred. The MyoD1 amplification plots
are shown in Figure 5.S. We then introduced the demethylated chromosome
into BieRS using MMeT to determine whether we would see a greater rate of
growth arrest than that seen with the untreated donor line. Results shown in
Table 5.4. We did not see any significant increase in the number of colonies
that underwent growth arrest with the demethylated chromosome vs. the
untreated chromosome. However we did see a significant improvement in
colony yield (4-5 fold) which may suggest either a subpopulation of donor
cells carrying silenced resistance markers or alternatively the demethylation of
a gene(s) beneficial to colony formation.
Through further experimentation we were able to more rigorously
define the phenotype, which we repeatedly observed following transfer of a
minimal region of chromosome 4 in various contexts. Through SA-l3gal
staining, BrdU labelling, and apoptotic rate determination we were able to
classify the growth-arrested phenotype as a delayed crisis. As the immortal
target cell line was both p53 and p161NK4A negative and telomerase positive
a replicative senescence and crisis bypass had clearly occurred and therefore
in a reversion to mortality the cell line could be expected to re-enter growth-
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Figure 5.6. Real-time peR analysis of MyoD1
MyoD1 expression in 5-aza-cytidine untreated, (a), and treated, (b), A9HYTK4
donor line. Yellow, red and green lines represent amplification curves for
three independent reactions. No amplification of amplicon is seen in
untreated reactions (a) whereas in treated reactions recordable amplification
of the amplicon is seen after 27-30 reactions (b)
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Table 5.4. Transfer of 5-aza-cytidine (5azaC)
treated chromosome 4 into BICR6
Following MMCT of chromosome 4, which had been pre-treated with the
demethylating agent 5azaC, no increase in the levels of growth-arresting
colonies was seen when compared to colonies arising from untreated control
chromosome 4 MMCT. This is suggestive of the locus not undergoing
promoter silencing through methylation on the murine background although
does not rule out such an epigenetic silencing in the human background.
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Recipient Line Chromosome Growth-Arrested Total Growth-
Hybrids Arrested Hybrids
BICR6 A9HYTK4 1/7 15%
BICR6 A9HYTK4-5azaC 7/31 23%
BICR6 A9HYTK4-5azaC 8/37 22%
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arrest by the most recently abrogated pathway. However crisis is thought to
occur through critically short telomeres and we could find no direct correlation
between the telomere size of our recipient cells and the phenotypic effect of
chromosome 4. Telomerase acts to stabilise and elongate the telomeres
according to the cellular situation however when our endogenous hTERT
expressing recipient lines were supplemented with an exogenous ectopic
copy we saw no ablation of the phenotype in the recipient lines which
responded. The donor chromosome when treated with demethylating agents
did not demonstrate any overall increase or reduction in the number of
colonies, which underwent growth-arrest although this does not determine
whether promoter repression forms a basis for transcriptional control over the
observed phenotype. Therefore the observed growth-arrest phenotype is not
mediated through a direct telomerase repression and does not appear to be
telomere-linked, although the observed delay prior to arrest, mitotic failures,
and multinucleate cells (see Figure 5.1) would imply a telomere involvement.
In Chapter 4 we described the definition of a 1.5Mb minimal region of loss in
our segregants therefore in Chapter 6 we shall discuss these in terms of
candidate potential.
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Chapter 6
224
6.1) Locus Definition Reveals Four Candidate Genes
Through fine mapping of the minimal region of loss identified in
Chapter 4 we were able to localise a region of 1.5Mb of chromosome 4
located on 4q22-q23 where we had evidence to suggest a cell mortality-
related cancer gene may be located. Through the recent progress in genome
sequencing the majority of the sequence of this chromosomal region was
available although not in an assembled consensus form. Using the Golden
Path algorithm Dr. S. Bryce (BICR) was able to assemble a contig covering
this identified region and to identify candidate genes on this region. This
approach has led to the identification of three (possibly four) candidate genes
within our region; GRI02, ETL1, PGDS, and possibly a fourth novel gene.
The ordering of these genes in relation to the microsatellite markers used to
map the minimal region are shown in Figure 6.1
6.1.1) Candidate1: GRID2; b2 Glutamate Receptor
The GRI02 gene (Hs.248130) maps to 4q22 and has been implicated
in a large number of neurodegenerative disorders where cell death results
from inappropriate activation of the glutamate receptor system (Hu et al.,
1998). Studies in GRI02 functions have been performed largely in the murine
system where a number of mutations have been characterised as GRID2-
based. The binding ligand for GRID2 is however unknown as it does not
seem to bind to glutamate. Hotfoot is a recessive mouse mutation which was
characterised by cerebral ataxia associated with mild cerebellar abnormalities,
a further mutation Lurcher is semi-dominant and affects postnatal cerebellar
development such that homozygous mice die promptly due to massive loss of
neurons in the mid- and hindbrain (Lalouette et al., 1998). Lurcher and
hotfoot were both discovered to be due to mutations in the GRI02 gene,
although the lurcher mutation led to a dysfunction of the ion channel and a
constitutive inward current which may lead to Purkinje cell death by an
excitotoxic process, whilst the hotfoot mutation leads to a loss or
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Figure 6.1. Microsatellite marker order and gene
sequence in minimal region
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abolishment of GRID2 activity. The neurodegeneration in lurcher mice does
not seem to occur in a p53-dependant manner but in both Purkinje and
cerebellar granule cells to lessening degrees is via a Sax-dependant pathway
although in Purkinje cells this is caspase-3-independant (Doughty et al.,
2000). The association of GRID2 predominantly to neurodegenerative
disorders does not necessarily preclude it from candidate potential as we
witnessed apoptotic death of growth-arrested hybrids in a p53-independant
manner and therefore have a potential phenotypic match. Unfortunately
GRID2 studies in human cell lines are minimal and therefore complementation
effects of the gene in a cell line are unknown. SAGE library analysis shows
GRID2 expression in two brain libraries, Duke 1273 and 88542 whitematter,
but no keratinocyte libraries.
6.1.2) Candidate 2: Novel Genes?
Within the minimal identified region there are two unigene clusters
represented as HS.162727 and Hs.1112936. HS.162727 consists of two EST
sequences, which combine to form a single contig of 438 nucleotides. BLAST
searches with these two EST sequences do not however reveal any matching
sequences in the databases. Sage libraries show variable expression levels,
which are highest in one normal cerebellum sample and approximately 3-fold
less expression in ovarian carcinoma, microvascular endothelial cells and a
further brain sample. Hs.105416 consists of a single EST of 333 nucleotides,
which does not match with any other sequences by BLAST search. Sage
libraries show variable expression levels again although a breast cancer line
(PTEN nuu) shows a greatly elevated tag count (although from a small tag
set), normal epithelium shows a two-fold reduction in tags from PTEN null
whilst colorectal carcinoma, ovarian carcinoma, primary colon tumour, and a
breast ductal carcinoma show a four-fold reduction from PTEN null levels.
Therefore both EST clusters do not seem to be obviously promiSing
candidates although both HS.162727 and Hs.105416 are expressed in normal
tissue with a general reduction in tumour lines. Hs.105416 is found in PTEN
null breast cancer lines at high levels whilst showing an overall expression
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reduction in different tumour types (colorectal, ovarian, and breast
carcinomas, and primary colon tumour). This may be indicative of the
HS.105416 locus gene product being under the repressional control of the
PTEN tsg. Hs.162727 and HS.105416 may therefore have candidate potential
although more sequence data on these two clusters would be required before
any further studies could take place.
6.1.3) Candidate 3: KlAA 1122
The unigene cluster HS.21356 consists of 87 EST sequences which
represent the protein KlAA1122 (Hirosawa et al., 1999). This protein is
expressed in a large number of tissue types; adipose, brain, breast, CNS,
colon, ear, germ cell, heart, kidney, lung, pancreas, skin, testis, tonsil, uterus,
embryo, connective tissue, lung, ovary although to differing degrees. PTEN
null breast cancer demonstrates the greatest tag count (although from a low
total tag count, normal cerebellum has approximately 1,4 less tags, normal
kidney cells and 293-IND have an approximate 2-fold reduction of tags whilst
medullablastoma, prostate carcinoma, normal epithelia, and ovarian
carcinoma display an approximate 4-fold reduction, and adenocarcinoma, and
Duke H54 lacZ have a 5-fold less count. This wide and varied distribution of
expression makes any immediate judgements difficult to formulate and must
await further data. The KIAA1122 protein shares homology with a number of
proteins from different species and belongs to the highly conserved SWI/SNF
family of ATPase proteins with putative helicase function. Members of this
family are seen in H.sapiens, M.musculus, G.Gal/us, D.melanogaster,
C.e/egans, S.cerevisiae, S.pombe, A.tha/iana, and P.fa/ciparum. The greatest
homology to KIAA1122 is shared with the M.musculus Enhancer Trap Locus-
1 (ETL-1) gene, which may therefore share functional similarities with
KIM1122.
Enhancer trap locus-1 (ETL-1) shares the greatest sequence homology
with KlAA1122 with approximately 92% aa sequence similarity. ETL-1
demonstrates widespread expression particularly in the CNS and epithelia
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and also shows homology to members of the SWI/SNF (yeast mating type
switching/sucrose non-fermenting) ATPase/helicase family including Brahma,
D.melanogaster trithorax homeotic gene regulator, SNF2/SWI2, yeast
transcriptional activator (Tamkun et al., 1992), RAD54 (recombination repair),
STH-1 and MOT1, yeast helicase-related proteins. No family members
display observable helicase activity suggesting this may not be a functional
domain. SWI/SNF proteins form complexes of approximately 2MDa in both
yeast and mammals where many components share homology (Wang et al.,
1996). ETL-1 was the first mammalian member of this now large (over 100
members) group of proteins which are implicated in gene regulation,
chromatin structure remodelling (Soininen et al., 1992) and mitotic
chromosome segregation, all containing a conserved region required for
binding and hydrolysis of ATP (Henikoff, 1993). ETL-1 belongs to a distinct
subfamily also containing FUN30p, neither however is essential for cell
viability or is ETL-1 required for DNA repair (double-strand breaks or
pyrimidine dimer excision) both therefore having relatively undefined
biological activity (Ouspenski et al., 1999; Schoor et al., 1999). ETL-1
knockout mice do demonstrate a number of post-embryonic developmental
defects, which would suggest a role in transcriptional switching as
development proceeds (Schoor et al., 1999). SNF2 and Brahma are strikingly
similar being of both a similar size (194 v's 185 kDa), sharing 57% homology
and containing patterns of motifs typical of helicases (Laurent et al., 1992).
The SNF2 family member MOT1 acts to dissociate TATA-binding protein
(TBP) from DNA in an ATP-driven manner with a minimum of two
conformational changes and hence regulate transcription, which may provide
a model behind the SNF2 ATPase domain functional mechanism (Auble et al.,
1997). This mechanism led to the theory that SWI/SNF complexes acted as
ATP-driven DNA translocases, which disassociated proteins from DNA
thereby disrupting nucleosome structure and facilitating transcription factor
binding to DNA. However, the observation that MOT1 did not act as DNA
translocase but rather dissociated TBP in a transient DNA-binding ATP-driven
manner suggests a more complex situation. Further clarification of the mode
of SWI/SNF complex action should reveal a great deal about chromatin
remodelling and transcriptional control. As a candidate mortality gene
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KIAA1122 may display a number of desirable characteristics although its
expression pattern may not fit an obvious expected pattern with no ubiquitous
down-regulation in tumour lines. However, further biological data on
functional roles of the protein should provide useful insight into transcriptional
mechanics.
6.1.4) Candidate 3: Prostaglandin 0 Synthase
The glutathione requiring hematopoietic prostaglandin D synthase (H-
PGDS) catalyses the isomerisation of PGH2, a common prostanoid precursor,
to PGD2 (Urade et al., 1995) and is the key enzyme for D and J prostanoid
production which are involved in the immune system and mast cells. H-PGDS
has functions in various peripheral tissues such as platelet aggregation
prevention, induction of vasodilation, and bronchoconstriction (Giles and Leff,
1988). PGD2 is further converted to 9a, 11~-PGF2, which has various
pharmacological actions and to PGJ2, which is then further converted in the
presence of serum albumin. The J series of PGs were shown to have an
antiproliferative effect on tumour cells through induction of G1 arrest in
neuroblastoma cell lines by N-myc suppression (Marui et al., 1990) and a
growth rate reduction in transformed epithelial cells and melanoma (Bregman
et al., 1986; Ikai et al., 1991). H-PGDS spans approximately 41kb and
consists of six exons divided by five introns and was the first recognised
vertebrate homologue of sigma-class glutathione S-transferase (Kanaoka et
al., 1997, 2000). In SAGE expression libraries there is no differentiation
between normal and tumour tissues with both demonstrating relatively low
levels. H-PGDS has recently been shown to undergo transcriptional control
through an OCT-1 element in the 5'-flanking region and an AP-2 site within
the untranslated first exon (Fujimori et al., 2000). The differential expression
patterns observed with H-PGDS do not immediately suggest candidate gene
potential although a number of other factors could potentially suggest
otherwise. Downstream molecules have been shown to have an
antiproliferative effect on tumour growth and furthermore the H-PGDS
promoter and non-translated regions have been shown to be recognition sites
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for at least two transcription factors, which suggests a tightly regulated control
of H-PGDS expression. Abrogation of H-PGDS could then conceivably have
a role in tumourigenesis although only further biological experimentation will
reveal what this may be.
6.1.5) Candidacy Potential
A danger lies in identifying novel genes or identifying a candidate to fill
a role, in that it can be easy to assume potential candidacy from the greatest
volume of available data and hence disregard others for whom the data
Sources remain sparse. Therefore from the four potential candidate genes in
the identified loci in the absence of further biological data only tentative
assumptions should be made.
GRID2 induces apoptotic cell death in a p53-independent manner
which itself fits with our observed phenotype. GRID2 expression has not
been shown in keratinocyte libraries which would infer against a required
abrogation for tumourigenesis, although would not rule out inappropriate
expression in keratinocyte cell lines causing the crisis-like growth-arrest.
The potentially novel genes represented by Hs.162727 and HS.105416
unigene clusters do not have any direct biological evidence to suggest
candidacy. Tissue expression analyses suggest that they have appropriate
profiles for genes with down-regulated functions in tumourigenesis through
silencing or mutation by their high and low expression levels in normal and
tumour tissues respectively.
KIAA 1122 has a degree of biological characterisation through
assumptions based on homology studies with the M.musculus homologue
ETL-1. The studies with ETL-1 suggest it is part of a larger SWI/SNF
complex, which is comprised of multiple proteins and conserved through to
yeast. These complexes are involved in chromatin remodelling,
transcriptional control and mitotic chromosome separation all of which have
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obvious potential roles in tumourigenesis. The expression patterns observed
with KIAA1122 do not fit an obvious role in tumourigenesis although tumour
stage and specificity may account for this.
H-PGDS does not assume obvious candidate potential, it has relatively
ubiquitous low expression in both normal and tumour tissue. It functions
mainly in the peripheral tissues and in the immune system although down
stream products have been shown to induce an uncharacterised G1 growth-
arrest in neuroblastomas and to inhibit growth in transformed epithelial cells
and melanomas which may be indicative of a loss advantageous to
tumourigenesis. As such, H-PGDS can also be considered a potential
candidate although further work is clearly required.
From the four candidates perhaps GRID2 and KIAA 1122 emerge as
potentially the most inviting genes to account for the observed phenotype.
However each of the potential candidate genes requires a biological assay in
the previously used cell types to determine whether a similar phenotype can
be observed and whether mutations or methylation silencing are present in
those immortal lines that show LOH in the region in question, thereby fitting
Knudson's 'two-hit' model for an abrogated in cancer gene.
6.2) Mortality Factor from chromosome 4
The early characterisation of a potential gene on chromosome 4 with
the ability to reverse an immortal phenotype was undertaken in cell-cell
fusions and then by MMCT into responsive cell lines (Pereira-Smith and
Smith, 1988; Ning et al., 1991). In early 1998 a report suggested that through
a serendipitous event the gene responsible for the earlier observed growth-
arrest phenotype had been cloned and was called Mortality Factor from
Chromosome 4 (MORF4) (Ehrenstein, 1998). MORF4 was observed to
induce growth-arrest in two cell lines (HeLa and T98G) which had responded
in a similar manner to the intact chromosome 4 and a cell line (HeLa) which
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responded to an 800kb fragment of chromosome 4 containing MORF4
(Bertram etal., 1999, 1999b).
Through collaborative ties we were granted access to the 800kb
fragment of chromosome 4 containing MORF4 (A9-F4) and to plasmids
containing the full length MORF4 construct, a MORF4 frameshift mutant
(MORF4-FS), and the empty vector, pexSVneo. We first performed MMGT of
A9-F4 into the recipient cell lines BIGR6 and HeLa to ascertain whether the
subchromosomal fragment mimicked the whole chromosome effect. The A9-
F4 fragment had no effect on BIGR6 and did not cause any growth-arrest
phenotype in 9 hybrids and furthermore the exogenous MORF4 gene was
retained (Bryce et al., 1999). Upon introduction of A9-F4 into HeLa we
observed growth-arrest in 64% (9/14) of hybrids. Although we could
reproduce the previously reported effect in HeLa cells we could observe no
discernible effect on BIGR6, results are shown in Table 6.1. We then
undertook a series of transfections into HeLa, BIGR6, and BIGR3 to
determine if the full-length construct would have any effect. The full length
construct caused 86% (6/7) Hela clones to undergo growth-arrest in a similar
manner to that observed with A9-F4, flattened and positively staining for SA-
Bgal. In BIGR6 we observed 0/12 colonies undergo growth-arrest with the
full-length construct, 0/12 colonies undergo growth-arrest with MORF4-FS,
and 0/10 with pexSVneo. The full-length construct caused 0/3 BIGR3 clones
to undergo growth-arrest. These results are shown in Table 6.2. To
determine that the transfections had been successful we PGR amplified the
plasmid Neomycin resistance cassette, result shown in Figure 6.2, and were
able to show that all clones, with one exception, had uptaken a copy of the
plasmid. We were unable to pursue expression analysis through RT-PGR of
MORF4 in the transfectant clones as the MORF4 and MRG15 sequences
(see below) are indistinguishable and the ubiquitous expression of MRG15
would have made such detection highly unlikely. We were unable to amplify
the MORF4 cassette from the plasmid pexSVneo through difficulties
encountered in plasmid sequencing which demonstrated that the insert had
been ligated into an incorrect site, Xbal rather than Nhel, which placed
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Table 6.1. MMCT with A9-F4 does not induce
growth-arrest BICR 6. MMCT with
chromosome 15 does not induce growth-
arrest in HT1080 or HeLa
Due to the lack of growth-arrest observed following monochromosome
transfer of A9-F4 into BICR6 we were able to conclude that MORF4 was not
the keratinocyte mortality gene. Chromosome 15 also failed to induce growth-
arrest in both HeLa and HT1080 immortal cell lines demonstrating an inability
to functionally complement any dysfunctional pathways.
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Chromosome Cell Total Growth-Arrested Total Growth-Arrested
Line Hybrids Hybrids (%)
A9-F4 BleR6 0/9 0%
A9-F4 HeLa 9/14 64%
A9HYTK15 HT1080 0/11 0%
A9HYTK15 HeLa 1/11 9%
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Table 6.2. Transfection of MORF4 into
keratinocyte lines suggests it is not the
chromosome 4 mortality gene
The failure of MORF4, following transfection into BleR6, to induce a growth-
arrest phenotype similar to that seen following MMCT of chromosome 4 into
the same cell line implies that it is not the keratinocyte mortality gene. The
growth-arrest phenotype observed in HeLa may be a consequence of
plasmid-driven MORF4 overexpression.
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Transfection Cell Line Total Growth-Arrested Total Growth-Arrested
(%)
MORF4 HeLa 6/7 86%
MORF4 BICR6 0/12 0%
MORF4FS BICR6 0/12 0%
pexSVneo BICR6 0/10 0%
MORF4 BICR3 0/3 0%
238
Figure 6.2. Amplified vector Neor cassette in
MORF4 transfectants
BICR3, BICRS, and HeLa MORF4 transfectants all demonstrated
amplification of the plasmid Neomycin resistance cassette and therefore their
transfectant status.
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MORF4 in an alternate multiple cloning site (see Chapter 2, Figure 2.1). This
therefore raised concerns surrounding plasmid integrity and as such we did
not pursue this line of investigation. We concluded from the MMCT
introduction of A9-F4, and tentatively from the MORF4 transfections, that
MORF4 was not the keratinocyte growth-arrest gene although we did see a
phenotype in HeLa.
MORF4 is a processed pseudogene whose direct lineage ancestor is
MRG15, which is located on chromosome 15. We introduced chromosome
15 into BICR 6, as described in Chapter 4, and observed 0/33 growth-arrested
hybrids. We then introduced chromosome 15 into two further cell lines
HT1080, and HeLa. HT1080 is a cell line, which was described as not
belonging to the same subset of cell lines that HeLa was part of and therefore
not thought to have a mutation of the growth-arrest gene on chromosome 4.
Chromosome 15 did not have any noticeable effect on HT1080 in 11 hybrids
examined although did induce growth-arrest in 9% (1/11) of HeLa hybrids.
HeLa has a background clonal attenuation rate of approximately 10%
(Bertram et al., 1999), which may be due to a down-regulation of telomerase
in these cells (Bryan et al., 1998) and this can therefore be taken as an
artifact of the experimental conditions.
We concluded from the above experiments that MORF4 was not the
keratinocyte mortality gene. Furthermore in MMCT experiments with the irradiated
fragments, A92i32 and i33 both induced a growth-arrest phenotype on BICR6 and
neither chromosomal fragment contains MORF4 (see Chapter 4). Furthermore
MORF4 did not lie within our minimal identified region and was not one the four
candidate genes, which we had identified.
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Chapter 7
242
7.1) Evidence for a Gene Abrogated in Cancer on
Chromosome 4
Evidence for a locus on chromosome 4 whose loss was beneficial to
tumourigenesis was first provided by subcutaneous injections of hybrids
resulting from cell-cell fusions between normal human fibroblasts and the
human fibrosarcoma cell lines into athymic mice (Benedict et al., 1984). The
tumourigenic potential of the HT1080 cell line was suppressed following these
fusions although in instances where tumours did emerge this was correlated
with the loss of both chromosomes 1 and 4 implying a loss beneficial to
tumour formation. A further implication from these studies is that on the
remaining copies of the lost chromosomes 1 and 4 the loci responsible for
suppression had undergone silencing through mutation or methylation. These
studies were reinforced through further cell-cell fusions between subsets of
immortal tumour lines which were matched on the basis of whether they
ceased proliferation following fusion, implying the complementation of a gene
lost during tumourigenesis by one of the fused lines, or continued proliferating
indefinitely, suggesting no complementation had occurred and the fused lines
had achieved immortality through abrogation of distinct mechanisms (Pereira-
Smith and Smith, 1988). MMCT based introduction of chromosome 4 into a
grouped subset of these lines (HeLa, J82, and T98G) identified chromosome
4 as capable of inducing the previously observed growth-arrest and therefore
of complementing the pathway which had undergone abrogation during the
progression to immortality (Ning et al., 1991). The growth-arrested hybrids
resulting from MMCT introduction into HeLa were predominantly shown to
contain an intact exogenous chromosome 4 through the use of polymorphic
markers, which showed the necessity of the locus complementation for the
phenotype. The line, HT1080, previously observed to escape from
Suppression to form tumours in athymic mice was, perhaps surprisingly, not
reported to undergo growth-arrest upon introduction of chromosome 4.
However in later studies HT1080 was observed to undergo growth arrest
following MMCT introduction of chromosome 4 whereas T98G did not display
any observable cessation of proliferation (Dr. S. Bryce, BICR, personal
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communication). The further observation that HeLa did not undergo growth-
arrest following cell-cell fusion with a complementing cell line (Berrington,
1999) and that suggests that the earlier subset assignments may have been
an oversimplification and that a great deal of complexity surrounds the
abrogated growth-arrest mechanisms in immortal tumour lines (Whitaker et
al., 1992; Duncan et al., 1993). The evidence provided by these observed
cell-cell fusions and MMCT experiments led to the conclusion that
chromosome 4 contained a locus which was capable of inducing a replicative
senescence-like growth arrest although no further locus identification was
performed in these studies.
7.2) Chromosome 4 Induces a Mortal Growth-Arrest in
Immortal HNSCC
Through MMCT of chromosome 4 into immortal keratinocyte cell lines
(BICRG, BICR31) we have been able to agree with earlier observations and
demonstrate an exogenous chromosome 4-specific growth-arrest. We have
added to this demonstration by showing that this only occurred in lines
demonstrating LOH on the endogenous chromosome 4q arm. This would
suggest that the shorter p arm of chromosome 4 does not carry the gene
responsible for this phenotype but does not rule out the existence of genes
involved in growth-arrest on this chromosomal arm, which may be abrogated
in other pathways to immortality. The specificity of the chromosome 4-
induced growth-arrest was further defined through the generation of truncated
fragments of chromosome 4 and consequent introduction into an immortal
keratinocyte cell line (BICR6), which defined a region on chromosome 4
defined by 4cen and 4q23. As growth-arrest was observed following MMCT
of truncated chromosomes, which lacked 4cen-p16 and 4q23-q35 this, implies
that the gene responsible for the phenotype, which we observed, did not lie in
these chromosomal regions. This is significant as no specific LOH was
Observed in the HNSCC lines on 4p (see Section 3.) although it had been
implicated by other studies. Furthermore, a number of studies had implicated
regions within 4q25-q35 as potential sites for cancer genes although these
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were not implicated in this study. The specificity of this growth-arrest was
further demonstrated by the MMCT introduction of a subset of chromosomes
{A9-F4, A9HYTK6, A9HYTK11, A9HYTK15 (see Chapter 2, Section 2.1) into
the immortal keratinocyte cell line, BICR6, which demonstrated that the
growth-arrest phenotype was specific to the 4cen-q23 locus and was not an
artifact of the experimental procedure such as the resistance gene selection
or murine material. Introduction by MMCT of chromosomes 11 and 15 into
the immortal keratinocyte line BICR31 showed that although 11 had no effect
a growth-arrest induction was observed following transfer with 15. This is
suggestive of a further pathway abrogation present in the BICR31 immortal
keratinocyte line, which is restored by the introduction of chromosome 15.
The recent demonstration of the chromosome 15 Pif1p helicase, yeast
homologue, causing inhibition of telomerase and telomeric shortening
perhaps provides a candidate for this phenotype (Zhou et al., 2000).
Furthermore, in immortal keratinocyte cell lines which did not display LOH on
the endogenous chromosome 4 copy (BICR3, BICR19) we did not observe
any growth-arrest following on from MMCT introduction of an exogenous copy
of the chromosome. The lack of observed phenotype in those lines which
displayed ROH of the endogenous chromosome 4 copy further demonstrate
the specificity of the phenotype to those cells displaying LOH and rule out the
phenotype occurring as both a consequence of introduction of any exogenous
chromosome, through the selection agent, as a dosage effect, and through
other artefacts of the experimental system such as contamination of the
human chromosome 4 with mouse material. Similar lines of study in HeLa
using MMCT to introduce a subset of truncated chromosomal fragments
suggest that the growth-arrest phenotype in these cells is located minimally to
4cen-q25 (Dr. S. Bryce, BICR, personal communication). This suggests that
the earlier functional complementation observed with HeLa and HT1080 may
be the same as that observed with the immortal keratinocyte lines. These
lines of evidence suggest that 4cen-q23 carries a locus which is functionally
abrogated in immortal HNSCC lines which show LOH in this region although
further pathways may exist represented by loci on other chromosomes as the
complementation did not occur in HNSCC cell lines which displayed intact
exogenous chromosome 4 copies.
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7.3) LOH Analysis in Immortal HNSCC lines Demonstrates
Losses in the Locus Identified Through Functional
Complementation
LOH on chromosome 4 has been shown in a number of studies and in
a number of different forms of cancer. 4qcen-25, as described in Section 7.2,
represents the region of chromosome 4 we identified through functional
complementation. Studies which show LOH or copy number decrease in this
region come from 4q21-q23 (CC), 4q21 .1-q22 (EA), 4q21.3-q22 (ESCC),
4q21 (HNSCC), 4q21-q22, 4q11-q25 (HCC), 4q11-q23 (SCLC), 4q21
(Sclerotylosis), 4q23 (IBD), and 4q21 (ADPKD) (Buetow et al., 1989; Mitra et
al., 1994; Pershouse et al., 1997; Bando et al., 1999; Petersen et al., 1997;
Cho et al., 1998; Rumpel et al., 1999; Torra et al., 1999; Hu et al., 2000; Lee
et al., 2000). Although studies of chromosome 4 LOH have revealed other
regions on the chromosome as implicit in tumour development we had
demonstrated that the functional complementation was due to a locus in the
4cen-q25 area by demonstrating a retention of phenotype where all other
regions where missing. We carried out an LOH study against a panel of
immortal HNSCC keratinocyte cell lines and demonstrated loss at 4cen-q25 in
half of those lines tested. This suggested that although there was a clear
correlation between LOH of this region and a functionally complemented
growth-arrest this was clearly not the case in all the cell lines which may have
abrogated other pathways on other chromosomes. Difficulties lie in the
interpretation of LOH studies where a small number of polymorphic markers
have been used to analyse the endogenous chromosomal heterozyqosity.
Where a small number of markers have been utilised and interpreted as
whole chromosomal losses this can clearly lead to inaccurate reporting as any
interstitial losses are undiscovered or alternatively retentions are missed
through smaller losses.
The microsatellite analysis of BICR31/Chromosome 4 hybrids revealed
complex break patterns and a general exogenous chromosomal instability.
This itself may be a response to the exogenous chromosome 4 specifically as
in studies involving the introduction of chromosome 6 into BICR31 through
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MMCT the majority of hybrids (63%, 12/19) retained intact exogenous
chromosomes (Dr. S. Fitzsimmons, BICR, personal communication). With
chromosome 4 the number of intact chromosomes was extremely minimal
(9%, 1/11) implying a different response of the recipient cell line to particular
exogenous materials. The observed phenotypes in both BICR6/ and
BICR31/Chromosome 4 hybrids were both sufficiently similar to appear to be
due to the same mechanism (Figure 5.1 and Figure 5.2). This was further
evidenced, as the ectopic hTERT catalytic subunit was not sufficient to block
the phenotype in either cell line. These lines of evidence suggest that a
similar mechanism is operating in both BICR6 and BICR31 hybrids which,
when functionally restored, drives the cells into a crisis-like growth-arrest hall-
marked by multinucleation and unsuccessful cytokinesis followed by
apoptosis in an apparently telomere-independent manner. This further
suggests that the restored mechanism recognises the aberrant nature of the
immortal keratinocyte HNSCC-derived cell lines and drives them into the
apoptotic pathway.
The strategy of segregant hybrid loss map construction to highlight
regions whose deletion is advantageous to tumour growth or disorder
progression has met with mixed success in previous studies (Leach et al.,
1989; Killary et al., 1992; Rimessi et al., 1994; England et al., 1996; Newbold
and Cuthbert, 1996; Nihei et al., 1996; Sandhu et al., 1996; Zhu et al., 1998;
Berrington, 1999; Miele et al., 2000). This approach led to the successful
confirmation of p161NK4Aand cloning of SURF1, a tsg and a factor involved in
Leigh syndrome (neurological disorder) respectively. In our study we have
used this approach to identify a minimal region within 4cen-q25 containing a
discrete number of potential candidate genes. Analysis of segregants arising
from whole and truncated chromosome 4 MMCT experiments has defined a
locus on 4q22.3-q23 of approximately 1.5Mb defined by the microsatellite
markers 04S423 and BIR0101. This locus has been implicated in studies on
CC, EA, ESCC, HCC, HNSCC, SCLC, and Sclerotylosis (see Chapter 3,
Section 3.). This locus could carry a gene whose function is abrogated in a
number of different tumours and disorders although only further biological
analysis can determine this. A number of hybrids with seemingly intact
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exogenous chromosomes have presumably silenced the target gene through
microdeletions on the introduced copy or methylation silencing. Further
analysis has revealed the existence of interstitial losses within the target locus
in at least one hybrid which otherwise appears completely intact (data not
shown). The benefits of this mapping strategy have limitations and the
density and informative nature of these markers provide two such examples.
Figure 4.15 demonstrates that across the minimal identified locus spanning
0482964 and BIR0101, 34% (10/29) of markers were not informative as
judged under denaturing sequence gels. These non-polymorphic markers
cause increasing difficulty in locus determination. The non-polymorphic
marker problem and the minimal physical distance drastically limit this
mapping strategy. The position we have arrived at may in fact represent the
endpoint of this strategy, albeit a relatively successful endpoint. Further
deletions are likely to be within the coding sequence of the target gene itself,
these will not be discovered until further sequencing and exon analysis
strategies are introduced. Precedence for microdeletions exist such as those
evidenced for p161NK4Awhere deletion of a single exon was shown after
MMCT introduction of chromosome 9 into murine cells (England et al., 1996).
The hygromycin resistance cassette is thought to be located in the
proximity of 048409 which itself is an explanation for the number of hybrid
segregants which retained this region. Due to the close proximity of our
identified locus to the resistance cassette this suggests that the generation of
a truncated chromosome 4 fragment through XMMCT, which did not carry the
locus, was extremely unlikely although not impossible. This technical problem
goes some way to explaining our inability to generate a truncated
chromosome, which did not carry the growth-arrest phenotype. The majority
of the generated truncated nuclei did exist as independent chromosomes on
the murine background, with the exception of A9i32 and possibly A9i33, and
therefore discredit the possibility of a murine effect. Previous MMCT control
experiments demonstrated the absence of a non-specific murine
Chromosome-effect. In the situation of a fused human-mouse chromosome
entering a recipient cell there would be no pressure for the maintenance of the
murine material, which would result in rapid loss through segregation or
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deletion. However the retention of markers telomeric to the identified locus in
BICR6 segregants demonstrates the specificity of the observed losses to the
abrogation of the growth-arrest phenotype. The control lines analysed had no
complex deletion patterns in the minimally lost region, which is further
suggestive of specificity to those cell lines with demonstrable LOH on 4q22.3-
q23. Analysis of HeLa segregants arising from whole and truncated
chromosome 4 transfers also implicate the identified region on 4q22.3-q23 as
being lost at greater frequencies than other sites and therefore likely to be
where the locus responsible for the phenotype lies (Dr. S. Bryce, BICR,
personal communication).
Through the approach outlined above we have identified the locus
spanning 4q22.3-q23 as the target site of deletion in immortal HNSCC
variants. The possibility exists that the strategy had successfully mapped a
recombinational hotspot characterised by a common breakpoint. However
this is unlikely as evidenced by the genetic distance being much less than the
physical distance (see Chapter 4, Figure 4.15). In the instance of a
recombinational hotspot the reverse would be expected with genetic distance
exceeding the physical distance through frequent recombinations with other
sites. However, as the genetic distance is the lesser of the two values (0.1cM
v's 1.5Mb) this would indicate a stable region suggesting against a breakpoint.
Statistical analyses of the marker losses also argue against these occurring in
a non-specific manner. Analysis of markers spanning 4cen-q23
demonstrates that losses in the region identified are the most significant by
both Fishers Exact and Chi2, this demonstrates that these losses are
occurring at a far greater frequency than background losses.
7.4) 4q23 is linked to human sec
Sclerotylosis is an autosomal dominant genodermatosis characterised
by congenital scleroatrophy of the distal extremities and early onset
aggressive SCC in the third to fourth decade of life followed sharply by
metastasis formation (Huriez et al., 1968; Hamm et al., 1996). The
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pathogenetic mechanism behind tumourigenesis in sclerotylosis is still
however, unknown. Linkage analysis of familial syndromes has lead to the
discovery of a number of important cancer genes (see Chapter1, Section 5.3).
A linkage study of two families in the north of France revealed a locus on
chromosome 4 displayed a maximum lod score of 12.22, which is highly
significant (Lee et al., 2000). The locus identified in this study ranges from
04S414 to 04S1591, which lies on 4q21-q24 and therefore also contains the
locus, which we have identified. As sufferers of this syndrome develop early-
onset SCC of the extremities, the gene responsible for this syndrome could
act in a rate-limiting manner, as described previously for the prototypic
'gatekeeper' gene APe in colorectal carcinoma (see Chapter 1, Section 1.2).
These lines of evidence are intriguing, and it remains possible that the
autosomal dominant sclerotylosis gene could be the same gene responsible
for the conversion of immortal HNSGC to a mortal phenotype.
7.5) Nature of the Chromosome 4 Mortal Phenotype
Previous definitions of the growth-arrest phenotype induced by
chromosome 4 suggested a flattening of cells with a concomitant cessation of
growth potential, both features reminiscent of replicative senescence (Pereira-
Smith and Smith, 1988; Ning et al., 1991). Through analysis of growth-
arrested BICR6/chromosome 4 hybrids we were able to define the observed
phenotype as a delayed crisis rather than a senescent arrest. Inappropriate
expression of SA-~gal at pH6 has been described as a biomarker of cells in
growth arrest (Oimri et al., 1995). Growth-arrested hybrids following MMCT of
chromosome 4 into BIGR6 and HeLa (Dr. S. Bryce, BIGR, personal
communication) both stain positively for this biomarker, this does not however
distinguish between senescence and crisis. A biological definition of a
senescent growth-arrest is a less than 5% nucleic acid analogue incorporation
after 24hrs, or rather 95% senescent cells remaining out of cycle (Cristofalo
and Sharf, 1973) and remaining resistant to apoptosis (Stein and Oulic, 1995).
Cells approaching crisis have an initial nucleic acid analogue labelling index
Similar to that seen in controls although as crisis approaches the incorporation
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plummets to levels similar to those seen in senescence but with a
concomitant increase in levels of cell death through apoptosis (Stein and
Dulic, 1995). We observed a nucleic acid analogue, BrdU, incorporation at a
rate approximately 25% that of the parental immortal cell line controls after a
48hrs labelling pulse and an increased rate of apoptosis of approximately 4-
fold that of parental immortal cell line controls as measured by the TUNEL
assay. This enables us to conclude that the growth-arrested hybrids resulting
from MMCT of chromosome 4, or fragments derived thereof, are undergoing a
form of crisis with a mean nucleic acid incorporation of 25% further suggesting
that these hybrids have a lifespan in culture following MMCT of approximately
14 weeks (Stein and Dulic, 1995) prior to apoptosis. The apoptotic and
nucleic acid incorporation analyses were performed after 12 weeks in culture;
through extrapolation to the values of Stein and Oulic this enables us to make
this conclusion regarding culture lifespan. The TUNEL method of apoptosis
detection has demonstrated a lack of sensitivity in previous studies (Labat-
Moleur et al., 1998), which raises the possibility that the actual rate of
apoptosis occurring was higher than that observed. The above described
apoptotic rates have also been observed in growth-arrested HeLa hybrids
following introduction of chromosome 4 by MMCT (Dr. S. Bryce and Mrs H.
Ireland, BICR, personal communication) which further suggests that the same
mechanism is undergoing functional complementation in the immortal HNSCC
lines with LOH on chromosome 4cen-q25 as in the HeLa cells. From the
available biochemical data we were able to conclude that the growth-arrested
hybrids were undergoing a form of crisis rather than senescent growth-arrest
and that this phenotype was similar in both HNSCC immortal keratinocyte
lines and the ovarian carcinoma line, HeLa. The immortal keratinocyte line
BICR6 has silenced the p53 gene through mutation, which suggests that
apoptosis is induced in a p53-independent manner in an as yet unclear
mechanism which has not yet been determined. However, recent data
suggests that one route may operate through the p53 homologue, p73 (see
Chapter 1, Section 3.2.3), which cannot be mechanistically ruled out at this
stage.
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7.6) Chromosome 4 does not Cause Crisis by Precipitating
Renewed Telomeric Attrition
A common mechanism of crisis is through telomeric attrition through
repeated proliferative divisions leading to chromosomal instability, an inability
to prevent the telomeric end being recognised as a double-strand break,
chromosomal fusions, and non-disjunction's during mitosis which ultimately
lead to cell death through apoptosis. The immortal cell lines used all
possessed positive telomerase activity which has been shown to maintain
telomeres in a stable manner and whose activity is generally required to
escape from crisis. Measurement of the telomere lengths of the lines used in
the MMGT experiments did not show a clear correlation between the
observed growth-arrest and recipient line telomere length. The cell lines,
which responded to the exogenous chromosome 4, BIGR6 and BICR31, had
mean telomere lengths of less than 4kb and 4-7kb respectively (Dr. K.
Gordon, BICR, personal communication). Assuming a maximal telomeric loss
of 100bp per division and an observed growth-arrest following approximately
10 population doublings then the telomeres would decrease to a mean length
of 3kb in BIGR6 and 6kb in BIGR31. Although we were not able to measure
the telomere length in growth-arrested hybrids it is unlikely that this shortening
would be sufficient to induce crisis. The telomeres in cells have been
reported to shorten to 1.5kb prior to the induction of crisis (Counter et al.,
1998), which would suggest that the apoptosis must have been occurring in a
telomere-independent manner. However the presence of a critically short
telomere or exposed telomere end within the growth-arrested hybrid cannot
be ruled out and this would possibly be sufficient to induce apoptotic death.
The telomere lengths of BICR3 and BICR19 are 4-5kb and 15kb respectively
(Dr. K. Gordon, BICR, personal communication) and neither of these lines
responded to the exogenous chromosome 4 copy following MMCT. The
implication from these findings is that the crisis growth-arrest which we
characterised in BIGR6 and observed in BIGR31 is not telomere-based
through a consequence critical shortening as insufficient doublings exist for
sufficient telomeric attrition to occur to drive the cell into apoptosis. However,
images of growth-arrested hybrids from both BIGR6 and BICR31 suggest
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cellular multinucleation resulting from failed mitotic separation and failed
cytokinesis, which is suggestive of telomeric dysfunction (see Figure 5.1 and
5.2).
The catalytic subunit of the enzyme telomerase is a minimal
requirement for escape from crisis and cellular immortality. This is achieved
through the rescue of telomere ends above the minimal threshold length and
stabilisation of the telomere ends through further unlimited cellular divisions.
Both the cell lines, which responded to the exogenous chromosome 4, and
those that did not, had positive telomerase expression and demonstrated LOH
at chromosome 3p. When we introduced chromosome 4 using MMCT into
the recipient lines BICR6 and BICR31, which had been stably infected with
the a retrovirus plasmid construct carrying an ectopic hTERT catalytic
component, we saw no abrogation of the crisis growth-arrest phenotype,
which suggested further that the apoptosis was not telomere-linked. Although
the telomere ends would theoretically be maintained by the ectopic hTERT if
the locus on 4cen-q23 interfered with the endogenous hTERT and thereby
prevent apoptosis we did not observe any growth-arrest rescue. Furthermore,
measurement of the telomere lengths in BICR6hTERT and BICR31hTERT
demonstrated that the ectopic hTERT had catalysed the addition of numerous
telomeric repeats onto the ends of the chromosomes. The telomeres on
BICR6 had elongated to approximately 20kb whereas those on BICR31 had
reached approximately 25kb, from starting lengths of less than 4kb and 4-7kb
respectively. We can conclude from this that the lengths of the telomeric
repeats on the end of the chromosome are not obviously involved in the
mortal phenotype, which we observed. Although the digestion of the telomere
ends of the hTERT-infected BICR6hTERT and BICR31hTERT may be
incomplete, this does not dissuade from both the observed phenotype and the
overall general appearance of telomeric extension in these cells. This does
not rule out an effect on a downstream component of the telomerase pathway,
or alternatively an element involved in telomeric stabilisation, or t-Ioop
formation. Through observations of growth-arrested hybrids the phenotype
looks to act at mitosis causing inappropriate mitotic separation which
suggests that the mechanism behind the growth-arrest may be a novel
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pathway or an uncharacterised mechanism carried out by an existing pathway
involved in this process.
As the observed growth-arrest phenotype does not occur through
disruption of the telomerase hTERT catalytic subunit this leaves the obvious
question, what is the mechanism behind the crisis-like phenotype in these
immortal cells? An alternative telomeric mechanism cannot be ruled out at
this stage as a number of different factors associate with and stabilise
telomere ends and assist in t-Ioop formation. The potential mechanism could
act through negative regulation of these telomere-associated proteins such as
TRF-1, TRF-2. Negative regulation of TRF-1 (or PIN2 (Shen et al., 1997))
could lead to an inhibition of 'telomeric curve' thereby preventing t-loop
formation and masking the telomeric 3'-overhang allowing its recognition as
DNA-damage, albeit in a p53-independent manner, leading to apoptotic cell
death. Similarly negative regulation of TRF-2, which has been shown to lead
to a DNA-damage apoptotic response (Karlseder et al., 1999), would expose
the 3'-overhang to damage-recognition factors. Both of these mechanisms
could conceivably occur in the presence of telomerase activity, as telomeric
extension would not prevent their recognition as DNA-damage due to the
exposed telomere ends. A similar phenotype to that which we described;
multinucleation, micronuclei, flattening, enlarged cytoplasm, and apoptotic
death, has been described in Hela cells following introduction of chromosome
4 by MMCT (Dr. S. Bryce, BICR, personal communication). This phenotype
has been induced in neonatal foreskin fibroblasts and Hela cells through
azelaic bishydroxamic acid (ABHA) (histone deacetylase inhibitor) treatment
(Qiu et al., 2000). This treatment leads to a loss of a G2 checkpoint resulting
in aberrant mitosis and the previously described phenotype. Intriguingly the
locus candidate gene KlAA1122 belongs to the SWI/SNF family, which has
been implicated in chromatin remodelling and transcriptional control. The
histone deacetylase inhibitor ABHA could conceivably cause the same
phenotype as the reintroduction of a chromatin-remodelling gene could induce
a retrospective silencing of inappropriate gene expression leading to the
observed phenotype.
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Evidence obtained by monitoring hybrids in limiting conditions
suggested that the locus responsible for the crisis-like phenotype had the
potential to undergo silencing in favourable growth conditions. Through
treatment of chromosome donor cells with demethylating agents followed by
introduction into the chromosome 4-responsive line BICR6 we did not see any
alteration in the number of hybrids which displayed the characteristic growth-
arrest phenotype. This would imply that the locus responsible does not
undergo promoter silencing through methylation on the murine background.
The hybrids in this experiment were not picked and seeded at minimal density
in stringent conditions and so we cannot draw any conclusions on phenotypic
rescue through promoter methylation in these hybrids. However, as silencing
did seem to occur in hybrids with apparently intact exogenous chromosomes
this would suggest that promoter methylation or microdeletions have occurred
in these hybrids.
7.7) Candidate Genes
The dual approach of functional complementation and exogenous loss
map construction in this instance has been a relative success in terms of this
project. We have identified a minimal locus, strongly supported by several
lines of evidence, which contains a number of candidate genes. These genes
have been identified through construction of EST clusters and sequence
alignment. However, this does not rule out the possibility of inappropriate
expression by an otherwise silent locus for which no EST exists. This
situation has precedence, as no EST exists for p14ARF due to its lack of
expression in ordinary situations. The three candidate genes, which we have
identified; KIAA 1122, GRID2, PGDS and the two EST clusters could all
potentially be the target of silencing in advanced HNSCC and other tumour
types. However the lack of expression of GRID2 and PGDs in normal
keratinocytes does argue strongly against the likelihood of either of these
genes being responsible for the observed phenotype.
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The KIAA 1122 gene has a number of characteristics, all derived
through family member homologs, which do not preclude it from candidacy.
The immediate homologue of KIAA 112 is the M.musculus ETL-1, which is a
member of the larger family of SWI/SNF chromatin ATP-dependent
remodelling complexes. ETL-1 shares homology with a number of members
of this large family although may function in a distinct manner. The brahma
D.melaongaster gene is one of these homologs and its direct homologue
BRG1 (Khavari et al., 1993) has been shown to be directly associated with the
RNA polymerase II holoenzyme suggesting an involvement in transcription.
Brahma itself has been shown in D.melanogaster to be a requirement for E2F
transcriptional activity suggesting a conservation of function between these
two species (Staehling-Hampton et al., 1999). Furthermore, when BRG1 was
overexpressed in mammalian cell lines it induced a senescence-like growth-
arrest, which was overridden by the ectopic expression of cyclin D and cyclin
E (Shanahan et al., 1999). These lines of evidence all suggest a role played
by SNF2 family member, BRG-1, in transcriptional regulation at the G1/S-
phase of the cell cycle. A further SWI/SNF family member SNF5 was
demonstrably shown to be a leading candidate for an initiating event in
malignant rhabdoid tumours (MRTs), which occur early in childhood
(Versteege et al., 1998). These paediatric tumours demonstrated frequent
deletions of one copy of the SNF5 gene and frequent somatic mutations of the
other thereby fitting the stringent characteristics of a tsg. Further mutational
studies revealed mutations in most rhabdoids, choroids plexus carcinomas,
primitive neuroectodermal tumours, and medulloblastomas. Mutations were
not demonstrated in breast cancers, Wilms' tumours, glioblastomas,
ependymomas, or sarcomas although most analysed cases showed LOH at
the SNF5 loci. Family members of the SWI/SNF multiprotein complexes have
been demonstrated to exert a control of transcriptional regulation through
chromatin remodelling and of being mutational targets in tumours. These are
family members, however, this does not necessitate the involvement of
KIAA1122 in tumourigenesis as distinct functions are demonstrated within
protein family groupings. As a member of a large multiprotein complex
forming family this gene may represent a novel target of mutation,
downstream effects could lead to dysregulation of transcriptional control and
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therefore, proliferation. Intriguingly the prototypic family members in yeast
were termed SWI/SNF, for yeast mating type switching (SWI) and sucrose
non-fermenting (SNF). As described in Chapter 1 (Section 4.5) calorific
restriction has been proposed as a mechanism to prolong lifespan in yeast.
Although this has not been conclusively demonstrated in mammals it remains
possible that the mutation of these genes could represent the abrogation of an
evolutionarily conserved mechanism whose disruption allows a lifting of
metabolic control and the potential to accumulate damaging mutations. A
further SWI/SNF2 family member is the RAD54 protein, which is involved in
DNA double-strand break homologous repair (Dasika et al., 1999) RAD52
epistasis group. Correct functioning of the repair complex requires the
presence of a number of group members including RAD54 (Tan et al., 1999).
RAD54 could therefore fit the 'caretaker' classification, as mutation of this
gene would allow the accumulation of unrepaired DNA double-strand breaks,
which could stimulate an apoptotic cellular response. There are therefore a
number of possible roles the ETL-1 homologue, KIAA1122, could have in
tumourigenesis through sharing common domain structures with SNF2 family
members. KIAA1122 could have a unique role however and homologue
analysis can only serve as an indicator of possible function.
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7.8) Future Plans
Differentiation between these candidates will require a number of
further analytical strategies. Candidate BACs and cDNAs will have to be
introduced into target cell lines, which have shown a response to the intact
and truncated chromosomes and observed for phenotypic alterations Le.
BICR6 and HeLa. Conversely these will have to be introduced into cell lines
which do not show a response to the intact chromosome Le. BICR19 and the
osteosarcoma line, 143B (Dr. S. Bryce, BICR, personal communication).
Once phenotypic alteration has been established mutation screening would
be required throughout immortal HNSCC lines where LOH has been
established in this region along with methylation-specific PCR, where
appropriate, to establish if alternative silencing has occurred. These analyses
will determine if the candidate genes fit the criteria of Knudson's model for
genes abrogated in cancer. Further determination will of course be required if
a candidate fulfils the criteria to establish pathways to which the gene belongs
and mechanisms through which it exerts its functions. This can be
determined through protein-protein interaction assays such as yeast two
hybrid screens, immunoaffinity chromatography, and immunoprecipitation,
and also generating an epitope-flagged molecule to determine cellular
localisation. Double-knock-out mice could be generated eventually (p53-null
as the cell lines respond in a p53-independent manner), if the mechanism
operates through destabilisation of the t-Ioop and 3'-overhang masking then
presumably a phenotype would be observable in a murine system as this
would bypass the situation encountered in telomerase-deficient mice.
7.9) Conclusions
The importance of a gene whose abrogation presumably can assist in
the immortalisation of advanced tumours and whose reintroduction can revert
the cells to a mortal phenotype could be of clinical significance. Mortal
tumours can undergo growth-arrest through replicative senescence although
abrogation of key gene pathways, p53 and pRB, can afford escape from this
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growth-arrest allowing, through abrogation of hTERT expression and escape
from crisis, progression into cellular immortality. Advanced cancers are
frequently aggressive and immortal which minimises both patient survival
rates and quality of life. Through three lines of evidence we have identified a
locus on chromosome 4, which is responsible for a mortal growth-arrest in
immortal HNSCC lines. This has been achieved through LOH analysis,
functional complementation, and segregant loss map construction. Others
have also implicated the identified locus through linkage analysis, in familial
early-onset sec, which suggests an involvement in tumourigenesis. The
chromosome 4 mortality gene may therefore provide an opportunity to identify
a novel cellular mortality mechanism, which induces both growth-arrest and
apoptosis in immortal cells regardless of genetic status or hTERT expression.
This could provide a novel mechanism to target advanced tumours in a p53-
independant, hTERT-independent manner and therefore minimise non-
specific cell toxicity's, which occur as a by-product of conventional therapies.
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Appendix 1
peR Primers
Primers used to amplify a portion of the hygromycin B resistance cassette
from pBabe Hygro:
F:CTGGGGCGCCCTCTGGTAAG
R:GCGTGGATATGTCCTGCGGG
product size: 209 bp
Primers used to amplify a portion of the neomycin resistance cassette from
psp72 containing a corrected PMC1 neo polA cassette:
F:ATGCTCTTCGTCCAGATCAT
R:AAAGTATCCATCATGGCTGAT
product size: 150 bp
Primers used to amplify the MORF4 gene:
F:AAATGGGCTAAATGCCGTAG
R:CACTTTACAGCATATCCCTG
Product size: 1526
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Appendix2
Sequencing Primers
MORF4 Sequencing Primers
Forward: S1-F CAGTGTGCTGTATTCAGGAG
S2-F ATTGGGATGATGGGGTTCCG
S3-F GCTCTTCTATCTTCCTGCCG
Reverse: S1-R CAGACCAGATGTCTTCTTTCC
S2-R CCCAACATTAGGTTGAAGTA
S3-R CTAACCTCTTCAAAGCACATCG
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Appendix 3: Microsatellite Markers
Marker Forward Primer Reverse Primer Min/Max
Name Length
0452936 cactcaagcctggggg tggcacatcaccaacaac 1 70/178
045431 aggcatactaggccgtatt ttcccatcagcgtcttc 252/256
0453009 atggcctgtgaatcaaccc aatcctttgaagacggccc 267/275
0451582 atcagggttctccacacaaa ttggttgaaacttgtggatataaa 114/122
0452926 ttaaccagtggaggccagt ctcttaaagaacagggtgtctgata 185/197
0453022 gccaagatagcgccac atagtctgtcccgaaccc 137/149
0452912 agctaaaccattatggcat tctagttaattctccgtttcat 222/234
0453045 tatgcgtcaggcactg ggcaaggacttccagg 117/121
0452978 acaaacaatgccaaagaa gatctggtgtaggtaaggg 267/271
045409 cttgccgtcagactcaaact caacctttcaatgttagggc 279/293
0452964 aagctaagacccaacttcttt tcatgcaatccacacag 177/189
0452922 cattggtccactccagttct ataaagggcagttagggatg 258-268
0451553 gctatgaaatgcttctgctt aaaagactgttagttaaacatcagg 202-206
0452932 gagcaaaactctgtctcaaaaataa ggcttacttggaaaggtctctt 209-221
0451538 tgagaattgcttggaaccga ccacacagcacggagacatt 149-161
0452462 agctcatataggtgtnctattca gtgggcctgtcctgtt 280-294
045423 ttgagtagttcctgaagcagc caaagtcctccatcttgagtg 111/119
0483037 gtttagttttccattcctgaattac ccaactcaaatgcctgtc 202-208
0482404 atatatatgatgcatgtcaaaatgg ctgggcaaactcatttcaac 131/N.d
BIR0101 ttgcccatcttttgatcagc tgtactttgtgagatccacc N.d/N.d
0451591 ggggagttcgaggctg aganctttttagggaagagtca 116/118
0451570 caagatgaaagcacaacgta cctggcccattatattcctt 187/187
0451564 agcccaggaggtgaag gagatttctaggaaacattgag 222/238
045406 ctggttttaaggcatgtttg tcctcagggaggtctaatca 242/250
0452985 ttacactgaagaatgtgagagcc ggccttggaactactgatgg 252/252
0452938 tgcaaattcgtgggac tggtgtagtattccatcgtg 164/170
045429 ggtgatccacctgcct aagccactgaccttcact 197/205
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Marker Forward Primer Reverse Primer Min/Max
Name Length
0483039 gacagcctattgtagtaacttgtgg tagtcagggtgctctagggg 167/169
0482959 agcttccatggtcattagagt tagggtcctccaaagaacaga 126/126
048422 ggcaagantccgtctcaa tgaagtaaaatttgggagattgt 85/87
0481576 attgtncatatatcatcacctgg acagcataaactaaaatttgggg 239/243
0481579 cccccaccttcctgac ctggagcatccgtgtg 146/148
0481610 gcatgggggtagaaatacac ttacatcgtcctaaaatcaaacat 169/169
0483008 taactgaatggatttgagactacc gcttgatcttgccttgga 267/270
0481548 tgccataaacaaggtgaaac ttacccaactgctacaccat 261/265
0481588 ccggacatctgaggtcttat tccagaaatggctagagaga 234/238
0482999 gtttgttgcctgaatttcc catgtccatttcctcaagtc 208/212
0482982 ccagtcaaccccaacac gaaatgaaacatgatgacacc 187/199
0482993 aagttggatgaaacacagc tttacctgtccctgactcttag 156/160
0481597 tatagtggcccctagtgttacat ttaggcttctcaaagcataagac 275/275
0482979 tttctgcagctaccatgaat tagtttgccaacccctagtc 145/157
0483028 tatccctaaactttaatgccttt gtctacacctcctacacccc 232/232
0483041 aatccctaggcaaataccat tcttgagtggctgaaactacat 131/133
0482943 ccttatgaaccaggtaaccc ctttcccagatatgtcgatttag 210/218
0482920 acacagcacagtttgtttga gacctgcctaagcctttg 110/112
0481554 cttgtttcctgttgagcact gaatgatgtactgatcacccagat 196/196
0482954 ccatttcagtgtctgtgacta ggaagccaattcctcata 127/131
0481535 acttgtgatatatacctgccg tgtgagagcagaatgttgag 183/183
048408 ggtctgatgaaaatgttctcaagc tagactgggttgttagggactctc 231/243
0483047 agaaggcccttgaagtgata tgacgacaggtcggtt 236/242
0483032 tgaaattctattgaccaatgatgtg tagcacctggatttaccatgac 139/139
0481540 tgaacccgtgaagtgg ggtgggatatgttaattgc 187/191
0482930 cctcatggtaggttaatcccacg tattgaatgcccgccatttg 217/219
N.d = Not Oefined.
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